US20080216828A1 - Heating unit for use in a drug delivery device - Google Patents
Heating unit for use in a drug delivery device Download PDFInfo
- Publication number
- US20080216828A1 US20080216828A1 US12/045,674 US4567408A US2008216828A1 US 20080216828 A1 US20080216828 A1 US 20080216828A1 US 4567408 A US4567408 A US 4567408A US 2008216828 A1 US2008216828 A1 US 2008216828A1
- Authority
- US
- United States
- Prior art keywords
- drug
- substrate
- supply unit
- aerosol
- air flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
- A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/047—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters by exothermic chemical reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3653—General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8268—Fuel storage cells
Definitions
- the present invention relates generally to drug supply units comprising a substrate having a plurality of holes. More particularly, embodiments of the invention relate to drug supply units intended to be used to vaporize a drug composition deposited on a surface of the substrate, drug delivery devices comprising such drug supply units, and methods of producing an aerosol using such drug delivery devices.
- inhalation therapy has played a relatively minor role in the administration of therapeutic agents when compared to more traditional drug administration routes of oral delivery and delivery via injection. Due to drawbacks associated with traditional routes of administration, including slow onset, poor patient compliance, inconvenience, and/or discomfort, alternative administration routes have been sought. Pulmonary delivery is one such alternative administration route which can offer several advantages over the more traditional routes. These advantages include rapid onset, the convenience of patient self-administration, the potential for reduced drug side-effects, the ease of delivery by inhalation, the elimination of needles, and the like. Many preclinical and clinical studies with inhaled compounds have demonstrated that efficacy can be achieved both within the lungs and systemically.
- Metered dose inhaler formulations involve a pressurized propellant, which is frequently a danger to the environment, and generally produces aerosol particle sizes undesirably large for systemic delivery by inhalation. Furthermore, the high speed at which the pressurized particles are released from metered dose inhalers makes the deposition of the particles undesirably dependent on the precise timing and rate of patient inhalation. Also, the metered dose inhaler itself tends to be inefficient because a portion of the dose is lost on the wall of the actuator, and due to the high speed of ejection of the aerosol from the nozzle, much of the drug impacts ballistically on the tongue, mouth, and throat, and never gets to the lung.
- Liquid aerosol formations similarly involve non-drug constituents, i.e. the solvent, as well as preservatives to stabilize the drug in the solvent.
- all liquid aerosol devices must overcome the problems associated with formulation of the compound into a stable liquid.
- Liquid formulations must be prepared and stored under aseptic or sterile conditions since they can harbor microorganisms. This necessitates the use of preservatives or unit dose packaging.
- solvents, detergents and other agents are used to stabilize the drug formulation.
- the dispersion of liquids generally involves complex and cumbersome devices and is effective only for solutions with specific physical properties, e.g. viscosity. Such solutions cannot be produced for many drugs due to the solubility properties of the drug.
- drug compound typically is deposited on a surface of a substrate, such as a stainless steel foil.
- the substrate is rapidly heated to volatilize the drug, followed by cooling of the vapor so that it condenses to form an aerosol (i.e., a condensation aerosol).
- Volatilization subjects the drug to potential chemical degradation via thermal, oxidative, and/or other means.
- the activation energies of these degradation reactions depend on molecular structure, energy transfer mechanisms, transitory configurations of the reacting molecular complexes, and the effects of neighboring molecules.
- One method to help control degradation during volatilization is the use of the flow of gas across the surface of the compound, to create a situation in which a compound's vapor molecules are swept away from its surface. (See e.g., Wensley et al., U.S. Publication No. US 2003/0062042 A1). Additionally, the use of thin films reduces the amount of thermal degradation by decreasing the temporal duration of close contact between the heated drug molecule and other molecules and/or the surface on which the drug is in contact.
- a drug supply unit comprising a substrate having a plurality of holes provides a number of advantages.
- the use of such drug supply units allows the formation of a condensation aerosol of higher purity.
- the use of such drug supply units allows formation of a condensation aerosol with a higher yield. This discovery forms the basis of the present invention.
- Embodiments of the invention include a drug supply unit comprising a substrate, wherein the substrate has a surface containing a plurality of holes, and wherein at least a portion of the surface is coated with a drug composition.
- an aerosol drug delivery device comprising: a housing defining an airway; a drug supply unit comprising a surface, wherein at least a portion of the surface includes a plurality of holes; a heating element operatively associated with the drug supply unit, wherein the heating element is configured to heat the substrate; and a drug composition coated onto at least a portion of the surface of the substrate, wherein the heating element is configured to configured to heat the substrate to a temperature sufficient to vaporize at least a portion of the drug.
- inventions include a method of producing a drug-containing aerosol, the method comprising: (a) providing an aerosol drug delivery device comprising a housing defining an airway; a drug supply unit comprising a surface, wherein at least a portion of the surface includes a plurality of holes; a heating element operatively associated with the drug supply unit; and a drug composition coated onto at least a portion of the surface of the substrate; wherein the heating element is configured to heat the substrate to a temperature sufficient to vaporize at least a portion of the drug; (b) providing an air flow through the plurality of holes while heating the substrate; and (c) allowing the vaporized drug to cool and condense into an aerosol comprising particles.
- FIG. 1A is a cross-section view of a drug supply unit according to one embodiment of the invention.
- FIG. 1B is a cut-away view of a drug supply unit according to one embodiment of the invention.
- FIG. 1C is a cut-away view of a drug delivery device according to one embodiment of the invention.
- FIG. 2A shows a perforated polyimide film substrate having holes measuring 2.8 ⁇ 10 ⁇ 3 in. by 5.25 ⁇ 10 ⁇ 3 in.
- FIG. 2B shows a perforated polyimide film substrate having holes measuring 8.8 ⁇ 10 ⁇ 3 in. ⁇ 9.8 ⁇ 10 ⁇ 2 in.
- FIG. 3 is a cross-sectional view of a polyimide film substrate, showing the polyimide film substrate, copper heater traces, and holes formed through the polyimide film.
- FIG. 4A is a schematic of an embodiment of a substrate screening apparatus.
- FIG. 4B is a cross-sectional view of the substrate screening apparatus embodiment shown in FIG. 4A .
- FIG. 5 is a schematic of another embodiment of a substrate screening apparatus.
- FIG. 6 shows a magnified image of a perforated stainless steel substrate.
- FIG. 7 is a bar graph showing aerosol purity (%) and yield (%) at various air flow ratios (across:bottom) for sildenafil free base.
- FIG. 8 is a plot showing aerosol purity (%) as a function of drug coating thickness (microns) for sildenafil free base.
- FIG. 9 is a bar graph showing aerosol purity (%) at various air flow ratios (across:bottom) for bumetanide free base.
- FIG. 10 is a plot showing aerosol purity (%) as a function of drug coating density (mg/cm 2 ) for bumetanide free base.
- FIG. 11 is a plot showing average MMAD as a function of air flow ratio (across:bottom) for bumetanide free base vaporized from a perforated 316 stainless substrates.
- FIG. 12 is a bar graph showing coated purity at various storage times (weeks) at 40° C. for fentanyl free base coated on polyimide film.
- FIG. 13 is a plot showing aerosol purity (%) as a function of drug coating thickness (microns) at various air flow ratios (across:bottom) for prochlorperazine free base using a perforated polyimide film substrate.
- FIG. 14 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for adenosine free base using a perforated polyimide film substrate.
- FIG. 15 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for baclofen free base using a perforated polyimide film substrate.
- FIG. 16 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for ciclesonide free base using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate.
- FIG. 17 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for cyclobenzaprine fumarate using a perforated polyimide film substrate.
- FIG. 18 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for diphenhydramine fumarate using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate.
- FIG. 19 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for flunisolide free base using a perforated polyimide film substrate, a perforated, heat-passivated stainless steel substrate, and a perforated SULFINERT®-treated stainless steel substrate.
- FIG. 20 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for fluticasone propionate using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate.
- FIG. 21 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for mometasone furoate using a perforated polyimide film substrate, a non-perforated, heat-passivated stainless steel substrate, and a non-perforated SULFINERT®-treated stainless steel substrate.
- FIG. 22 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for paroxetine fumarate using a perforated polyimide film substrate and non-perforated, heat-passivated stainless steel substrate.
- FIG. 23 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for tadalafil free base using a perforated, heat-passivated stainless steel substrate.
- FIG. 24 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for tizanadine free base using a perforated polyimide film substrate, a non-perforated, heat-passivated stainless steel substrate, and a non-perforated, (non-heat-passivated) stainless steel substrate.
- FIG. 25 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for vardenafil free base using a perforated polyimide film substrate and a perforated, heat-passivated stainless steel substrate.
- FIG. 26 is a plot showing aerosol purity (%) as function of coated density (mg/cm 2 ) at various air flow ratios and temperatures for zaleplon free base using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate.
- “Aerodynamic diameter” of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
- “Aerosol” refers to a collection of solid or liquid particles suspended in a gas.
- Condensation aerosol refers to an aerosol that has been formed by the vaporization of a composition and subsequent cooling of the vapor, such that the vapor condenses to form particles.
- Decomposition index refers to a number derived from an assay described in Example 20. The number is determined by subtracting the purity of the generated aerosol, expressed as a fraction, from 1.
- Drug means any substance that is used in the prevention, diagnosis, alleviation, treatment or cure of a condition.
- the drug is preferably in a form suitable for thermal vapor delivery, such as an ester, free acid, or free base form.
- the drugs are preferably other than recreational drugs. More specifically, the drugs are preferably other than recreational drugs used for non-medicinal recreational purposes, e.g., habitual use to solely alter one's mood, affect, state of consciousness, or to affect a body function unnecessarily, for recreational purposes.
- the terms “drug”, “compound”, and “medication” are used herein interchangeably.
- Drug composition refers to a composition that comprises only pure drug, two or more drugs in combination, or one or more drugs in combination with additional components. Additional components can include, for example, pharmaceutically acceptable excipients, carriers, and surfactants.
- Drug degradation product and “thermal degradation product” are used interchangeably and mean any byproduct which results from heating the drug(s) and is not responsible for producing a therapeutic effect.
- Drug supply article and “drug supply unit” are used interchangeably and refer to a substrate with at least a portion of its surface coated with one or more drug compositions.
- Drug supply articles of the invention may also include additional elements such as, for example, but not limitation, a heating element.
- Fraction drug degradation product refers to the quantity of drug degradation products present in the aerosol particles divided by the quantity of drug plus drug degradation product present in the aerosol, i.e. (sum of quantities of all drug degradation products present in the aerosol)/((quantity of drug(s) present in the aerosol)+(sum of quantities of all drug degradation products present in the aerosol)).
- percent drug degradation product refers to the fraction drug degradation product multiplied by 100%, whereas “purity” of the aerosol refers to 100% minus the percent drug degradation products.
- Heat stable drug refers to a drug that has a TSR ⁇ 9 when vaporized from a film of some thickness between 0.05 ⁇ m and 20 ⁇ m. A determination of whether a drug classifies as a heat stable drug can be made as described in Example 20.
- Mass median aerodynamic diameter” or “MMAD” of an aerosol refers to the aerodynamic diameter for which half of the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.
- “Purity” as used herein, with respect to the aerosol purity means the fraction of drug composition in the aerosol/the fraction of drug composition in the aerosol plus drug degradation products. Thus purity is relative with regard to the purity of the starting material. For example, when the starting drug or drug composition used for substrate coating contained detectable impurities, the reported purity of the aerosol does not include those impurities present in the starting material that were also found in the aerosol, e.g., in certain cases if the starting material contained a 1% impurity and the aerosol was found to contain the identical 1% impurity, the aerosol purity may nevertheless be reported as >99% pure, reflecting the fact that the detectable 1% purity was not produced during the vaporization-condensation aerosol generation process.
- “Support” refers to a material on which the composition is adhered, typically as a coating or thin film.
- support and “substrate” are used herein interchangeably.
- a “perforated substrate” refers to a substrate wherein a surface of the substrate has a plurality of holes that extend through the substrate. As described below, these holes allow a gas (e.g., air) to flow through the substrate.
- a “non-perforated substrate” refers to a substrate without any holes.
- substantially free of means that the material, compound, aerosol, etc., being described is at least 95% free of the other component from which it is said to be substantially free.
- “Therapeutically effective amount” means the amount required to achieve a therapeutic effect.
- the therapeutic effect could be any therapeutic effect ranging from prevention, symptom amelioration, symptom treatment, to disease termination or cure.
- Thermal stability ratio means the % purity/(100%-% purity) if the % purity is ⁇ 99.9%, and 1000 if the % purity is ⁇ 99.9%.
- TSR Thermal stability ratio
- Thermal vapor refers to a vapor phase, aerosol, or mixture of aerosol-vapor phases, formed preferably by heating.
- the thermal vapor may comprise a drug and optionally a carrier, and may be formed by heating the drug and optionally a carrier.
- vapor phase refers to a gaseous phase.
- aerosol phase refers to solid and/or liquid particles suspended in a gaseous phase.
- Vapor refers to a gas
- vapor phase refers to a gas phase
- thermal vapor refers to a vapor phase, aerosol, or mixture of aerosol-vapor phases, formed preferably by heating.
- the drug supply units described herein may be used to form condensation aerosols.
- One such method involves the heating of a composition to form a vapor, followed by cooling of the vapor so that it forms an aerosol (i.e., a condensation aerosol).
- the composition is deposited on a substrate, and then the substrate is heated to vaporize the composition.
- the drug supply unit of the invention comprises a substrate and a drug composition deposited on at least a portion of the substrate, wherein the surface of the substrate has a plurality of holes formed therein that extend through the substrate. As described below, these holes allow a gas (e.g., air) to flow through the substrate.
- the substrate is a heat-conductive substrate.
- the drug supply unit is particularly suited for use in a device for inhalation therapy for delivery of a therapeutic agent to the lungs of a patient, for local or systemic treatment.
- the unit is also suited for use in a device that generates an air stream, for application of aerosol particles to a target site.
- a stream of gas carrying aerosol particles can be applied to treat an acute or chronic skin condition, can be applied during surgery at the incision site, or can be applied to an open wound.
- the devices and methods of the invention are applicable not only to a unit consisting of the above components but also to any drug supply unit that consists of these and any other additional number of components up to, and including, the complete drug delivery device itself. Discussed below are aspects of the substrate, the drug composition film, aerosol purity, and surface area features of the substrate for delivery of therapeutic amounts of a drug composition.
- Drug supply unit 130 is comprised of a substrate 108 having a plurality of holes 132 .
- the substrates are heat-conductive and include metals or alloys, such as aluminum, iron, copper, stainless steel, gold, titanium and the like, alloys.
- the holes in the substrate may be formed by any method known in the art.
- the heat-conductive substrate is a sheet of stainless steel foil that has had holes etched or drilled thorough it.
- stainless steel has advantages over materials like aluminum because it has a lower thermal conductivity value, without an appreciable increase in thermal mass. Low thermal conductivity is helpful because heat generated by the process needs to remain in the immediate area of interest.
- a drug supply unit of the invention may also comprise treated substrates, which have been described as providing improve purity of the drug composition aerosol generated from films applied thereon.
- Exemplary substrates of this type are described in Bennett et al., U.S. Publication No. 2005/0034723, which is incorporated herein by reference.
- Metal substrates disclosed therein have a treated exterior surface.
- the treated exterior surface is typically an acid treated, heat treated, or metal oxide-enriched surface.
- the treatment approaches disclosed therein are applicable to a diversity of metals and alloys, including without limitation steel, stainless steel, aluminum, chromium, copper, iron, titanium, and the like, with aluminum, copper, and steel, especially stainless steel, being particularly preferred embodiments.
- the heat-conductive substrate is a sheet of SULFINERT®-treated stainless steel.
- the substrate may comprise a ceramic or polymer.
- the heat-conductive substrate is a sheet of polyimide film (KAPTON® polyimide film, DuPont, Wilmington, Del.) comprising a plurality of holes.
- the drug supply unit can further comprise a heater element disposed on or within the polymeric substrate.
- a thin sheet of polyimide film (5 ⁇ 10 ⁇ 4 in. to 1 ⁇ 10 ⁇ 3 in.) may be used.
- electrically conductive heater traces can be formed on a surface of the polyimide film sheet.
- the heater traces typically comprise copper, it is also contemplated herein that the traces can be formed of other conductive materials, such as aluminum, nickel, or gold.
- the substrate typically has a thickness of at least 5 ⁇ 10 ⁇ 4 in.
- the substrate comprises a metal (e.g., stainless steel)
- the substrate typically has a thickness within the range of about 5 ⁇ 10 ⁇ 4 in. to about 1 ⁇ 10 ⁇ 2 in.
- the substrate comprises a polymer (e.g., polyimide film)
- the substrate typically has a thickness within the range of about 5 ⁇ 10 ⁇ 4 in. to about 5 ⁇ 10 ⁇ 3 in.
- At least a portion of the surface of the substrate comprises a plurality of holes through which a flow of gas can pass.
- the substrate comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 250, at least 500, or more, holes.
- a gas e.g., air
- the gas may be drawn into the device by the act of inhalation, or may otherwise be provided (e.g., stored within the device under pressure until inhalation).
- the holes have a regular shape, such as a circle, an ellipse, a square, a rectangle, or a regular polygon.
- the substrate comprises a plurality of small, circular, regularly spaced holes, typically of the same or similar size.
- the holes could be of irregular shape, and/or have varying sizes and/or spacing.
- the plurality of holes may have different shapes (e.g., a combination of circular and rectangular holes).
- the dimensions of the holes typically remain uniform as they extend through the substrate, but it is within the scope of the invention that the holes can vary in shape and dimension as they extend through the substrate.
- the holes could have a tapered, conical shape, so that the holes have a larger diameter on one surface of the substrate than on another.
- the holes are preferably located between the heater traces, as shown in FIGS. 2A and 2B , which show polyimide film substrates having smaller and larger size holes, respectively.
- the substrate 200 shown in FIG. 2A has smaller holes measuring 2.8 ⁇ 10 ⁇ 3 in. by 5.25 ⁇ 10 ⁇ 3 in.
- the spacing between holes is 1.5 ⁇ 10 ⁇ 2 in.
- the heater 20 shown in FIG. 2B has larger holes measuring 8.8 ⁇ 10 ⁇ 3 in. by 9.8 ⁇ 10 ⁇ 2 in.
- the polyimide films have a thickness of 1 ⁇ 10 ⁇ 3 in.
- FIG. 3 is a schematic illustration of a polyimide film substrate 300 , showing the polyimide film 302 , copper heater traces 304 , and holes 306 formed through the polyimide film 302 .
- the holes are arranged in a regular pattern across the substrate. However, it is also contemplated herein that the holes could be arranged in an irregular pattern or even randomly across the substrate.
- the holes may be formed in the substrate using any conventional technique known in the art, including without limitation, laser etching, drilling, wet chemical etching, plasma etching, stamping, punching, and combinations thereof.
- a drug is typically coated onto a portion of the substrate.
- the drug-coated portion of the substrate typically has a surface area within the range of about 8 mm 2 to about 20 cm 2 ; more typically, within the range of about 9 mm 2 to about 15 cm 2 .
- the holes typically occupy between about 1% to about 70%; more typically, between about 10% to about 60%; and, most typically, between about 20% to about 50%, of the drug-coated surface area.
- the drug is typically coated to a coating density ranging from about 0.1 mg/cm 2 to about 10 mg/cm 2 on the substrate surface. This roughly corresponds to a coating thickness within the range of about 1 ⁇ m to about 100 ⁇ m.
- the drug may be coated onto the substrate surface using any conventional coating technique known in the art, including without limitation, spray coating, dip coating, and inkjet printing.
- the drug is coated onto the polyimide film side of the heating unit. It is also contemplated herein that the drug may be coated onto the side of the heating unit having the conductive heater traces, or onto both sides of the heating unit.
- Drug supply units for use in the present invention are typically electrical drug supply units, where current is passed through an electrical resistance element.
- heating of the substrate may be accomplished by passing current through a thin metallic substrate, or through electrically conductive traces formed on the surface of a polymeric substrate (as described above).
- other types of heating methods known in the art may be used.
- heating of the substrate may be accomplished using optical, radiative, convection, or chemical energy sources.
- the substrate for use in the heating unit of the invention can either be an exterior surface of a heating unit itself, or can be a separate material operatively associated with the heating unit (e.g., in direct contact with or in proximity to the exterior surface of the heating unit).
- the minimum temperature required for volatilization of the drug and, thus, the maximum allowable spacing between the substrate and the heating unit will, of course, vary with the particular drug, among other factors.
- the perforated substrate can be of virtually any geometry, but is most typically square or rectangular in shape.
- the perforated substrate of the drug supply unit illustrated in FIG. 1A is shown as having a substantially planar geometry, having an upper surface 134 (upon which drug composition 138 has been deposited) and lower surface 136 . “Across” air flow is directed over the surface on which the drug composition has been deposited (e.g., parallel to and in the same plane as upper surface 134 ) while “bottom” air flow is directed through holes 132 , from lower surface 136 to upper surface 134 .
- FIG. 1B is a perspective, cut-away view of an alternative geometry of the aerosol delivery article.
- Article 140 is comprised of a hollow, cylindrically-shaped substrate 142 formed from a heat-conductive material.
- Substrate 142 has a perforated exterior surface 144 .
- Drug composition (not shown) is deposited on the exterior surface 144 .
- the substrate of the aerosol delivery article is heated to vaporize all or a portion of the drug film.
- “across” air flow is directed over exterior surface 144 of the substrate and “bottom” air flow is directed through the holes in substrate 142 , from the hollow interior of substrate 142 to the exterior surface 144 .
- the substrate is typically heated to a temperature of at least about 150° C., preferably of at least about 250° C., more preferably at least about 300° C. or 350° C. Heating the substrate produces a thermal vapor that in the presence of the flowing gas (both across and through the substrate) generates aerosol particles.
- the drug supply unit can further comprise a heating element for supplying heat to the substrate to produce a substrate temperature greater than 150° C. and to volatilize all or a portion of the drug composition film from the substrate.
- the temperature is sufficient to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less, more preferably in less than 1 second, still more preferably in less than 500 milliseconds, and most preferably in less than 200 milliseconds.
- the substrate surface is partially cut-away in the figure to expose a heating element 146 disposed in interior of substrate 142 .
- the substrate can be hollow with a heating element inserted into the hollow space.
- the heating element in the embodiment shown takes the form of an electrical resistive wire that produces heat when a current flows through the wire.
- Other heating elements are suitable, including but not limited to a solid chemical fuel, chemical components that undergo an exothermic reaction, inductive heat, etc. Heating of the substrate by conductive heating is also suitable.
- the optimal means of heating may vary depending on the choice of substrate material.
- a preferred means of heating typically is electrical resistive heating.
- a preferential means to vaporize the drug composition on the substrate surface typically is by conductive means, i.e., by bringing the aluminum in contact with a heat source (e.g., a halogen bulb), rather than electrical resistance means, due to the higher thermal conductivity and higher electrical conductivity of aluminum relative to stainless steel.
- the aerosol delivery article comprises a drug composition deposited on the substrate, typically as a film or coating. As shown in FIG. 1A , deposited on all or a portion of the upper surface 134 of the substrate is a film 138 of the drug composition.
- the drug composition can consist of two or more drugs. Preferably, however, the drug composition comprises pure drug.
- the drug composition is deposited on the substrate by coating the drug composition as film.
- the film can be of varying thickness depending on the compound and the maximum amount of thermal degradation that can be tolerated.
- the film has a thickness less than 50 micron, and generally the film has a thickness in the range from 0.05 to 20 microns. More typically, the film has a thickness in the range from 0.1 to 15 microns, from 0.2 to 10 microns, or from 1 to 5 microns.
- Drug composition deposition is achieved by a variety of methods, depending in part on the physical properties of the drug and on the desired drug film thickness. Exemplary methods include, but are not limited to, preparing a solution of drug in solvent, applying the solution to the exterior surface and removing the solvent to leave a film of drug. The drug solution can be applied by dipping the substrate into the solution, spraying, brushing, or otherwise applying the solution to the substrate. Alternatively, a melt of the drug can be prepared and applied to the substrate. For drugs that are liquids at room temperature, thickening agents can be admixed with the drug to permit application of a solid drug film. Examples of drug film deposition on a variety of substrates are given below.
- the drug composition films used in the Examples were formed by applying a solution containing the drug onto the substrate.
- a solution of the drug in a solvent was prepared.
- solvents can be used and selection is based, in part, on the solubility properties of the drug and the desired solution concentration. Common solvent choices included methanol, acetone, chloroform, dichloromethane, other volatile organic solvents, dimethylformamide, water, and solvent mixtures.
- the drug solutions were applied to the substrates by spray coating, yet other methods such as dip coating are contemplated as well.
- a substrate containing a drug film of a certain thickness was prepared. To determine the thickness of the drug film deposited on the substrate, one method that can be used is to determine the area of the substrate and calculate drug film thickness using the following relationship:
- film thickness (cm) drug mass (g)/[drug density (g/cm 3 ) ⁇ substrate area (cm 2 )]
- the drug mass can be determined by weighing the substrate before and after formation of the drug film or by extracting the drug and measuring the amount analytically.
- Drug density can be experimentally determined by a variety of techniques known by those of skill in the art or found in the literature or in reference texts, such as in the CRC. An assumption of unit density is acceptable if an actual drug density is not known.
- the film thickness can be measured directly by techniques known by those of skill in the art, such as, for example, optical reflectometry, beta backscattering, SEM, etc.
- purity As used herein, with respect to the aerosol purity, means [the fraction of drug composition in the aerosol]/[the fraction of drug composition in the aerosol plus drug degradation products]. Thus purity is relative with regard to the purity of the starting material.
- the reported purity of the aerosol does not include those impurities present in the starting material that were also found in the aerosol, e.g., in certain cases if the starting material contained a 1% impurity and the aerosol was found to contain the identical 1% impurity, the aerosol purity may nevertheless be reported as >99% pure, reflecting the fact that the detectable 1% purity was not produced during the vaporization-condensation aerosol generation process.
- the aerosol is collected in a trap, such as a filter, glass wool, an impinger, a solvent trap, or a cold trap, with collection in a filter particularly preferred.
- the trap is then typically extracted with a solvent, e.g. acetonitrile, and the extract subjected to analysis by any of a variety of analytical methods known in the art, with gas and liquid chromatography preferred methods, and high performance liquid chromatography particularly preferred.
- the gas or liquid chromatography method includes a detector system, such as a mass spectrometry detector or ultraviolet absorption detector. Ideally, the detector system allows determination of the quantity of the components of the drug composition and drug degradation product by weight.
- the substrate surface area is typically such that a therapeutic dose of the drug aerosol is delivered in a single use of the device when used by a subject such that dose titration by the patient to deliver a minimum effective dose is possible.
- the yield from a single dose may be determined by collecting the thermal vapor evolved upon actuation of the device or assembly and analyzing its composition as described herein, and comparing the results of analysis of the thermal vapor to those of a series of reference standards containing known amounts of the drug.
- the amount of drug or drugs required in the starting composition for delivery as a thermal vapor depends on the amount of drug or drugs entering the thermal vapor phase when heated (i.e., the dose produced by the starting drug or drugs), the bioavailability of the thermal vapor phase drug or drugs, the volume of patient inhalation, and the potency of the thermal vapor drug or drugs as a function of plasma drug concentration.
- the bioavailability of thermal vapors ranges from 20-100% and is preferably in the range of 50-100% relative to the bioavailability of drugs infused intravenously.
- the potency of the thermal vapor drug or drugs per unit plasma drug concentration is preferably equal to or greater than that of the drug or drugs delivered by other routes of administration. It may substantially exceed that of oral, intramuscular, or other routes of administration in cases where the clinical effect is related to the rate of rise in plasma drug concentration more strongly than the absolute plasma drug concentration.
- the effective human therapeutic dose of that drug in thermal vapor form is generally less than the standard oral dose. Preferably it will be less than 80%, more preferably less than 40%, and most preferably less than 20% of the standard oral dose.
- the drug dose in a thermal vapor will generally be similar to or less than the standard intravenous dose. Preferably it will be less than 200%, more preferably less than 100%, and most preferably less than 50% of the standard intravenous dose.
- Determination of the appropriate dose of thermal vapor to be used to treat a particular condition can be performed via animal experiments and a dose-finding (Phase I/II) clinical trial.
- Preferred animal experiments involve measuring plasma drug concentrations after exposure of the test animal to the drug thermal vapor. These experiments may also be used to evaluate possible pulmonary toxicity of the thermal vapor. Because accurate extrapolation of these results to humans is facilitated if the test animal has a respiratory system similar to humans, mammals such as dogs or primates are a preferred group of test animals. Conducting such experiments in mammals also allows for monitoring of behavioral or physiological responses in mammals.
- Initial dose levels for testing in humans will generally be less than or equal to the least of the following: current standard intravenous dose, current standard oral dose, dose at which a physiological or behavioral response was obtained in the mammal experiments, and dose in the mammal model which resulted in plasma drug levels associated with a therapeutic effect of drug in humans. Dose escalation may then be performed in humans, until either an optimal therapeutic response is obtained or dose-limiting toxicity is encountered.
- the actual effective amount of drug for a particular patient can vary according to the specific drug or combination thereof being utilized, the particular composition formulated, the mode of administration and the age, weight, and condition of the patient and severity of the episode being treated.
- the amount of drug that is required to provide a therapeutic dose is generally known in the art or can be determined as discussed above.
- the amount of drug that is required to provide a therapeutic dose is generally known in the art or can be determined as discussed above.
- the required dosage, discussed above, and the determined film thickness of the instant methods dictate the minimum required substrate area in accordance with the following relationship:
- drug density can be determined experimentally or from the literature, or if unknown, can be assumed to be 1 g/cc.
- the minimum substrate surface area is determined using the relationships described above to determine a substrate area for a determined film thickness (according to the methods of the instant invention) that will yield a therapeutic dose of drug aerosol.
- the actual dose of drug delivered i.e., the percent yield or percent emitted, from the drug-supply article will depend on, along with other factors, the percent of drug film that is vaporized upon heating the substrate.
- the relationship between dose, thickness, and area given above correlates directly to the dose provided to the user.
- adjustments in the substrate area can be made as needed to provide the desired dose.
- larger substrate areas other than the minimum calculated area for a particular film thickness can be used to deliver a therapeutically effective dose of the drug.
- the film need not coat the complete surface area if a selected surface area exceeds the minimum required for delivering a therapeutic dose from a selected film thickness.
- Also disclosed herein is a method of producing a drug-containing condensation aerosol comprising providing a substrate having the drug deposited on its surface, wherein the surface of the substrate has a plurality of holes formed therein.
- the substrate is heated to a temperature sufficient to vaporize the drug while simultaneously providing an air flow across the substrate and through the substrate via the plurality of holes.
- the drug is preferably heated to a temperature and for a duration that results in an acceptably low level of decomposition.
- the vaporized drug is preferably rapidly mixed into the air flow to cool and preclude additional decomposition of the drug.
- the vaporized drug is then allowed to condense into an aerosol comprising particles.
- air air flow
- gas gas
- ambient air any other appropriate (i.e., physiologically acceptable, non-explosive) gases, including compressed gases.
- the device of the invention could be attached to a separate tank of compressed gas that blows air or another suitable gas up through the perforations in the substrate concurrently with heating of the substrate.
- the aerosolized drug preferably has a purity level of at least 90%; more preferably, at least 95%; more preferably, at least 96%; more preferably, at least 97%.
- pure refers to an aerosolized drug that contains no thermal degradation products, excipients, or other contaminants.
- an aerosolized drug that is at least 97% pure contains less than 3% of thermal degradation products, excipients, or other contaminants.
- thermal degradation product means any byproduct which results from heating the drug.
- the aerosol is preferably characterized by less than 10% by weight of a thermal degradation product, more preferably, less than 5%, more preferably, less than 1%, more preferably, less than 0.5%, more preferably, less than 0.1%, or, more preferably, less than 0.03% by weight of a thermal degradation product.
- the substrate can comprise an electrically resistive material such as a foil.
- the substrate can be a stainless steel foil and can include a layer of one or more materials such as a gold layer to facilitate, for example, forming an electrical connection, and/or modifying the electrical properties such as the resistance of a portion of the foil.
- the appropriate dimensions for a substrate can depend at least in part, on the desired resistance, the amount of drug disposed on the substrate, the amount of energy needed to vaporize the drug disposed on the substrate, and/or on mechanical stability considerations.
- a drug supply unit 130 having a heat-conductive substrate 108 comprising a plurality of holes 132 extending therethrough.
- a composition coating 134 is at least a portion of the upper surface 134 .
- FIG. 1B provides a perspective, cut-away view of another embodiment of drug supply unit 140 .
- the drug supply unit comprises a cylindrical substrate 142 .
- This substrate may be formed from a heat-conductive material, for example.
- the substrate 142 includes a plurality of holes 144 extending therethrough.
- a thin layer of a drug (not shown) for aerosolization is coated onto external surface 142 .
- the substrate 142 can be hollow with a heating element inserted into the hollow space, or solid with a heating element incorporated into the substrate. “Bottom” gas flow into the hollow space passes through the substrate via the plurality of holes while “across” gas flow passes over the external surface of substrate 142 .
- the illustrative heating element 146 shown in FIG. 1B is shown as an electrical resistive wire that produces heat when a current flows through it, but as noted above, a number of different heating methods and corresponding devices are acceptable.
- acceptable heat sources can supply heat to the drug supply unit at rates that rapidly achieve a temperature sufficient to completely vaporize the composition from the support surface.
- heat sources that achieve a temperature of 200° C. to 500° C. or more within a period of 2 seconds or less are typical, although it should be appreciated that the temperature chosen will be dependent upon the vaporization properties of the composition, but typically the vaporization temperature will be at least about 200° C.; preferably, at least about 250° C.; more preferably, at least about 300° C. or 350° C.
- Heating the substrate 142 produces a drug composition vapor that in the presence of a flowing gas generates aerosol particles in the desired size range.
- the presence of the gas flow is generally prior to, simultaneous with, or subsequent to heating the substrate.
- the substrate is heated for a period of less than about 1 second, and more preferably for less than about 500 milliseconds, still more preferably for less than about 200 milliseconds.
- the drug aerosol particles are inhaled by a subject for delivery to the lung.
- FIG. 1C is a perspective view of an embodiment drug delivery device 150 that incorporates an embodiment of the drug supply unit of the invention.
- Housing 152 comprises a first air inlet 154 and a second air inlet 156 , which lead, respectively, to first airway 164 and second airway 166 .
- Substrate 158 is disposed between first airway 164 and second airway 166 .
- Substrate 158 includes a plurality of holes (not shown) fluidly connecting first airway 164 and second airway 166 .
- a drug for aerosolization (not shown) is disposed on a portion of the surface of substrate 158 in communication with first airway 164 .
- first airflow 174 in first airway 164 When a user places the device 150 in his/her mouth and inhales a breath through tapered mouthpiece 160 , air flows through inlets 156 and 158 , establishing a first airflow 174 in first airway 164 , and a second airflow 176 in second airway 166 , such that second airflow 176 passes from second airway 166 to first airway 164 through the holes in substrate 158 .
- the combined first air flow 174 and second airflow 176 carry the aerosol to the subject through mouthpiece/outlet 160 .
- the devices described herein may additionally contain a variety of components to facilitate aerosol delivery.
- the device may include any component known in the art to control the timing of drug aerosolization relative to inhalation (e.g., breath-actuation).
- the device may include a component to provide feedback to patients on the rate and/or volume of inhalation, or a component to prevent excessive use (i.e., “lockout” feature).
- the device may further include a component to prevent use by unauthorized individuals, and a component to record dosing histories. These components may be used alone, or in combination with other components.
- the element that allows cooling may be of any configuration.
- it may be an inert passageway linking the heating means to the inhalation means.
- the element permitting inhalation by a user may be of any configuration.
- it may be an exit portal that forms a connection between the cooling element and the user's respiratory system.
- the device as shown has apertures that control the gas flow ratio.
- the across air flow or bottom air flow may be regulated by a gas-flow control valve(s) disposed upstream of the solid support.
- the gas-flow valve(s) may, for example, include an inlet port communicating with the chamber, and a deformable flap adapted to divert or restrict airflow away from the port increasingly, with increasing pressure drop across the valve.
- the gas-flow valve may include an actuation switch. In this variation, the valve movement would be in response to an air pressure differential across the valve, which for example, could function to close the switch.
- the gas-flow valve may also include an orifice designed to limit the rate of airflow into the chamber.
- the device may also include a bypass valve communicating with the chamber downstream of the unit for offsetting the decrease in airflow produced by the gas-flow control valve, as the user draws air into the chamber.
- the bypass valve could cooperate with the gas-control valve to control the flow through the condensation region of the chamber as well as the total amount of air being drawn through the device.
- the total volumetric airflow through the device in this variation would be the sum of the volumetric airflow rate through the gas-control valve and the volumetric airflow rate through the bypass valve.
- compositions described herein typically comprise at least one drug compound.
- the drug compositions may comprise other compounds as well.
- the composition may comprise a mixture of drug compounds, a mixture of a drug compound and a pharmaceutically acceptable excipient, or a mixture of a drug compound with other compounds having useful or desirable properties.
- the composition may comprise a pure drug compound as well.
- the composition consists essentially of pure drug and contains no propellants or solvents.
- Drugs that can be used include, for example but not limitation, those listed in U.S. Pat. No. 7,090,830.
- the drugs of use in the invention have a molecular weight in the range of about 150-700, preferably in the range of about 200-700, more preferably in the range of 250-600, still more preferably in the range of about 250-500. In some variations, the drugs have a molecular weight in the range 350-600 and in others the drugs have a molecular weight in the range of about 300-450. In other variations, where the drug is a heat stable drug, the drug can have a molecular weight of 350 or greater.
- the compound is in its ester, free acid, or free-base form.
- the compound will be vaporizable from its salt form.
- a variety of pharmaceutically acceptable salts are suitable for aerosolization.
- Illustrative salts include, without limitation, the following: hydrochloric acid, hydrobromic acid, acetic acid, maleic acid, formic acid, and fumaric acid salts. Salt forms can be purchased commercially, or can be obtained from their corresponding free acid or free base forms using methods well-known in the art.
- Suitable pharmaceutically acceptable excipients may be volatile or nonvolatile. Volatile excipients, when heated, are concurrently volatilized, aerosolized and inhaled with the drug. Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents. The following is a list of exemplary carriers within these classes: water; terpenes, such as menthol; alcohols, such as ethanol, propylene glycol, glycerol and other similar alcohols; dimethylformamide; dimethylacetamide; wax; supercritical carbon dioxide; dry ice; and mixtures thereof.
- compositions may be included in the composition.
- examples of such materials are known in the art.
- the aerosols are substantially free of organic solvents and propellants. Additionally, water is typically not added as a solvent for the drug, although water from the atmosphere may be incorporated in the aerosol during formation, in particular, while passing air over the film and during the cooling process. In other variations, the aerosols are completely devoid of organic solvents and propellants. In yet other variations, the aerosols are completely devoid of organic solvents, propellants, and any excipients. These aerosols comprise only pure drug, less than 10% drug degradation products, and a carrier gas, which is typically air.
- the drug has a decomposition index less than 0.15.
- the drug has a decomposition index less than 0.10. More preferably, the drug has a decomposition index less than 0.05. Most preferably, the drug has a decomposition index less than 0.025
- the condensation aerosol comprises at least 5% by weight of condensation drug aerosol particles. In other variations, the aerosol comprises at least 10%, 20%, 30%, 40%, 50%, 60%, or 75% by weight of condensation drug aerosol particles. In still other variations, the aerosol comprises at least 95%, 99%, or 99.5% by weight of condensation aerosol particles.
- the condensation aerosol particles comprise less than 10% by weight of a thermal degradation product. In other variations, the condensation drug aerosol particles comprise less than 5%, 1%, 0.5%, 0.1%, or 0.03% by weight of a thermal degradation product.
- the drug aerosol has a purity of between 90% and 99.8%, or between 93% and 99.7%, or between 95% and 99.5%, or between 96.5% and 99.2%.
- the aerosol has a number concentration greater than 10 6 particles/mL. In other variations, the aerosol has a number concentration greater than 10 7 particles/mL. In yet other variations, the aerosol has a number concentration greater than 10 8 particles/mL, greater than 10 9 particles/mL, greater than 10 10 particles/mL, or greater than 10 11 particles/mL.
- the gas in which the aerosol particles are suspended is typically air. It is contemplated, however, that other gases, in particular inert gases, such as argon, nitrogen, helium, and the like, also may be used.
- the gas can also include vapor of the composition that has not yet condensed to form particles.
- the gas does not include propellants or vaporized organic solvents.
- the condensation aerosol comprises at least 5% by weight of condensation drug aerosol particles. In other variations, the aerosol comprises at least 10%, 20%, 30%, 40%, 50%, 60%, or 75% by weight of condensation drug aerosol particles. In still other variations, the aerosol comprises at least 95%, 99%, or 99.5% by weight of condensation aerosol particles.
- the condensation drug aerosol has an MMAD in the range of about 1-3 ⁇ m. In some variations the geometric standard deviation around the MMAD of the condensation drug aerosol particles is less than 3.0. In other variations, the geometric standard deviation around the MMAD of the condensation drug aerosol particles is less than 2.5, or less than 2.0.
- FIG. 4A is a schematic of an embodiment of the substrate screening apparatus 400 .
- FIG. 4B is a cross-sectional view of the substrate screening apparatus 400 .
- the substrate screening apparatus 400 is made of a machined plastic (polyoxymethylene, DELRIN® Acetal Resin, DuPont, Wilmington, Del.) block 402 with a 2 cm 2 cross-sectional area for mounting a substrate 412 .
- Block 402 includes a first airway 404 extending from first inlet 414 to outlet 422 .
- Block 402 also include a second airway 406 extending from second inlet 416 to substrate 412 , where it typically joins the first airway.
- the substrate 412 is mounted in the substrate screening apparatus 400 across two electrodes 420 .
- a first air flow 414 is established in first airway 404 and a second air flow 416 is established in second airway 406 such that the second air flow 416 passes from the second airway 406 to first airway 404 through holes in the substrate 412 .
- the substrate 412 is heated, typically by discharging a capacitor (not shown) across the substrate 412 .
- the flow of air passing through holes in the substrate 412 is in a direction orthogonal to that of air flow 414 .
- Substrate 412 is coated with a drug composition film. The substrate 412 is heated to vaporized all or a portion of the drug composition. The vaporized drug subsequently cools and condenses to form a condensation aerosol that is carried to the outlet by air flow 414 , joined by air flow 416 ). Accordingly, the condensation aerosol is emitted from the outlet 422 .
- FIG. 6 shows a magnification of a representative test substrate 600 , having regularly spaced, circular holes formed in the stainless steel sheet. The distance between the edge of one hole to the edge of an adjacent hole is indicated as “d” on FIG. 6 . The distance “d” is also referred to herein as “hole spacing” or “spacing between holes.”
- % porosity refers to the percentage of the nominal total surface area of the substrate (i.e., the surface area if there were no holes) that is occupied by the holes. Thus, a rectangular substrate measuring 0.5 in. ⁇ 3 in. would have a nominal total surface area of 1.5 in 2 . If the substrate had 400 circular holes having a diameter of 0.01 square inch, it would have a porosity of approximately 2.1%.
- test substrates were meticulously cleaned to remove any contamination from previous processing by ultrasonication in a 60° C., 6.5% Ridoline bath for 5 minutes followed by ultrasonication in a reverse-osmosis deionized (RODI) water bath at 40° C. for 1 minute followed by a 3-cycle dump rinse using RODI.
- RODI reverse-osmosis deionized
- the test substrates were dipped in an isopropanol bath and transferred to a 40° C. drying oven for solvent removal.
- Some test substrates were also subjected to heat oxidation step, performed by laying the stainless steel substrates on a sheet of aluminum foil and placing them in an oven at 350° C. for 6 hours. These “heat passivated” substrates were then re-cleaned as described above.
- test substrates were then coated with a drug composition.
- the drug was typically dissolved in a volatile organic solvent (e.g., dichloromethane/methanol mixture or acetone or other suitable organic solvent) and then spray-coated onto the test substrates using an automated spray coater.
- Coating parameters such as the drug concentration in the coating solution, solution flow rate, were selected to obtain a uniform drug coating of the desired coating density (i.e., mass/area).
- ⁇ is the thickness of the drug coating
- SA is the surface area of the drug coating
- ⁇ is the density of the drug.
- the density was generally assumed to be 1.0 g/cm 3 unless a different literature value was known. Therefore, 1 mg deposited over an area of 5 cm 2 results in a nominal coating thickness of 2 ⁇ m.
- the coating thickness is most easily varied by either altering the drug concentration in the coating solution and/or the flow rate.
- Total air flow through the substrate screening apparatus was set by providing air flows 414 and 416 at a desired ratio. (As used herein, “across” air flow refers to air flow 414 and “bottom” air flow refers to air flow 416 .) Brass electrodes 420 attached to the substrate screening apparatus 400 were used to clamp the substrate 412 in place and provide electrical connections. For most experiments, a 1-Farad capacitor was used as the energy source. The capacitor was typically charged to 11-14 volts, depending on the desired substrate temperature. A high current relay was used to connect the circuit and discharge the capacitor across the substrate to induce heating and vaporization of the drug.
- FIG. 5 is a schematic of another embodiment of a substrate screening apparatus 500 that was used to direct air flow through the holes of coated polyimide film (KAPTON® polyimide film) substrates (see FIGS. 2A and 2B ).
- Substrate screening apparatus 500 is similar in configuration and operation to substrate screening apparatus 400 , with the exception that substrate screening apparatus 500 includes two electrodes 502 on the same side of the screening apparatus 500 , whereas substrate screening apparatus 400 includes two electrodes 420 on opposite sides of the screening apparatus 400 .
- a polyimide film substrate coated with a drug composition was placed in substrate screening apparatus 500 across electrodes 502 .
- a computer-controlled power supply was connected to the electrodes. The power supply was typically capable of heating the polyimide film substrate to the target temperature within 300 milliseconds, and the substrate was kept at the target temperature for a duration of 1 second.
- a 2 ⁇ m Teflon filter (ZEFLUOR PTFE filters, available from Zefon International, Inc., Ocala, Fla.) was placed immediately downstream from the screening apparatus during aerosol generation. After the aerosol was collected from the air stream, the filter was removed, extracted with a known volume of HPLC-grade methanol, and analyzed for both drug content and purity. The “used” test substrate was also extracted for residual drug, and the airway of the screening apparatus was swabbed for determination of the amount of aerosol deposition within the apparatus.
- ZVFLUOR PTFE filters available from Zefon International, Inc., Ocala, Fla.
- the filter extracts were analyzed by HPLC using a C-18 reverse phase column (4.6 mm ID ⁇ 150 mm length, 5 ⁇ m packing, Capcell Pak UG120, available from Shiseido Fine Chemicals, Tokyo, Japan) eluted with (1) water/0.1% trifluoroacetic acid and (2) acetonitrile/0.1% trifluoroacetic acid at a flow rate of 1 mL/minute with a linear gradient over 24 minutes and a total run time of 36 minutes.
- Detection was from 200-400 nm using a photodiode array detector. Purity was calculated by measuring peak areas from the chromatogram obtained at 225 nm. Confirmatory purity evaluations were additionally performed by inspection of the full 200-400 nm wavelength range.
- a portion of the filter extracts is analyzed by HPLC with mass spectrometric detection. Analyses by these alternate methods yielded similar purity results when compared to the primary HPLC analysis.
- An Anderson Cascade Impactor (ACI), an inertial impaction size separating device, was used to determine the particle size distribution of the aerosol.
- the ACI consists of several stages, with each successive stage having a smaller size cutoff. By extracting and determining the mass of drug deposited at each stage, it is possible to estimate the particle size distribution of the aerosol.
- the ACI was placed immediately downstream from the screening apparatus. Again, the airway and substrate were extracted to determine the mass balance for each actuation of the device.
- Loperamide and flunisolide condensation aerosols were produced by the substrate screening apparatus using 304 stainless steel perforated substrates having the % porosities, hole spacings, and hole diameters shown in Table 1.
- the substrates were spray-coated with loperamide free base or flunisolide free base at coating densities of 0.3 mg/cm 2 and 0.4 mg/cm 2 , respectively.
- Air flow ratios (across:bottom) of 23:5 and 18:10 were evaluated.
- the substrate was rapidly heated to approximately 400° C. for loperamide and approximately 375° C. for flunisolide.
- Aerosol purity results for loperamide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 23:5 are presented in Table 2.
- Aerosol purity results for loperamide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 18:10 are presented in Table 3.
- Aerosol purity results for flunisolide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 23:5 are presented in Table 4.
- Aerosol purity results for flunisolide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 18:10 are presented in Table 5.
- Sildenafil aerosols were produced by the substrate screening apparatus using 0.005′′ thick 316 stainless steel substrates having a regular staggered pattern of circular, 0.006′′ diameter holes.
- the distance “d” between the holes was 3.5 ⁇ 10 ⁇ 3 in.
- the substrates were spray-coated with a 15 mg/mL solution of sildenafil free base (isolated from pills, available from Pfizer, Inc., New York, N.Y.) dissolved in dichloromethane/methanol (2:1 volume:volume) at coating densities of 0.18, 0.50, and 1.07 mg/cm 2 (approximate coating thicknesses: 1.8, 5.0, and 10.7 ⁇ m).
- Total (across+bottom) air flow rate was 28.3 liters/minute.
- Various airflow ratios and vaporization temperatures were evaluated.
- FIG. 7 is a bar graph 700 showing aerosol purity (%) and yield (%) 702 for a sildenafil coating density of 0.18 mg/cm 2 at various air flow ratio conditions 704 at 400° C. and 360° C. (last set of data).
- the highest aerosol purity and yield were obtained when 90% of the air flow was directed from under the bottom (uncoated side) of the substrate (refer to FIG. 2B ), and 10% from across the substrate.
- Sildenafil aerosols were produced by the substrate screening apparatus using the perforated 316 stainless steel substrates described above and a solid (i.e., non-perforated) 304 stainless steel substrate.
- the substrates were spray-coated with a 15 mg/mL solution of sildenafil free base (isolated from pills, available from Pfizer, Inc., New York, N.Y.) dissolved in dichloromethane/methanol (2:1 volume:volume) at various drug coating densities.
- Total (across+bottom) air flow rate was 28.3 liters/minute.
- Various airflow ratios were evaluated.
- FIG. 8 is a plot 800 showing aerosol purity (%) 802 of sildenafil free base as a function of drug coating thickness 804 .
- Curve 806 represents aerosol purity for the perforated substrates;
- curve 808 represents aerosol purity for the solid substrates.
- aerosol purity levels 97% or more were obtained with drug coating thicknesses up to 6 ⁇ m.
- drug coating thicknesses greater than about 1 ⁇ m resulted in aerosol purity levels below 97%.
- aerosol purity levels decreased to 94% and below.
- Bumetanide condensation aerosols were produced by the substrate screening apparatus using the perforated 316 stainless steel substrates described above.
- the substrates were spray-coated with a 50 mg/mL solution of bumetanide free base (available from Solmag S.p.A., Garbagnate, Italy) dissolved in methanol/acetone (50:50 volume:volume) at a coating density of 0.07 mg/cm 2 (approximate coating thickness: 0.7 ⁇ m).
- Total air flow rate was 20 liters/minute.
- FIG. 9 is a bar graph 900 showing aerosol purity (%) 902 of bumetanide free base at various air flow ratios 904 .
- aerosol purity level decreased as the percentage of air flow coming across (as opposed to from under the bottom, uncoated side) the substrate increased.
- aerosol purity level remained at 98% when as little as 5% of the air flow was coming through the substrate.
- the aerosol purity of bumetanide aerosolized from heat-oxidized, perforated 316 stainless steel substrates was measured as a function of both drug coating density and air flow ratio. Drug coating densities of 0.07, 0.10, and 0.14 mg/cm 2 were tested, at across:bottom air flow ratios of 0:100, 50:50, and 100:0. Total air flow rate was 20 liters/minute.
- the emitted drug dose was calculated using the following equation:
- FIG. 10 is a plot 1000 showing aerosol purity (%) 1002 of bumetanide free base as a function of drug coating density 1004 .
- the data shown in Tables 7 and 8 and FIG. 10 corroborate the results shown in FIG. 9 , where greater aerosol purities were observed as a greater proportion of the air flow was directed through the substrate.
- Drug coating density was approximately 0.07 mg/cm 2 .
- Total air flow rate was 28.3 liters/minute.
- the particle size (MMAD) tended to decrease as the proportion of the air flow coming through the substrate (as opposed to across the substrate) was increased, allowing the aerosolized drug particle size to be tuned to a desired range by simply varying the across:bottom air flow ratio.
- the very small drug particle size obtained at the 0:100 across:bottom air flow ratio may indicate that there was substantially more dilution of the vaporized drug compound into the airstream than with the conventional (100% across) air flow arrangement.
- MMAD mass median aerodynamic diameter
- SD standard deviation
- FIG. 11 is a plot 1100 of average MMAD 902 as a function of air flow ratio (across:bottom) 1104 .
- Curves 1106 , 1108 , and 1110 represent drug coating densities of 0.08, 0.26, and 0.58 mg/cm 2 , respectively.
- Vardenafil condensation aerosols were produced by the substrate screening apparatus using perforated stainless steel substrates.
- the substrates were spray-coated with a 20 mg/mL solution of vardenafil free base (isolated from the HCl trihydrate salt available from Bosche Scientic, LLC, New Brunswick, N.J.) in dichloromethane/methanol (3:1 volume:volume) at drug coating densities of 0.112, 0.334, and 0.883 mg/cm 2 (approximate coating thickness: 1.12, 3.34, and 8.83 ⁇ m).
- Total air flow rate was 28.3 liters/minute.
- Various airflow ratios and vaporization temperatures were evaluated.
- the 75:25 (across:bottom) air flow ratio produced good results in terms of both aerosol purity and drug yield for vardenafil aerosolized from a perforated 316 stainless steel substrate.
- both aerosol purity and yield were good with the 75:25 air flow ratio and a drug film thickness of less than 3.3 ⁇ m.
- substrate temperatures of 400° C. and 425° C. both aerosol purity and yield were very similar with either the 75:25 or 100:0 air flow ratios.
- Tadalafil condensation aerosols were produced by the substrate screening apparatus using perforated stainless steel substrates.
- the substrates were spray-coated with a 20 mg/mL solution of tadalafil free-base (isolated from the HCl trihydrate salt available from Bosch Scientific, LLC, New Brunswick, N.J.) in dichloromethane/methanol (3:1 volume:volume) at drug coating densities of 0.236, 0.604, and 1.17 mg/cm 2 (approximate coating thickness: 2.36, 6.04, and 11.7 Mm).
- Total air flow rate was 28.3 liters/minute.
- Various airflow ratios and vaporization temperatures were evaluated.
- the 75:25 (across:bottom) air flow ratio produced good results in terms of both aerosol purity and drug yield for tadalafil aerosolized from a perforated 316 stainless steel substrate.
- the 100:0 air flow ratio resulted in lower drug yields ( ⁇ 85%), even at substrate temperatures of 400° C.
- Substrate temperatures of 375° C. and 400° C. result in yields of about 80%.
- the 75:25 air flow ratio, at substrate temperatures of 375° C. and drug film thicknesses of 11.7 ⁇ m resulted in good drug yields and drug purities of about 96%.
- Fentanyl condensation aerosols were produced by the substrate screening apparatus using non-perforated polyimide film (KAPTON® polyimide film, available from DuPont, Wilmington, Del.).
- the substrates were spray-coated with fentanyl free base.
- FIG. 12 is a bar graph 1200 showing aerosol purity (%) 1202 of a fentanyl-coated polyimide film as a function of storage time 1204 at 40° C.
- the aerosol purity of fentanyl coated onto polyimide film remained very high ( ⁇ 99.7%) after 90 weeks storage.
- Prochlorperazine condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film (KAPTON® polyimide film, available from DuPont, Wilmington, Del.). Copper heater traces were formed on one surface of a sheet of polyimide film. Holes were formed between the heater traces by chemical etching. The polyimide film heating units were spray-coated on the polyimide film surface with a 25 mg/mL solution of prochlorperazine free base (available from Industria Chimica Milanese, Milano, Italy) in acetone. Total air flow rate was 28.3 liters/minute. Various airflow ratios were evaluated.
- KAPTON® polyimide film available from DuPont, Wilmington, Del.
- Copper heater traces were formed on one surface of a sheet of polyimide film. Holes were formed between the heater traces by chemical etching.
- the polyimide film heating units were spray-coated on the polyimide film surface with a 25 mg/mL solution of pro
- FIG. 13 is a plot 1300 showing aerosol purity (%) 1302 of prochlorperazine at various drug coating thicknesses 1304 .
- Curves 1306 , 1308 , and 1310 represent across:bottom air flow ratios of 0:100, 90:10, and 100:0, respectively.
- curve 1312 represents aerosolization of prochlorperazine from a non-perforated 304 stainless steel substrate.
- Dotted line 1314 represents the coated aerosol purity.
- aerosol purity level As previously observed with aerosolization of various drugs from perforated stainless steel substrates, as the percentage of air flow coming from under the bottom side of the substrate increased, aerosol purity level also increased, and a greater drug coating thickness can be used. When 100% of the air flow came through the substrate, aerosol purity levels of 98% or greater were obtained up to at least 30 ⁇ m drug coating thickness.
- the coated aerosol purity was compared with the aerosol purity of prochlorperazine vaporized from polyimide film substrates having “small” and “large” holes (refer to FIGS. 2A and 2B ).
- Drug coating thickness was 14 ⁇ m; total air flow was set at 30 liters/minute. The data from this set of experiments are shown in Table 15, below.
- Adenosine condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates.
- the substrates were spray-coated with adenosine free base at various coating densities.
- Various airflow ratios and vaporization temperatures were evaluated.
- FIG. 14 is a plot 1400 showing aerosol purity (%) 1402 of aerosolized adenosine free base as a function of drug coating density (mg/cm 2 ) 1404 .
- Curves 1406 and 1408 represent an across:bottom air flow ratio of 3:1 (21:7 liters per minute) and vaporization temperatures of 375° C. and 350° C., respectively.
- Curves 1410 and 1412 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 375° C. and 350° C., respectively.
- Baclofen condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates.
- the substrates were spray-coated with baclofen free base at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 15 is a plot 1500 showing aerosol purity (%) 1502 of aerosolized baclofen free base as a function of drug coating density (mg/cm 2 ) 1504 .
- Curves 1506 and 1508 represent an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 330° C. and 350° C., respectively.
- Curves 1510 and 1512 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 330° C. and 350° C., respectively.
- Data points 1514 represent an across:bottom air flow ratio of 27:1 and a vaporization temperature of 350° C.
- Ciclesonide condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with ciclesonide free base at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 16 is a plot 1600 showing aerosol purity (%) 1602 of aerosolized ciclesonide free base as a function of drug coating density (mg/cm 2 ) 1604 .
- Curves 1606 , 1608 , 1610 , and 1612 show aerosol purity data for drug vaporized from perforated polyimide film substrates.
- Curves 1606 and 1608 represent an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 325° C. and 360° C., respectively.
- Curves 1610 and 1612 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 325° C. and 360° C., respectively.
- Curves 1614 and 1616 show aerosol purity data for drug vaporized from non-perforated heat-passivated 304 stainless steel substrates, with no air flow ratio (i.e., 100% of the air flow was directed across the substrate). Curves 1614 and 1616 represent vaporization temperatures of 320° C. and 350° C., respectively.
- Cyclobenzaprine fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates.
- the substrates were spray-coated with cyclobenzaprine fumarate at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 17 is a plot 1700 showing aerosol purity (%) 1702 of aerosolized cyclobenzaprine fumarate as a function of drug coating density (mg/cm 2 ) 1704 .
- Curve 1706 represents a drug coating control.
- Curve 1708 represents an across:bottom air flow ratio of 6:1 (24:4 LPM) and a vaporization temperature of 375° C.
- Curve 1710 represents an across:bottom air flow ratio of 3:1 (21:7 LPM) and a vaporization temperature of 350° C.
- Curve 1712 represents an across:bottom air flow ratio of 1:1 (14:14 LPM) and a vaporization temperature of 350° C.
- Diphenhydramine fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with diphenhydramine fumarate at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 18 is a plot 1800 showing aerosol purity (%) 1802 of aerosolized diphenhydramine fumarate as a function of drug coating density (mg/cm 2 ) 1804 .
- Curves 1806 , 1808 , 1810 , and 1812 show aerosol purity data for drug vaporized from perforated polyimide film substrates.
- Curves 1806 and 1808 represent an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 325° C. and 350° C., respectively.
- Curves 1810 and 1812 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 325° C. and 350° C., respectively.
- Curves 1814 and 1986 show aerosol purity data for drug vaporized from non-perforated heat-passivated 304 stainless steel substrates, with no air flow ratio (i.e., 100% of the air flow was directed across the substrate). Curves 1814 and 1816 represent vaporization temperatures of 350° C. and 400° C.
- Flunisolide condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates, perforated heat-passivated stainless steel substrates, and perforated SULFINERT-treated stainless steel substrates.
- SULFINERT is an amorphous silicon.
- the SULFINERT-treated stainless steel substrates were obtained from Restek Corp., Bellefonte, Pa.)
- the substrates were spray-coated with flunisolide free base at various coating densities. All samples were tested using an across:bottom air flow ratio of 3:1 (21:7 LPM). Various vaporization temperatures were evaluated.
- FIG. 19 is a plot 1900 showing aerosol purity (%) 1902 of aerosolized flunisolide free base as a function of drug coating density (mg/cm 2 ) 1904 .
- Curve 1906 represents a drug coating control.
- Curves 1908 and 1910 show aerosol purity data for drug vaporized from perforated heat-passivated 316 stainless steel substrates at vaporization temperatures of 325° C. and 375° C., respectively.
- Curves 1912 and 1914 show aerosol purity data for drug vaporized from perforated SULFINERT-treated 316 stainless steel substrates at vaporization temperatures of 325° C. and 375° C., respectively.
- Curves 1916 and 1918 show aerosol purity data for drug vaporized from perforated polyimide film substrates at vaporization temperatures of 350° C. and 375° C., respectively.
- Fluticasone propionate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with fluticasone propionate at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 20 is a plot 2000 showing aerosol purity (%) 2002 of aerosolized fluticasone propionate as a function of drug coating density (mg/cm 2 ) 2004 .
- Curves 2006 , 2008 , 2010 , and 2012 show aerosol purity data for drug vaporized from perforated polyimide film substrates.
- Curves 2006 and 2008 represent an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 325° C. and 350° C., respectively.
- Curves 2010 and 2012 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 325° C. and 350° C., respectively.
- Curves 2014 and 2016 show aerosol purity data for drug vaporized from non-perforated heat-passivated 304 stainless steel substrates, with no air flow ratio (i.e., 100% of the air flow was directed across the substrate). Curves 2014 and 2016 represent vaporization temperatures of 320° C. and 350° C., respectively.
- Mometasone fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates, non-perforated heat-passivated stainless steel substrates, and non-perforated SULFINATE-treated stainless steel substrates.
- the substrates were spray-coated with mometasone fumarate at various coating densities.
- the polyimide film samples were evaluated using an across:bottom air flow ratio of 3:1 (21:7 LPM).
- the stainless steel samples were evaluated with no air flow ratio.
- Various vaporization temperatures were evaluated.
- FIG. 21 is a plot 2100 showing aerosol purity (%) 2102 of aerosolized mometasone fumarate as a function of drug coating density (mg/cm 2 ) 2104 .
- Curves 2106 , 2108 , and 2110 show aerosol purity data for drug vaporized from perforated polyimide film substrates at vaporization temperatures of 280° C., 325° C., and 375° C., respectively.
- Data point 2112 shows aerosol purity data for drug vaporized from non-perforated SULFINERT-treated stainless steel 304 substrates at a vaporization temperature of 350° C.
- Data point 2114 shows aerosol purity data for drug vaporized from non-perforated heat-passivated stainless steel 304 substrates at a vaporization temperature of 350° C.
- Paroxetine fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with paroxetine fumarate at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 22 is a plot 2200 showing aerosol purity (%) 2202 of aerosolized paroxetine fumarate as a function of drug coating density (mg/cm 2 ) 2204 .
- Curves 2206 , 2208 , 2210 , and 2212 show aerosol purity data for drug vaporized from perforated polyimide film substrates.
- Curves 2206 and 2208 represent an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperature of 375° C. and 350° C., respectively.
- Curves 2210 and 2212 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 375° C. and 350° C., respectively.
- Curves 2214 and 2216 show aerosol purity data for drug vaporized from non-perforated heat-passivated 304 stainless steel substrates, with no air flow ratio (i.e., 100% of the air flow was directed across the substrate). Curves 2214 and 2216 represent vaporization temperatures of 320° C. and 400° C., respectively.
- Tadalafil condensation aerosols were produced by the substrate screening apparatus using perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with tadalafil free base at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 23 is a plot 2300 showing aerosol purity 2302 of aerosolized tadalafil free base as a function of drug coating density (mg/cm 2 ) 2304 .
- Curve 2306 represents a drug coating control.
- Curves 2308 , 2310 , 2312 , and 2314 represent an across:bottom air flow ratio of 1:0 (27:0 LPM) and vaporization temperatures of 325° C., 350° C., 375° C., and 400° C., respectively.
- Curves 2316 , 2318 , 2320 , and 2322 represent an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 325° C., 350° C., 375° C., and 400° C., respectively.
- Tizanadine condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates, non-perforated heat-passivated stainless steel substrates, and non-perforated non-passivated stainless steel substrates.
- the substrates were spray-coated with tizanadine free base at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 24 is a plot 2400 showing aerosol purity (%) 2402 of aerosolized tizanadine free base as a function of drug coating density (mg/cm 2 ) 2404 .
- Curve 2406 represents the drug coating control.
- Curves 2408 , 2410 , and 2412 show aerosol purity data for drug vaporized from non-perforated heat-passivated 304 stainless steel substrates, with no air flow ratio and vaporization temperatures of 320° C., 350° C., and 400° C., respectively.
- Curve 2414 shows aerosol purity data for drug vaporized from non-perforated non-passivated 304 stainless steel substrates, with no air flow ratio and a vaporization temperature of 400° C.
- Curves 2416 and 2418 show aerosol purity data for drug vaporized from perforated polyimide film substrates. Curves 2416 and 2418 represent across:bottom air flow ratios of 3:1 (21:7 LPM) and 1:3 (7:21 LPM), respectively, and a vaporization temperature of 350° C.
- both of the polyimide film samples showed excellent (>98%) aerosol purity, regardless of the air flow ratio.
- aerosol purity declined with increases in vaporization temperature and drug coating density.
- the non-passivated stainless steel substrates performed most poorly of all.
- Vardenafil condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with vardenafil free base at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 25 is a plot 2500 showing aerosol purity (%) 2502 of aerosolized vardenafil free base as a function of drug coating density (mg/cm 2 ) 2504 .
- Curve 2506 represents a drug coating control.
- Curves 2508 , 2510 , and 2512 show aerosol purity data for drug vaporized from perforated heat-passivated 316 stainless steel substrates, at an across:bottom air flow ratio of 1:0 and vaporization temperatures of 350° C., 400° C., and 425° C., respectively.
- Curves 2514 , 2516 , and 2518 show aerosol purity data for drug vaporized from perforated heat-passivated 316 stainless steel substrates, at an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 350° C., 400° C., and 425° C., respectively.
- Curves 2520 and 2522 show aerosol purity data for drug vaporized from perforated polyimide film substrates, at an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 350° C. and 375° C., respectively.
- Zaleplon condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates.
- the substrates were spray-coated with zaleplon free base at various coating densities.
- Various air flow ratios and vaporization temperatures were evaluated.
- FIG. 26 is a plot 2600 showing aerosol purity (%) 2602 of aerosolized zaleplon free base as a function of drug coating density (mg/cm 2 ) 2604 .
- Curve 2606 represents a drug coating control.
- Curves 2608 and 2610 show aerosol purity data for drug vaporized from perforated polyimide film substrates, at an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 380° C. and 420° C., respectively.
- Curves 2612 and 2614 show aerosol purity data for drug vaporized from non-perforated heat-passivated stainless steel substrates, with no air flow ratio and vaporization temperatures of 380° C. and 420° C., respectively.
- Drug is dissolved or suspended in a solvent (e.g., dichloromethane or methanol).
- a solvent e.g., dichloromethane or methanol.
- the solution or suspension is coated to about a 4 micron thickness on a stainless steel substrate of about 8 cm 2 surface area.
- the substrate may either be a standard stainless steel foil or a heat-passivated stainless steel foil.
- the substrate is heated to a temperature sufficient to generate a thermal vapor (generally ⁇ 350° C.) but at least to a temperature of 200° C. with an air flow typically of 20 L/min (1 m/s) passing over the film during heating.
- the heating is done in a volatilization chamber fitted with a trap (such as described in the Examples above).
- the resultant aerosol is analyzed for purity using the methods disclosed herein. If the resultant aerosol contains less than 10% drug degradation product, i.e., the TSR ⁇ 9, then the drug is a heat stable drug. If, however, at about 4 micron thickness, greater than 10% degradation is determined, the experiment is repeated at the same conditions, except that film thicknesses of about 1.5 microns, and of about 0.5 micron, respectively, are used. If a decrease in degradation products relative to the 4 micron thickness is seen at either of these thinner film thicknesses, a plot of film thickness versus purity is graphed and extrapolated out to a film thickness of 0.05 microns. The graph is used to determine if there exists a film thickness where the purity of the aerosol would be such that it contains less than 10% drug degradation products. If such a point exists on the graph, then the drug is defined as a heat stable drug.
- Drug (1 mg) is dissolved or suspended in a minimal amount of solvent (e.g., dichloromethane or methanol).
- solvent e.g., dichloromethane or methanol.
- the solution or suspension is pipetted onto the middle portion of a 3 cm by 3 cm piece of aluminum foil.
- the coated foil is wrapped around the end of a 11 ⁇ 2 cm diameter vial and secured with parafilm.
- a hot plate is preheated to approximately 300° C., and the vial is placed on it foil side down.
- the vial is left on the hotplate for 10 s after volatilization or decomposition has begun. After removal from the hotplate, the vial is allowed to cool to room temperature.
- the foil is removed, and the vial is extracted with dichloromethane followed by saturated aqueous NaHCO 3 .
- the organic and aqueous extracts are shaken together, separated, and the organic extract is dried over Na 2 SO 4 .
- An aliquot of the organic solution is removed and injected into a reverse-phase HPLC with detection by absorption of 225 nm light.
- a drug is preferred for aerosolization where the purity of the drug isolated by this method is greater than 85%.
- Such a drug has a decomposition index less than 0.15.
- the decomposition index is arrived at by subtracting the aerosol purity fraction (i.e., 0.85) from 1.
Abstract
Drug supply units are disclosed which comprise substrates having a plurality of holes formed therein.
Description
- This application claims the priority of earlier filed U.S. Provisional Application Ser. No. 60/894,116, filed Mar. 9, 2007. The entire content of that provisional application is expressly incorporated by reference herein.
- The present invention relates generally to drug supply units comprising a substrate having a plurality of holes. More particularly, embodiments of the invention relate to drug supply units intended to be used to vaporize a drug composition deposited on a surface of the substrate, drug delivery devices comprising such drug supply units, and methods of producing an aerosol using such drug delivery devices.
- Traditionally, inhalation therapy has played a relatively minor role in the administration of therapeutic agents when compared to more traditional drug administration routes of oral delivery and delivery via injection. Due to drawbacks associated with traditional routes of administration, including slow onset, poor patient compliance, inconvenience, and/or discomfort, alternative administration routes have been sought. Pulmonary delivery is one such alternative administration route which can offer several advantages over the more traditional routes. These advantages include rapid onset, the convenience of patient self-administration, the potential for reduced drug side-effects, the ease of delivery by inhalation, the elimination of needles, and the like. Many preclinical and clinical studies with inhaled compounds have demonstrated that efficacy can be achieved both within the lungs and systemically.
- However, despite such results, the role of inhalation therapy in the health care field has remained limited mainly to treatment of asthma, in part due to a set of problems unique to the development of inhalable drug formulations and their delivery modalities, especially formulations for, and delivery by, inhalation.
- Metered dose inhaler formulations involve a pressurized propellant, which is frequently a danger to the environment, and generally produces aerosol particle sizes undesirably large for systemic delivery by inhalation. Furthermore, the high speed at which the pressurized particles are released from metered dose inhalers makes the deposition of the particles undesirably dependent on the precise timing and rate of patient inhalation. Also, the metered dose inhaler itself tends to be inefficient because a portion of the dose is lost on the wall of the actuator, and due to the high speed of ejection of the aerosol from the nozzle, much of the drug impacts ballistically on the tongue, mouth, and throat, and never gets to the lung.
- While solving some of the problems with metered dose inhalers, dry powder formulations are prone to aggregation and low flowability phenomena which considerably diminish the efficiency of dry powder-based inhalation therapies. Such problems are particularly severe for dry powders having an aerosol particle size small enough to be optimal for deep lung delivery, as difficulty of particle dispersion increases as particle size decreases. Thus, excipients are needed to produce powders that can be dispersed. This mix of drug and excipient must be maintained in a dry atmosphere lest moisture cause agglomeration of the drug into larger particles. Additionally, it is well known that many dry powders expand as they are delivered to the patient's airways due to the high levels of moisture present in the lung.
- Liquid aerosol formations similarly involve non-drug constituents, i.e. the solvent, as well as preservatives to stabilize the drug in the solvent. Thus, all liquid aerosol devices must overcome the problems associated with formulation of the compound into a stable liquid. Liquid formulations must be prepared and stored under aseptic or sterile conditions since they can harbor microorganisms. This necessitates the use of preservatives or unit dose packaging. Additionally, solvents, detergents and other agents are used to stabilize the drug formulation. Moreover, the dispersion of liquids generally involves complex and cumbersome devices and is effective only for solutions with specific physical properties, e.g. viscosity. Such solutions cannot be produced for many drugs due to the solubility properties of the drug.
- Recently, devices and methods for generating aerosols via volatilization of the drug has been developed, which addresses many of these above mentioned problems. (See, e.g., Rabinowitz et al., U.S. Publication No's US 2003/0015190, Cross et al., U.S. Publication No. 2005/0268911; Hale et al., U.S. Pat. No. 7,090,830, each incorporated by reference in its entirety). These devices and methods eliminate the need for excipients to improve flowability and prevent aggregation, solvents or propellants to disperse the compound, solution stabilizers, compound solubility, etc. and hence, the associated problems with these added materials. Additionally, devices and methods have been developed that allow for consistent particle size generation using volatilization. With such devices, drug compound typically is deposited on a surface of a substrate, such as a stainless steel foil. The substrate is rapidly heated to volatilize the drug, followed by cooling of the vapor so that it condenses to form an aerosol (i.e., a condensation aerosol).
- Volatilization, however, subjects the drug to potential chemical degradation via thermal, oxidative, and/or other means. The activation energies of these degradation reactions depend on molecular structure, energy transfer mechanisms, transitory configurations of the reacting molecular complexes, and the effects of neighboring molecules. One method to help control degradation during volatilization is the use of the flow of gas across the surface of the compound, to create a situation in which a compound's vapor molecules are swept away from its surface. (See e.g., Wensley et al., U.S. Publication No. US 2003/0062042 A1). Additionally, the use of thin films reduces the amount of thermal degradation by decreasing the temporal duration of close contact between the heated drug molecule and other molecules and/or the surface on which the drug is in contact.
- Now, the inventors have discovered, unexpectedly and surprisingly, that a drug supply unit comprising a substrate having a plurality of holes provides a number of advantages. In particular, the inventors have found that the use of such drug supply units allows the formation of a condensation aerosol of higher purity. In addition, the inventors have discovered that the use of such drug supply units allows formation of a condensation aerosol with a higher yield. This discovery forms the basis of the present invention.
- Embodiments of the invention include a drug supply unit comprising a substrate, wherein the substrate has a surface containing a plurality of holes, and wherein at least a portion of the surface is coated with a drug composition.
- Other embodiments of the invention include an aerosol drug delivery device comprising: a housing defining an airway; a drug supply unit comprising a surface, wherein at least a portion of the surface includes a plurality of holes; a heating element operatively associated with the drug supply unit, wherein the heating element is configured to heat the substrate; and a drug composition coated onto at least a portion of the surface of the substrate, wherein the heating element is configured to configured to heat the substrate to a temperature sufficient to vaporize at least a portion of the drug. Other embodiments of the invention include a method of producing a drug-containing aerosol, the method comprising: (a) providing an aerosol drug delivery device comprising a housing defining an airway; a drug supply unit comprising a surface, wherein at least a portion of the surface includes a plurality of holes; a heating element operatively associated with the drug supply unit; and a drug composition coated onto at least a portion of the surface of the substrate; wherein the heating element is configured to heat the substrate to a temperature sufficient to vaporize at least a portion of the drug; (b) providing an air flow through the plurality of holes while heating the substrate; and (c) allowing the vaporized drug to cool and condense into an aerosol comprising particles.
- These and other objects, aspects, embodiments, features, and advantages of the present invention will be clearly understood through a consideration of the following detailed description. It will be understood that the embodiments described are illustrative of some of the applications of the principles of the present invention. Modifications may be made without departing from the spirit and scope of the invention, including those combinations of features that are individually disclosed and claimed herein.
-
FIG. 1A is a cross-section view of a drug supply unit according to one embodiment of the invention.FIG. 1B is a cut-away view of a drug supply unit according to one embodiment of the invention.FIG. 1C is a cut-away view of a drug delivery device according to one embodiment of the invention. -
FIG. 2A shows a perforated polyimide film substrate having holes measuring 2.8×10−3 in. by 5.25×10−3 in. -
FIG. 2B shows a perforated polyimide film substrate having holes measuring 8.8×10−3 in.×9.8×10−2 in. -
FIG. 3 is a cross-sectional view of a polyimide film substrate, showing the polyimide film substrate, copper heater traces, and holes formed through the polyimide film. -
FIG. 4A is a schematic of an embodiment of a substrate screening apparatus. -
FIG. 4B is a cross-sectional view of the substrate screening apparatus embodiment shown inFIG. 4A . -
FIG. 5 is a schematic of another embodiment of a substrate screening apparatus. -
FIG. 6 shows a magnified image of a perforated stainless steel substrate. -
FIG. 7 is a bar graph showing aerosol purity (%) and yield (%) at various air flow ratios (across:bottom) for sildenafil free base. -
FIG. 8 is a plot showing aerosol purity (%) as a function of drug coating thickness (microns) for sildenafil free base. -
FIG. 9 is a bar graph showing aerosol purity (%) at various air flow ratios (across:bottom) for bumetanide free base. -
FIG. 10 is a plot showing aerosol purity (%) as a function of drug coating density (mg/cm2) for bumetanide free base. -
FIG. 11 is a plot showing average MMAD as a function of air flow ratio (across:bottom) for bumetanide free base vaporized from a perforated 316 stainless substrates. -
FIG. 12 is a bar graph showing coated purity at various storage times (weeks) at 40° C. for fentanyl free base coated on polyimide film. -
FIG. 13 is a plot showing aerosol purity (%) as a function of drug coating thickness (microns) at various air flow ratios (across:bottom) for prochlorperazine free base using a perforated polyimide film substrate. -
FIG. 14 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for adenosine free base using a perforated polyimide film substrate. -
FIG. 15 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for baclofen free base using a perforated polyimide film substrate. -
FIG. 16 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for ciclesonide free base using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate. -
FIG. 17 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for cyclobenzaprine fumarate using a perforated polyimide film substrate. -
FIG. 18 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for diphenhydramine fumarate using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate. -
FIG. 19 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for flunisolide free base using a perforated polyimide film substrate, a perforated, heat-passivated stainless steel substrate, and a perforated SULFINERT®-treated stainless steel substrate. -
FIG. 20 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for fluticasone propionate using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate. -
FIG. 21 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for mometasone furoate using a perforated polyimide film substrate, a non-perforated, heat-passivated stainless steel substrate, and a non-perforated SULFINERT®-treated stainless steel substrate. -
FIG. 22 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for paroxetine fumarate using a perforated polyimide film substrate and non-perforated, heat-passivated stainless steel substrate. -
FIG. 23 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for tadalafil free base using a perforated, heat-passivated stainless steel substrate. -
FIG. 24 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for tizanadine free base using a perforated polyimide film substrate, a non-perforated, heat-passivated stainless steel substrate, and a non-perforated, (non-heat-passivated) stainless steel substrate. -
FIG. 25 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for vardenafil free base using a perforated polyimide film substrate and a perforated, heat-passivated stainless steel substrate. -
FIG. 26 is a plot showing aerosol purity (%) as function of coated density (mg/cm2) at various air flow ratios and temperatures for zaleplon free base using a perforated polyimide film substrate and a non-perforated, heat-passivated stainless steel substrate. - As defined herein, the following terms shall have the following meanings when reference is made to them throughout the specification.
- “Aerodynamic diameter” of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
- “Aerosol” refers to a collection of solid or liquid particles suspended in a gas.
- “Condensation aerosol” refers to an aerosol that has been formed by the vaporization of a composition and subsequent cooling of the vapor, such that the vapor condenses to form particles.
- “Decomposition index” refers to a number derived from an assay described in Example 20. The number is determined by subtracting the purity of the generated aerosol, expressed as a fraction, from 1.
- “Drug” means any substance that is used in the prevention, diagnosis, alleviation, treatment or cure of a condition. The drug is preferably in a form suitable for thermal vapor delivery, such as an ester, free acid, or free base form. The drugs are preferably other than recreational drugs. More specifically, the drugs are preferably other than recreational drugs used for non-medicinal recreational purposes, e.g., habitual use to solely alter one's mood, affect, state of consciousness, or to affect a body function unnecessarily, for recreational purposes. The terms “drug”, “compound”, and “medication” are used herein interchangeably.
- “Drug composition” refers to a composition that comprises only pure drug, two or more drugs in combination, or one or more drugs in combination with additional components. Additional components can include, for example, pharmaceutically acceptable excipients, carriers, and surfactants.
- “Drug degradation product” and “thermal degradation product” are used interchangeably and mean any byproduct which results from heating the drug(s) and is not responsible for producing a therapeutic effect.
- “Drug supply article” and “drug supply unit” are used interchangeably and refer to a substrate with at least a portion of its surface coated with one or more drug compositions. Drug supply articles of the invention may also include additional elements such as, for example, but not limitation, a heating element.
- “Fraction drug degradation product” refers to the quantity of drug degradation products present in the aerosol particles divided by the quantity of drug plus drug degradation product present in the aerosol, i.e. (sum of quantities of all drug degradation products present in the aerosol)/((quantity of drug(s) present in the aerosol)+(sum of quantities of all drug degradation products present in the aerosol)). The term “percent drug degradation product” as used herein refers to the fraction drug degradation product multiplied by 100%, whereas “purity” of the aerosol refers to 100% minus the percent drug degradation products.
- “Heat stable drug” refers to a drug that has a TSR≧9 when vaporized from a film of some thickness between 0.05 μm and 20 μm. A determination of whether a drug classifies as a heat stable drug can be made as described in Example 20.
- “Mass median aerodynamic diameter” or “MMAD” of an aerosol refers to the aerodynamic diameter for which half of the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.
- “Purity” as used herein, with respect to the aerosol purity, means the fraction of drug composition in the aerosol/the fraction of drug composition in the aerosol plus drug degradation products. Thus purity is relative with regard to the purity of the starting material. For example, when the starting drug or drug composition used for substrate coating contained detectable impurities, the reported purity of the aerosol does not include those impurities present in the starting material that were also found in the aerosol, e.g., in certain cases if the starting material contained a 1% impurity and the aerosol was found to contain the identical 1% impurity, the aerosol purity may nevertheless be reported as >99% pure, reflecting the fact that the detectable 1% purity was not produced during the vaporization-condensation aerosol generation process.
- “Support” refers to a material on which the composition is adhered, typically as a coating or thin film. The terms “support” and “substrate” are used herein interchangeably. A “perforated substrate” refers to a substrate wherein a surface of the substrate has a plurality of holes that extend through the substrate. As described below, these holes allow a gas (e.g., air) to flow through the substrate. A “non-perforated substrate” refers to a substrate without any holes.
- “Substantially free of” means that the material, compound, aerosol, etc., being described is at least 95% free of the other component from which it is said to be substantially free.
- “Therapeutically effective amount” means the amount required to achieve a therapeutic effect. The therapeutic effect could be any therapeutic effect ranging from prevention, symptom amelioration, symptom treatment, to disease termination or cure.
- “Thermal stability ratio” or “TSR” means the % purity/(100%-% purity) if the % purity is <99.9%, and 1000 if the % purity is ≧99.9%. For example, a respiratory drug vaporizing at 90% purity would have a TSR of 9. An example of how to determine whether a respiratory drug is heat stable is provided in Example 20.
- “Thermal vapor” refers to a vapor phase, aerosol, or mixture of aerosol-vapor phases, formed preferably by heating. The thermal vapor may comprise a drug and optionally a carrier, and may be formed by heating the drug and optionally a carrier. The term “vapor phase” refers to a gaseous phase. The term “aerosol phase” refers to solid and/or liquid particles suspended in a gaseous phase.
- “Vapor” refers to a gas, and “vapor phase” refers to a gas phase. The term “thermal vapor” refers to a vapor phase, aerosol, or mixture of aerosol-vapor phases, formed preferably by heating.
- The drug supply units described herein may be used to form condensation aerosols. One such method involves the heating of a composition to form a vapor, followed by cooling of the vapor so that it forms an aerosol (i.e., a condensation aerosol).
- Typically, the composition is deposited on a substrate, and then the substrate is heated to vaporize the composition. The drug supply unit of the invention comprises a substrate and a drug composition deposited on at least a portion of the substrate, wherein the surface of the substrate has a plurality of holes formed therein that extend through the substrate. As described below, these holes allow a gas (e.g., air) to flow through the substrate.
- Typically, the substrate is a heat-conductive substrate. The drug supply unit is particularly suited for use in a device for inhalation therapy for delivery of a therapeutic agent to the lungs of a patient, for local or systemic treatment. The unit is also suited for use in a device that generates an air stream, for application of aerosol particles to a target site. For example, a stream of gas carrying aerosol particles can be applied to treat an acute or chronic skin condition, can be applied during surgery at the incision site, or can be applied to an open wound. As one of skill in the art can readily appreciate, the devices and methods of the invention are applicable not only to a unit consisting of the above components but also to any drug supply unit that consists of these and any other additional number of components up to, and including, the complete drug delivery device itself. Discussed below are aspects of the substrate, the drug composition film, aerosol purity, and surface area features of the substrate for delivery of therapeutic amounts of a drug composition.
- 1. Substrate Materials, Surface Characteristics, and Geometry
- An illustrative example of one type of drug supply unit of the invention is shown in cross-sectional view in
FIG. 1A .Drug supply unit 130 is comprised of asubstrate 108 having a plurality ofholes 132. - A number of different materials may be used to construct the substrate. Typically, the substrates are heat-conductive and include metals or alloys, such as aluminum, iron, copper, stainless steel, gold, titanium and the like, alloys. The holes in the substrate may be formed by any method known in the art. In one variation, the heat-conductive substrate is a sheet of stainless steel foil that has had holes etched or drilled thorough it. In some embodiments, stainless steel has advantages over materials like aluminum because it has a lower thermal conductivity value, without an appreciable increase in thermal mass. Low thermal conductivity is helpful because heat generated by the process needs to remain in the immediate area of interest.
- A drug supply unit of the invention may also comprise treated substrates, which have been described as providing improve purity of the drug composition aerosol generated from films applied thereon. Exemplary substrates of this type are described in Bennett et al., U.S. Publication No. 2005/0034723, which is incorporated herein by reference. Metal substrates disclosed therein have a treated exterior surface. The treated exterior surface is typically an acid treated, heat treated, or metal oxide-enriched surface. The treatment approaches disclosed therein are applicable to a diversity of metals and alloys, including without limitation steel, stainless steel, aluminum, chromium, copper, iron, titanium, and the like, with aluminum, copper, and steel, especially stainless steel, being particularly preferred embodiments. In one variation, the heat-conductive substrate is a sheet of SULFINERT®-treated stainless steel.
- Alternatively, the substrate may comprise a ceramic or polymer. In one variation, the heat-conductive substrate is a sheet of polyimide film (KAPTON® polyimide film, DuPont, Wilmington, Del.) comprising a plurality of holes. In such case, the drug supply unit can further comprise a heater element disposed on or within the polymeric substrate. In order to lower the thermal mass, in some preferred embodiments, a thin sheet of polyimide film (5×10−4 in. to 1×10−3 in.) may be used. In some embodiments, electrically conductive heater traces can be formed on a surface of the polyimide film sheet. Although the heater traces typically comprise copper, it is also contemplated herein that the traces can be formed of other conductive materials, such as aluminum, nickel, or gold.
- The substrate typically has a thickness of at least 5×10−4 in. When the substrate comprises a metal (e.g., stainless steel), the substrate typically has a thickness within the range of about 5×10−4 in. to about 1×10−2 in. When the substrate comprises a polymer (e.g., polyimide film), the substrate typically has a thickness within the range of about 5×10−4 in. to about 5×10−3 in.
- At least a portion of the surface of the substrate comprises a plurality of holes through which a flow of gas can pass. Typically, the substrate comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 250, at least 500, or more, holes.
- Typically, a gas (e.g., air) flows through the holes upon inhalation by a subject using the drug delivery device. The gas may be drawn into the device by the act of inhalation, or may otherwise be provided (e.g., stored within the device under pressure until inhalation).
- Typically, the holes have a regular shape, such as a circle, an ellipse, a square, a rectangle, or a regular polygon. In a preferred embodiment, the substrate comprises a plurality of small, circular, regularly spaced holes, typically of the same or similar size. However, the invention is not so limited and the holes could be of irregular shape, and/or have varying sizes and/or spacing. The plurality of holes may have different shapes (e.g., a combination of circular and rectangular holes).
- The dimensions of the holes typically remain uniform as they extend through the substrate, but it is within the scope of the invention that the holes can vary in shape and dimension as they extend through the substrate. For example, the holes could have a tapered, conical shape, so that the holes have a larger diameter on one surface of the substrate than on another.
- In the case of a drug supply unit comprising a polymeric substrate (e.g., polyimide film) with heater traces, the holes are preferably located between the heater traces, as shown in
FIGS. 2A and 2B , which show polyimide film substrates having smaller and larger size holes, respectively. Thesubstrate 200 shown inFIG. 2A has smaller holes measuring 2.8×10−3 in. by 5.25×10−3 in. The spacing between holes is 1.5×10−2 in. Theheater 20 shown inFIG. 2B has larger holes measuring 8.8×10−3 in. by 9.8×10−2 in. The polyimide films have a thickness of 1×10−3 in. -
FIG. 3 is a schematic illustration of apolyimide film substrate 300, showing thepolyimide film 302, copper heater traces 304, and holes 306 formed through thepolyimide film 302. - Typically, the holes are arranged in a regular pattern across the substrate. However, it is also contemplated herein that the holes could be arranged in an irregular pattern or even randomly across the substrate.
- The holes may be formed in the substrate using any conventional technique known in the art, including without limitation, laser etching, drilling, wet chemical etching, plasma etching, stamping, punching, and combinations thereof.
- A drug is typically coated onto a portion of the substrate. The drug-coated portion of the substrate typically has a surface area within the range of about 8 mm2 to about 20 cm2; more typically, within the range of about 9 mm2 to about 15 cm2. The holes typically occupy between about 1% to about 70%; more typically, between about 10% to about 60%; and, most typically, between about 20% to about 50%, of the drug-coated surface area.
- The drug is typically coated to a coating density ranging from about 0.1 mg/cm2 to about 10 mg/cm2 on the substrate surface. This roughly corresponds to a coating thickness within the range of about 1 μm to about 100 μm.
- The drug may be coated onto the substrate surface using any conventional coating technique known in the art, including without limitation, spray coating, dip coating, and inkjet printing.
- In a preferred embodiment of a polyimide film heating unit, the drug is coated onto the polyimide film side of the heating unit. It is also contemplated herein that the drug may be coated onto the side of the heating unit having the conductive heater traces, or onto both sides of the heating unit.
- Drug supply units for use in the present invention are typically electrical drug supply units, where current is passed through an electrical resistance element. For example, heating of the substrate may be accomplished by passing current through a thin metallic substrate, or through electrically conductive traces formed on the surface of a polymeric substrate (as described above). However, it is also within the scope of the present invention that other types of heating methods known in the art may be used. For example, heating of the substrate may be accomplished using optical, radiative, convection, or chemical energy sources.
- As contemplated herein, the substrate for use in the heating unit of the invention can either be an exterior surface of a heating unit itself, or can be a separate material operatively associated with the heating unit (e.g., in direct contact with or in proximity to the exterior surface of the heating unit). The minimum temperature required for volatilization of the drug and, thus, the maximum allowable spacing between the substrate and the heating unit will, of course, vary with the particular drug, among other factors.
- The perforated substrate can be of virtually any geometry, but is most typically square or rectangular in shape. The perforated substrate of the drug supply unit illustrated in
FIG. 1A is shown as having a substantially planar geometry, having an upper surface 134 (upon which drug composition 138 has been deposited) and lower surface 136. “Across” air flow is directed over the surface on which the drug composition has been deposited (e.g., parallel to and in the same plane as upper surface 134) while “bottom” air flow is directed throughholes 132, from lower surface 136 toupper surface 134. -
FIG. 1B is a perspective, cut-away view of an alternative geometry of the aerosol delivery article.Article 140 is comprised of a hollow, cylindrically-shapedsubstrate 142 formed from a heat-conductive material.Substrate 142 has a perforatedexterior surface 144. Drug composition (not shown) is deposited on theexterior surface 144. As will be described in more detail below, in use, the substrate of the aerosol delivery article is heated to vaporize all or a portion of the drug film. During vaporization, “across” air flow is directed overexterior surface 144 of the substrate and “bottom” air flow is directed through the holes insubstrate 142, from the hollow interior ofsubstrate 142 to theexterior surface 144. - 2. Heating of the Substrate
- Typically, heat is applied to the substrate to vaporize the drug composition film. It will be appreciated that the temperature to which the substrate is heated will vary according to the drug's vaporization properties and the selected minimum purities and yields of the aerosol, but the substrate is typically heated to a temperature of at least about 150° C., preferably of at least about 250° C., more preferably at least about 300° C. or 350° C. Heating the substrate produces a thermal vapor that in the presence of the flowing gas (both across and through the substrate) generates aerosol particles. Thus, the drug supply unit can further comprise a heating element for supplying heat to the substrate to produce a substrate temperature greater than 150° C. and to volatilize all or a portion of the drug composition film from the substrate. Preferably, the temperature is sufficient to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less, more preferably in less than 1 second, still more preferably in less than 500 milliseconds, and most preferably in less than 200 milliseconds.
- In
FIG. 1B , the substrate surface is partially cut-away in the figure to expose aheating element 146 disposed in interior ofsubstrate 142. As shown, the substrate can be hollow with a heating element inserted into the hollow space. The heating element in the embodiment shown takes the form of an electrical resistive wire that produces heat when a current flows through the wire. Other heating elements are suitable, including but not limited to a solid chemical fuel, chemical components that undergo an exothermic reaction, inductive heat, etc. Heating of the substrate by conductive heating is also suitable. - As one of skill in the art will recognize, depending on the choice of substrate material, the optimal means of heating may vary. For example, if the substrate material is stainless steel, a preferred means of heating typically is electrical resistive heating. On the other hand, if the substrate material is aluminum, a preferential means to vaporize the drug composition on the substrate surface typically is by conductive means, i.e., by bringing the aluminum in contact with a heat source (e.g., a halogen bulb), rather than electrical resistance means, due to the higher thermal conductivity and higher electrical conductivity of aluminum relative to stainless steel.
- In studies conducted in support of the invention, a variety of drugs were deposited on stainless steel and polyimide film (KAPTON®) substrates. However, as disclosed above, and as one of skill in the art will recognize, a variety of different substrates can be used.
- In addition to the substrate, the aerosol delivery article comprises a drug composition deposited on the substrate, typically as a film or coating. As shown in
FIG. 1A , deposited on all or a portion of theupper surface 134 of the substrate is a film 138 of the drug composition. The drug composition can consist of two or more drugs. Preferably, however, the drug composition comprises pure drug. - Typically, the drug composition is deposited on the substrate by coating the drug composition as film. The film can be of varying thickness depending on the compound and the maximum amount of thermal degradation that can be tolerated. Typically, the film has a thickness less than 50 micron, and generally the film has a thickness in the range from 0.05 to 20 microns. More typically, the film has a thickness in the range from 0.1 to 15 microns, from 0.2 to 10 microns, or from 1 to 5 microns.
- Drug composition deposition is achieved by a variety of methods, depending in part on the physical properties of the drug and on the desired drug film thickness. Exemplary methods include, but are not limited to, preparing a solution of drug in solvent, applying the solution to the exterior surface and removing the solvent to leave a film of drug. The drug solution can be applied by dipping the substrate into the solution, spraying, brushing, or otherwise applying the solution to the substrate. Alternatively, a melt of the drug can be prepared and applied to the substrate. For drugs that are liquids at room temperature, thickening agents can be admixed with the drug to permit application of a solid drug film. Examples of drug film deposition on a variety of substrates are given below.
- The drug composition films used in the Examples were formed by applying a solution containing the drug onto the substrate. As described in the Examples below, a solution of the drug in a solvent was prepared. A variety of solvents can be used and selection is based, in part, on the solubility properties of the drug and the desired solution concentration. Common solvent choices included methanol, acetone, chloroform, dichloromethane, other volatile organic solvents, dimethylformamide, water, and solvent mixtures. In the Examples below, the drug solutions were applied to the substrates by spray coating, yet other methods such as dip coating are contemplated as well. In the Examples discussed below, a substrate containing a drug film of a certain thickness was prepared. To determine the thickness of the drug film deposited on the substrate, one method that can be used is to determine the area of the substrate and calculate drug film thickness using the following relationship:
-
film thickness (cm)=drug mass (g)/[drug density (g/cm3)×substrate area (cm2)] - The drug mass can be determined by weighing the substrate before and after formation of the drug film or by extracting the drug and measuring the amount analytically. Drug density can be experimentally determined by a variety of techniques known by those of skill in the art or found in the literature or in reference texts, such as in the CRC. An assumption of unit density is acceptable if an actual drug density is not known. Alternatively, the film thickness can be measured directly by techniques known by those of skill in the art, such as, for example, optical reflectometry, beta backscattering, SEM, etc.
- In studies conducted in support of the invention, a variety of drugs were deposited onto a variety of substrates and the substrates were heated to a temperature sufficient to generate a thermal vapor. Purity of drug-aerosol particles in the thermal vapor was determined. The term “purity” as used herein, with respect to the aerosol purity, means [the fraction of drug composition in the aerosol]/[the fraction of drug composition in the aerosol plus drug degradation products]. Thus purity is relative with regard to the purity of the starting material. For example, when the starting drug or drug composition used for substrate coating contained detectable impurities, the reported purity of the aerosol does not include those impurities present in the starting material that were also found in the aerosol, e.g., in certain cases if the starting material contained a 1% impurity and the aerosol was found to contain the identical 1% impurity, the aerosol purity may nevertheless be reported as >99% pure, reflecting the fact that the detectable 1% purity was not produced during the vaporization-condensation aerosol generation process.
- To determine the percent or fraction drug degradation product, and hence the purity of the aerosol, typically, the aerosol is collected in a trap, such as a filter, glass wool, an impinger, a solvent trap, or a cold trap, with collection in a filter particularly preferred. The trap is then typically extracted with a solvent, e.g. acetonitrile, and the extract subjected to analysis by any of a variety of analytical methods known in the art, with gas and liquid chromatography preferred methods, and high performance liquid chromatography particularly preferred. The gas or liquid chromatography method includes a detector system, such as a mass spectrometry detector or ultraviolet absorption detector. Ideally, the detector system allows determination of the quantity of the components of the drug composition and drug degradation product by weight. This is achieved in practice by measuring the signal obtained upon analysis of one or more known mass(es) of components of the drug composition or drug degradation product (standards) and comparing the signal obtained upon analysis of the aerosol to that obtained upon analysis of the standard(s), an approach well known in the art. In many cases, the structure of a drug degradation product may not be known or a standard of the drug degradation product may not be available. In such cases, it is acceptable to calculate the weight fraction of the drug degradation product by assuming that the drug degradation product has an identical response coefficient (e.g. for ultraviolet absorption detection, identical extinction coefficient) to the drug component or components in the drug composition. When conducting such analysis, for practicality drug degradation products present at less than a very small fraction of the drug compound, e.g. less than 0.2% or 0.1% or 0.03% of the drug compound, are generally excluded from analysis. Because of the frequent necessity to assume an identical response coefficient between drug and drug degradation product in calculating a weight percentage of drug degradation products, it is preferred to use an analytical approach in which such an assumption has a high probability of validity. In this respect, high performance liquid chromatography with detection by absorption of ultraviolet light at 225 nm is a preferred approach. UV absorption at other than 225 nm, most commonly 250 nm, is used for detection of compounds in limited cases where the compound absorbs substantially more strongly at 250 nm or for other reasons one skilled in the art would consider detection at 250 nm the most appropriate means of estimating purity by weight using HPLC analysis. In certain cases where analysis of the drug by UV is not viable, other analytical tools such as GC/MS or LC/MS may be used to determine purity.
- Another feature of the aerosol delivery article is that the substrate surface area is typically such that a therapeutic dose of the drug aerosol is delivered in a single use of the device when used by a subject such that dose titration by the patient to deliver a minimum effective dose is possible. For a drug delivery device of the invention, the yield from a single dose may be determined by collecting the thermal vapor evolved upon actuation of the device or assembly and analyzing its composition as described herein, and comparing the results of analysis of the thermal vapor to those of a series of reference standards containing known amounts of the drug. The amount of drug or drugs required in the starting composition for delivery as a thermal vapor depends on the amount of drug or drugs entering the thermal vapor phase when heated (i.e., the dose produced by the starting drug or drugs), the bioavailability of the thermal vapor phase drug or drugs, the volume of patient inhalation, and the potency of the thermal vapor drug or drugs as a function of plasma drug concentration.
- Typically, the bioavailability of thermal vapors ranges from 20-100% and is preferably in the range of 50-100% relative to the bioavailability of drugs infused intravenously. The potency of the thermal vapor drug or drugs per unit plasma drug concentration is preferably equal to or greater than that of the drug or drugs delivered by other routes of administration. It may substantially exceed that of oral, intramuscular, or other routes of administration in cases where the clinical effect is related to the rate of rise in plasma drug concentration more strongly than the absolute plasma drug concentration. Thus, for medications currently given orally, the effective human therapeutic dose of that drug in thermal vapor form is generally less than the standard oral dose. Preferably it will be less than 80%, more preferably less than 40%, and most preferably less than 20% of the standard oral dose. For medications currently given intravenously, the drug dose in a thermal vapor will generally be similar to or less than the standard intravenous dose. Preferably it will be less than 200%, more preferably less than 100%, and most preferably less than 50% of the standard intravenous dose.
- Determination of the appropriate dose of thermal vapor to be used to treat a particular condition can be performed via animal experiments and a dose-finding (Phase I/II) clinical trial. Preferred animal experiments involve measuring plasma drug concentrations after exposure of the test animal to the drug thermal vapor. These experiments may also be used to evaluate possible pulmonary toxicity of the thermal vapor. Because accurate extrapolation of these results to humans is facilitated if the test animal has a respiratory system similar to humans, mammals such as dogs or primates are a preferred group of test animals. Conducting such experiments in mammals also allows for monitoring of behavioral or physiological responses in mammals. Initial dose levels for testing in humans will generally be less than or equal to the least of the following: current standard intravenous dose, current standard oral dose, dose at which a physiological or behavioral response was obtained in the mammal experiments, and dose in the mammal model which resulted in plasma drug levels associated with a therapeutic effect of drug in humans. Dose escalation may then be performed in humans, until either an optimal therapeutic response is obtained or dose-limiting toxicity is encountered.
- The actual effective amount of drug for a particular patient can vary according to the specific drug or combination thereof being utilized, the particular composition formulated, the mode of administration and the age, weight, and condition of the patient and severity of the episode being treated. The amount of drug that is required to provide a therapeutic dose is generally known in the art or can be determined as discussed above.
- The amount of drug that is required to provide a therapeutic dose is generally known in the art or can be determined as discussed above. The required dosage, discussed above, and the determined film thickness of the instant methods (as set by the selected minimum aerosol purities and yield) dictate the minimum required substrate area in accordance with the following relationship:
-
film thickness (cm)×drug density (g/cm3)×substrate area (cm2)=dose (g) - As noted above, drug density can be determined experimentally or from the literature, or if unknown, can be assumed to be 1 g/cc. To form a drug supply article comprising a drug film on a heat-conductive substrate that is capable of administering an effective human therapeutic dose, the minimum substrate surface area is determined using the relationships described above to determine a substrate area for a determined film thickness (according to the methods of the instant invention) that will yield a therapeutic dose of drug aerosol.
- The actual dose of drug delivered, i.e., the percent yield or percent emitted, from the drug-supply article will depend on, along with other factors, the percent of drug film that is vaporized upon heating the substrate. Thus, for drug films that yield upon
heating 100% of the drug film and aerosol particles that have 100% drug purity, the relationship between dose, thickness, and area given above correlates directly to the dose provided to the user. As the percent yield and/or particle purity decrease, adjustments in the substrate area can be made as needed to provide the desired dose. Also, as one of skill in the art will recognize, larger substrate areas other than the minimum calculated area for a particular film thickness can be used to deliver a therapeutically effective dose of the drug. Moreover, as can be appreciated by one of skill in art, the film need not coat the complete surface area if a selected surface area exceeds the minimum required for delivering a therapeutic dose from a selected film thickness. - Also disclosed herein is a method of producing a drug-containing condensation aerosol comprising providing a substrate having the drug deposited on its surface, wherein the surface of the substrate has a plurality of holes formed therein. The substrate is heated to a temperature sufficient to vaporize the drug while simultaneously providing an air flow across the substrate and through the substrate via the plurality of holes. The drug is preferably heated to a temperature and for a duration that results in an acceptably low level of decomposition. The vaporized drug is preferably rapidly mixed into the air flow to cool and preclude additional decomposition of the drug. The vaporized drug is then allowed to condense into an aerosol comprising particles. The terms “air”, “air flow”, and “gas” are used interchangeably herein, and are intended to encompass ambient air as well as any other appropriate (i.e., physiologically acceptable, non-explosive) gases, including compressed gases. For example, the device of the invention could be attached to a separate tank of compressed gas that blows air or another suitable gas up through the perforations in the substrate concurrently with heating of the substrate.
- The aerosolized drug preferably has a purity level of at least 90%; more preferably, at least 95%; more preferably, at least 96%; more preferably, at least 97%. As used herein, the term “pure” refers to an aerosolized drug that contains no thermal degradation products, excipients, or other contaminants. For example, an aerosolized drug that is at least 97% pure contains less than 3% of thermal degradation products, excipients, or other contaminants. As used herein, the term “thermal degradation product” means any byproduct which results from heating the drug.
- The aerosol is preferably characterized by less than 10% by weight of a thermal degradation product, more preferably, less than 5%, more preferably, less than 1%, more preferably, less than 0.5%, more preferably, less than 0.1%, or, more preferably, less than 0.03% by weight of a thermal degradation product.
- In certain embodiments, for example, when the drug delivery device is designed for portable use with a battery power source, efficient energy use can be desirable. Minimization of the energy used to release the drug from the substrate can, at least in part, depend on the shape and dimensions of the substrate, the materials forming the substrate, and the placement of the substrate within the airway. In certain embodiments, the substrate can comprise an electrically resistive material such as a foil. In certain embodiments, the substrate can be a stainless steel foil and can include a layer of one or more materials such as a gold layer to facilitate, for example, forming an electrical connection, and/or modifying the electrical properties such as the resistance of a portion of the foil. The appropriate dimensions for a substrate can depend at least in part, on the desired resistance, the amount of drug disposed on the substrate, the amount of energy needed to vaporize the drug disposed on the substrate, and/or on mechanical stability considerations.
- Delivery Devices
- As shown in
FIG. 1A , there is adrug supply unit 130 having a heat-conductive substrate 108 comprising a plurality ofholes 132 extending therethrough. Acomposition coating 134 is at least a portion of theupper surface 134. -
FIG. 1B provides a perspective, cut-away view of another embodiment ofdrug supply unit 140. The drug supply unit comprises acylindrical substrate 142. This substrate may be formed from a heat-conductive material, for example. Thesubstrate 142 includes a plurality ofholes 144 extending therethrough. A thin layer of a drug (not shown) for aerosolization is coated ontoexternal surface 142. As shown in the cut-away portion, there is aheating element 146 disposed in thesubstrate 142. Thesubstrate 142 can be hollow with a heating element inserted into the hollow space, or solid with a heating element incorporated into the substrate. “Bottom” gas flow into the hollow space passes through the substrate via the plurality of holes while “across” gas flow passes over the external surface ofsubstrate 142. - The
illustrative heating element 146 shown inFIG. 1B is shown as an electrical resistive wire that produces heat when a current flows through it, but as noted above, a number of different heating methods and corresponding devices are acceptable. For example, acceptable heat sources can supply heat to the drug supply unit at rates that rapidly achieve a temperature sufficient to completely vaporize the composition from the support surface. For example, heat sources that achieve a temperature of 200° C. to 500° C. or more within a period of 2 seconds or less are typical, although it should be appreciated that the temperature chosen will be dependent upon the vaporization properties of the composition, but typically the vaporization temperature will be at least about 200° C.; preferably, at least about 250° C.; more preferably, at least about 300° C. or 350° C. Heating thesubstrate 142 produces a drug composition vapor that in the presence of a flowing gas generates aerosol particles in the desired size range. The presence of the gas flow is generally prior to, simultaneous with, or subsequent to heating the substrate. In one embodiment, the substrate is heated for a period of less than about 1 second, and more preferably for less than about 500 milliseconds, still more preferably for less than about 200 milliseconds. The drug aerosol particles are inhaled by a subject for delivery to the lung. -
FIG. 1C is a perspective view of an embodimentdrug delivery device 150 that incorporates an embodiment of the drug supply unit of the invention.Housing 152 comprises afirst air inlet 154 and asecond air inlet 156, which lead, respectively, tofirst airway 164 and second airway 166. Substrate 158 is disposed betweenfirst airway 164 and second airway 166. Substrate 158 includes a plurality of holes (not shown) fluidly connectingfirst airway 164 and second airway 166. A drug for aerosolization (not shown) is disposed on a portion of the surface of substrate 158 in communication withfirst airway 164. When a user places thedevice 150 in his/her mouth and inhales a breath through taperedmouthpiece 160, air flows throughinlets 156 and 158, establishing a first airflow 174 infirst airway 164, and a second airflow 176 in second airway 166, such that second airflow 176 passes from second airway 166 tofirst airway 164 through the holes in substrate 158. The combined first air flow 174 and second airflow 176 carry the aerosol to the subject through mouthpiece/outlet 160. - The devices described herein may additionally contain a variety of components to facilitate aerosol delivery. For instance, the device may include any component known in the art to control the timing of drug aerosolization relative to inhalation (e.g., breath-actuation). Similarly, the device may include a component to provide feedback to patients on the rate and/or volume of inhalation, or a component to prevent excessive use (i.e., “lockout” feature). In addition, the device may further include a component to prevent use by unauthorized individuals, and a component to record dosing histories. These components may be used alone, or in combination with other components.
- The element that allows cooling may be of any configuration. For example, it may be an inert passageway linking the heating means to the inhalation means. Similarly, the element permitting inhalation by a user may be of any configuration. For example, it may be an exit portal that forms a connection between the cooling element and the user's respiratory system.
- The device as shown has apertures that control the gas flow ratio. In an alternative embodiment, the across air flow or bottom air flow may be regulated by a gas-flow control valve(s) disposed upstream of the solid support. The gas-flow valve(s) may, for example, include an inlet port communicating with the chamber, and a deformable flap adapted to divert or restrict airflow away from the port increasingly, with increasing pressure drop across the valve. Similarly, the gas-flow valve may include an actuation switch. In this variation, the valve movement would be in response to an air pressure differential across the valve, which for example, could function to close the switch. The gas-flow valve may also include an orifice designed to limit the rate of airflow into the chamber.
- The device may also include a bypass valve communicating with the chamber downstream of the unit for offsetting the decrease in airflow produced by the gas-flow control valve, as the user draws air into the chamber. In this way, the bypass valve could cooperate with the gas-control valve to control the flow through the condensation region of the chamber as well as the total amount of air being drawn through the device. Thus the total volumetric airflow through the device in this variation would be the sum of the volumetric airflow rate through the gas-control valve and the volumetric airflow rate through the bypass valve.
- The compositions described herein typically comprise at least one drug compound. The drug compositions may comprise other compounds as well. For example, the composition may comprise a mixture of drug compounds, a mixture of a drug compound and a pharmaceutically acceptable excipient, or a mixture of a drug compound with other compounds having useful or desirable properties. The composition may comprise a pure drug compound as well. In preferred embodiments, the composition consists essentially of pure drug and contains no propellants or solvents.
- Any suitable drug compound may be used. Drugs that can be used include, for example but not limitation, those listed in U.S. Pat. No. 7,090,830.
- Typically, the drugs of use in the invention have a molecular weight in the range of about 150-700, preferably in the range of about 200-700, more preferably in the range of 250-600, still more preferably in the range of about 250-500. In some variations, the drugs have a molecular weight in the range 350-600 and in others the drugs have a molecular weight in the range of about 300-450. In other variations, where the drug is a heat stable drug, the drug can have a molecular weight of 350 or greater.
- Typically, the compound is in its ester, free acid, or free-base form. However, it is also a possibility that the compound will be vaporizable from its salt form. Indeed, a variety of pharmaceutically acceptable salts are suitable for aerosolization. Illustrative salts include, without limitation, the following: hydrochloric acid, hydrobromic acid, acetic acid, maleic acid, formic acid, and fumaric acid salts. Salt forms can be purchased commercially, or can be obtained from their corresponding free acid or free base forms using methods well-known in the art.
- Suitable pharmaceutically acceptable excipients may be volatile or nonvolatile. Volatile excipients, when heated, are concurrently volatilized, aerosolized and inhaled with the drug. Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents. The following is a list of exemplary carriers within these classes: water; terpenes, such as menthol; alcohols, such as ethanol, propylene glycol, glycerol and other similar alcohols; dimethylformamide; dimethylacetamide; wax; supercritical carbon dioxide; dry ice; and mixtures thereof.
- Additionally, pharmaceutically acceptable carriers, surfactants, enhancers, and inorganic compounds may be included in the composition. Examples of such materials are known in the art.
- In some variations, the aerosols are substantially free of organic solvents and propellants. Additionally, water is typically not added as a solvent for the drug, although water from the atmosphere may be incorporated in the aerosol during formation, in particular, while passing air over the film and during the cooling process. In other variations, the aerosols are completely devoid of organic solvents and propellants. In yet other variations, the aerosols are completely devoid of organic solvents, propellants, and any excipients. These aerosols comprise only pure drug, less than 10% drug degradation products, and a carrier gas, which is typically air.
- Typically, the drug has a decomposition index less than 0.15. Preferably, the drug has a decomposition index less than 0.10. More preferably, the drug has a decomposition index less than 0.05. Most preferably, the drug has a decomposition index less than 0.025
- In some variations, the condensation aerosol comprises at least 5% by weight of condensation drug aerosol particles. In other variations, the aerosol comprises at least 10%, 20%, 30%, 40%, 50%, 60%, or 75% by weight of condensation drug aerosol particles. In still other variations, the aerosol comprises at least 95%, 99%, or 99.5% by weight of condensation aerosol particles.
- In some variations, the condensation aerosol particles comprise less than 10% by weight of a thermal degradation product. In other variations, the condensation drug aerosol particles comprise less than 5%, 1%, 0.5%, 0.1%, or 0.03% by weight of a thermal degradation product.
- In certain embodiments of the invention, the drug aerosol has a purity of between 90% and 99.8%, or between 93% and 99.7%, or between 95% and 99.5%, or between 96.5% and 99.2%.
- Typically, the aerosol has a number concentration greater than 106 particles/mL. In other variations, the aerosol has a number concentration greater than 107 particles/mL. In yet other variations, the aerosol has a number concentration greater than 108 particles/mL, greater than 109 particles/mL, greater than 1010 particles/mL, or greater than 1011 particles/mL.
- The gas in which the aerosol particles are suspended is typically air. It is contemplated, however, that other gases, in particular inert gases, such as argon, nitrogen, helium, and the like, also may be used. The gas can also include vapor of the composition that has not yet condensed to form particles. Typically, the gas does not include propellants or vaporized organic solvents. In some variations, the condensation aerosol comprises at least 5% by weight of condensation drug aerosol particles. In other variations, the aerosol comprises at least 10%, 20%, 30%, 40%, 50%, 60%, or 75% by weight of condensation drug aerosol particles. In still other variations, the aerosol comprises at least 95%, 99%, or 99.5% by weight of condensation aerosol particles.
- In some variations the condensation drug aerosol has an MMAD in the range of about 1-3 μm. In some variations the geometric standard deviation around the MMAD of the condensation drug aerosol particles is less than 3.0. In other variations, the geometric standard deviation around the MMAD of the condensation drug aerosol particles is less than 2.5, or less than 2.0.
-
FIG. 4A is a schematic of an embodiment of thesubstrate screening apparatus 400.FIG. 4B is a cross-sectional view of thesubstrate screening apparatus 400. - The
substrate screening apparatus 400 is made of a machined plastic (polyoxymethylene, DELRIN® Acetal Resin, DuPont, Wilmington, Del.) block 402 with a 2 cm2 cross-sectional area for mounting a substrate 412.Block 402 includes afirst airway 404 extending fromfirst inlet 414 to outlet 422. Block 402 also include asecond airway 406 extending fromsecond inlet 416 to substrate 412, where it typically joins the first airway. The substrate 412 is mounted in thesubstrate screening apparatus 400 across twoelectrodes 420. Afirst air flow 414 is established infirst airway 404 and asecond air flow 416 is established insecond airway 406 such that thesecond air flow 416 passes from thesecond airway 406 tofirst airway 404 through holes in the substrate 412. While providingair flows air flow 414. Substrate 412 is coated with a drug composition film. The substrate 412 is heated to vaporized all or a portion of the drug composition. The vaporized drug subsequently cools and condenses to form a condensation aerosol that is carried to the outlet byair flow 414, joined by air flow 416). Accordingly, the condensation aerosol is emitted from the outlet 422. - Test substrates having dimensions 0.50 in. wide by 2-3 in. long cut from sheets of 304 stainless steel and 316 stainless steel.
FIG. 6 shows a magnification of arepresentative test substrate 600, having regularly spaced, circular holes formed in the stainless steel sheet. The distance between the edge of one hole to the edge of an adjacent hole is indicated as “d” onFIG. 6 . The distance “d” is also referred to herein as “hole spacing” or “spacing between holes.” As used herein, the term “% porosity” of the substrate refers to the percentage of the nominal total surface area of the substrate (i.e., the surface area if there were no holes) that is occupied by the holes. Thus, a rectangular substrate measuring 0.5 in.×3 in. would have a nominal total surface area of 1.5 in2. If the substrate had 400 circular holes having a diameter of 0.01 square inch, it would have a porosity of approximately 2.1%. - The test substrates were meticulously cleaned to remove any contamination from previous processing by ultrasonication in a 60° C., 6.5% Ridoline bath for 5 minutes followed by ultrasonication in a reverse-osmosis deionized (RODI) water bath at 40° C. for 1 minute followed by a 3-cycle dump rinse using RODI. To prevent water spots, the test substrates were dipped in an isopropanol bath and transferred to a 40° C. drying oven for solvent removal. Some test substrates were also subjected to heat oxidation step, performed by laying the stainless steel substrates on a sheet of aluminum foil and placing them in an oven at 350° C. for 6 hours. These “heat passivated” substrates were then re-cleaned as described above.
- The test substrates were then coated with a drug composition. The drug was typically dissolved in a volatile organic solvent (e.g., dichloromethane/methanol mixture or acetone or other suitable organic solvent) and then spray-coated onto the test substrates using an automated spray coater. Coating parameters, such as the drug concentration in the coating solution, solution flow rate, were selected to obtain a uniform drug coating of the desired coating density (i.e., mass/area).
- After coating, a sampling of coated substrates was extracted to determine if the mass of coated drug is within tolerance. The mass of drug coated per test article was determined by high performance liquid chromatography (HPLC) analysis and used to calculate a nominal coating thickness metric using the following formula:
-
- where λ is the thickness of the drug coating, SA is the surface area of the drug coating, and ρ is the density of the drug. The density was generally assumed to be 1.0 g/cm3 unless a different literature value was known. Therefore, 1 mg deposited over an area of 5 cm2 results in a nominal coating thickness of 2 μm. The coating thickness is most easily varied by either altering the drug concentration in the coating solution and/or the flow rate.
- Total air flow through the substrate screening apparatus was set by providing
air flows air flow 414 and “bottom” air flow refers toair flow 416.)Brass electrodes 420 attached to thesubstrate screening apparatus 400 were used to clamp the substrate 412 in place and provide electrical connections. For most experiments, a 1-Farad capacitor was used as the energy source. The capacitor was typically charged to 11-14 volts, depending on the desired substrate temperature. A high current relay was used to connect the circuit and discharge the capacitor across the substrate to induce heating and vaporization of the drug. -
FIG. 5 is a schematic of another embodiment of asubstrate screening apparatus 500 that was used to direct air flow through the holes of coated polyimide film (KAPTON® polyimide film) substrates (seeFIGS. 2A and 2B ).Substrate screening apparatus 500 is similar in configuration and operation tosubstrate screening apparatus 400, with the exception thatsubstrate screening apparatus 500 includes twoelectrodes 502 on the same side of thescreening apparatus 500, whereassubstrate screening apparatus 400 includes twoelectrodes 420 on opposite sides of thescreening apparatus 400. In the examples using polyimide film substrates described below, a polyimide film substrate coated with a drug composition was placed insubstrate screening apparatus 500 acrosselectrodes 502. A computer-controlled power supply was connected to the electrodes. The power supply was typically capable of heating the polyimide film substrate to the target temperature within 300 milliseconds, and the substrate was kept at the target temperature for a duration of 1 second. - To determine aerosol purity and emitted dose, a 2 μm Teflon filter (ZEFLUOR PTFE filters, available from Zefon International, Inc., Ocala, Fla.) was placed immediately downstream from the screening apparatus during aerosol generation. After the aerosol was collected from the air stream, the filter was removed, extracted with a known volume of HPLC-grade methanol, and analyzed for both drug content and purity. The “used” test substrate was also extracted for residual drug, and the airway of the screening apparatus was swabbed for determination of the amount of aerosol deposition within the apparatus.
- The filter extracts were analyzed by HPLC using a C-18 reverse phase column (4.6 mm ID×150 mm length, 5 μm packing, Capcell Pak UG120, available from Shiseido Fine Chemicals, Tokyo, Japan) eluted with (1) water/0.1% trifluoroacetic acid and (2) acetonitrile/0.1% trifluoroacetic acid at a flow rate of 1 mL/minute with a linear gradient over 24 minutes and a total run time of 36 minutes. Detection was from 200-400 nm using a photodiode array detector. Purity was calculated by measuring peak areas from the chromatogram obtained at 225 nm. Confirmatory purity evaluations were additionally performed by inspection of the full 200-400 nm wavelength range. In addition, a portion of the filter extracts is analyzed by HPLC with mass spectrometric detection. Analyses by these alternate methods yielded similar purity results when compared to the primary HPLC analysis.
- An Anderson Cascade Impactor (ACI), an inertial impaction size separating device, was used to determine the particle size distribution of the aerosol. The ACI consists of several stages, with each successive stage having a smaller size cutoff. By extracting and determining the mass of drug deposited at each stage, it is possible to estimate the particle size distribution of the aerosol. The ACI was placed immediately downstream from the screening apparatus. Again, the airway and substrate were extracted to determine the mass balance for each actuation of the device.
- Loperamide and flunisolide condensation aerosols were produced by the substrate screening apparatus using 304 stainless steel perforated substrates having the % porosities, hole spacings, and hole diameters shown in Table 1. The substrates were spray-coated with loperamide free base or flunisolide free base at coating densities of 0.3 mg/cm2 and 0.4 mg/cm2, respectively. Air flow ratios (across:bottom) of 23:5 and 18:10 were evaluated. The substrate was rapidly heated to approximately 400° C. for loperamide and approximately 375° C. for flunisolide.
-
TABLE 1 Characteristics of Perforated 304 Stainless Steel SubstratesSubstrate # Hole Diameter Hole Spacing % Porosity 1 0.005″ 0.015″ 5 2 0.005″ 0.009″ 10 3 0.005″ 0.005″ 20 4 0.010″ 0.03″ 5 5 0.010″ 0.018″ 10 6 0.010″ 0.010″ 20 7 0.010″ 0.004″ 40 8 0.020″ 0.059″ 5 9 0.020″ 0.036″ 10 10 0.020″ 0.020″ 20 11 0.020″ 0.008″ 40 12 0.040″ 0.118″ 5 13 0.040″ 0.016″ 40 - Aerosol purity results for loperamide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 23:5 are presented in Table 2.
-
TABLE 2 Aerosolization of Loperamide from Perforated Stainless Steel Substrates Aerosol Purity (% ± SD) Hole Diameter % Porosity 0.005″ 0.010″ 0.020″ 0.040″ 5 94.6 ± 0 95.4 ± 1.1 95.3 ± 0.2 91.5 ± 0.1 10 96.3 ± 0.1 94.4 ± 0.3 94.9 ± 0.2 — 20 96.8 ± 0.4 96.3 ± 0.2 89.6 ± 0.8 — 40 — 96.1 ± 0.2 95.2 ± 0.6 94.1 ± 0.2 - Aerosol purity results for loperamide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 18:10 are presented in Table 3.
-
TABLE 3 Aerosolization of Loperamide from Perforated Stainless Steel Substrates Aerosol Purity (% ± SD) Hole Diameter % Porosity 0.005″ 0.010″ 0.020″ 0.040″ 5 93.9 ± 0 95.9 ± 0 95.2 ± 0.3 90.5 ± 0.4 10 96.9 ± 0.4 94 ± 0.2 94.8 ± 0.2 — 20 97.4 ± 0.1 96.4 ± 0.1 89.8 ± 0.6 — 40 — 96.8 ± 0.2 95 ± 0.5 94.5 ± 0.3 - Aerosol purity results for flunisolide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 23:5 are presented in Table 4.
-
TABLE 4 Aerosolization of Flunisolide from Perforated Stainless Steel Substrates Aerosol Purity (% ± SD) Hole Diameter % Porosity 0.005″ 0.010″ 0.020″ 0.040″ 5 73.6 ± 2.3 76.1 ± 0.1 77.9 ± 1.1 68.6 ± 1.1 10 82.7 ± 1.4 71.4 ± 0.7 72.7 ± 1.8 — 20 87.9 ± 2 80.6 ± 3.1 69.9 ± 0.3 — 40 — 84.2 ± 0.1 80 ± 1.3 74.3 ± 7.3 - Aerosol purity results for flunisolide aerosolized from perforated 304 stainless steel substrates at an across:bottom air flow ratio of 18:10 are presented in Table 5.
-
TABLE 5 Aerosolization of Flunisolide from Perforated Stainless Steel Substrates Aerosol Purity (% ± SD) Hole Diameter % Porosity 0.005″ 0.010″ 0.020″ 0.040″ 5 80.1 ± 1.8 83.6 ± 1.4 77.8 ± 2 70.4 ± 1.1 10 81.4 ± 0.9 75.4 ± 1.2 77.2 ± 2.8 — 20 90.7 ± 0.7 80.8 ± 1.4 74.7 ± 1 — 40 — 85.6 ± 0.8 81.9 ± 1.2 77 ± 1 - Both compounds exhibited similar trends in aerosol purity with increasing hole diameter and porosity. Both compounds exhibited the greatest aerosol purity at a hole diameter of 0.005″ and 20% porosity (
Substrate # 3 in Table 1). Loperamide was less sensitive to changes in air flow than flunisolide. - Sildenafil aerosols were produced by the substrate screening apparatus using 0.005″ thick 316 stainless steel substrates having a regular staggered pattern of circular, 0.006″ diameter holes. The holes, which were formed in the substrate by chemical etching, occupied approximately 27% of the total surface area of the substrate. The distance “d” between the holes was 3.5×10−3 in.
- The substrates were spray-coated with a 15 mg/mL solution of sildenafil free base (isolated from pills, available from Pfizer, Inc., New York, N.Y.) dissolved in dichloromethane/methanol (2:1 volume:volume) at coating densities of 0.18, 0.50, and 1.07 mg/cm2 (approximate coating thicknesses: 1.8, 5.0, and 10.7 μm). Total (across+bottom) air flow rate was 28.3 liters/minute. Various airflow ratios and vaporization temperatures were evaluated.
-
FIG. 7 is abar graph 700 showing aerosol purity (%) and yield (%) 702 for a sildenafil coating density of 0.18 mg/cm2 at various airflow ratio conditions 704 at 400° C. and 360° C. (last set of data). Of the tested air flow ratios, the highest aerosol purity and yield were obtained when 90% of the air flow was directed from under the bottom (uncoated side) of the substrate (refer toFIG. 2B ), and 10% from across the substrate. - Sildenafil aerosols were produced by the substrate screening apparatus using the perforated 316 stainless steel substrates described above and a solid (i.e., non-perforated) 304 stainless steel substrate. The substrates were spray-coated with a 15 mg/mL solution of sildenafil free base (isolated from pills, available from Pfizer, Inc., New York, N.Y.) dissolved in dichloromethane/methanol (2:1 volume:volume) at various drug coating densities. Total (across+bottom) air flow rate was 28.3 liters/minute. Various airflow ratios were evaluated.
-
FIG. 8 is aplot 800 showing aerosol purity (%) 802 of sildenafil free base as a function ofdrug coating thickness 804.Curve 806 represents aerosol purity for the perforated substrates; curve 808 represents aerosol purity for the solid substrates. As shown inplot 800, when the perforated substrates were tested with a 1:9 across:bottom air flow ratio, aerosol purity levels of 97% or more were obtained with drug coating thicknesses up to 6 μm. For the solid substrates with 100% of the air flow directed across the substrate, aerosol purity dropped off rapidly as the drug coating thickness increased. Drug coating thicknesses greater than about 1 μm resulted in aerosol purity levels below 97%. When the drug coating thickness was increased to 2 μm, aerosol purity levels decreased to 94% and below. - Bumetanide condensation aerosols were produced by the substrate screening apparatus using the perforated 316 stainless steel substrates described above. The substrates were spray-coated with a 50 mg/mL solution of bumetanide free base (available from Solmag S.p.A., Garbagnate, Italy) dissolved in methanol/acetone (50:50 volume:volume) at a coating density of 0.07 mg/cm2 (approximate coating thickness: 0.7 μm). Total air flow rate was 20 liters/minute.
- As discussed above, in certain cases, oxidizing the stainless steel substrates prior to drug vaporization yields increased aerosol purity. Therefore, the perforated stainless steel substrates were heat-oxidized and re-cleaned according to the procedure described above prior to coating with drug.
-
FIG. 9 is abar graph 900 showing aerosol purity (%) 902 of bumetanide free base at variousair flow ratios 904. As shown ingraph 900, as the percentage of air flow coming across (as opposed to from under the bottom, uncoated side) the substrate increased, aerosol purity level decreased. However, aerosol purity level remained at 98% when as little as 5% of the air flow was coming through the substrate. - Table 6 presents aerosol purity data as a function of air flow ratio and drug coating density for aerosolization of bumetanide free base from a heat-oxidized, perforated 316 stainless steel substrate (n=3 for each condition tested). Total air flow rate was 20 liters/minute.
-
TABLE 6 Aerosolization of Bumetanide from Perforated Stainless Steel Substrates Air Flow Drug Coating Density (mg/cm2) (Across:Bottom) 0.08 0.26 0.58 100:0 95.8 ± 0.6 94.8 ± 0.2 90.7 ± 0.4 90:10 99.2 ± 0.1 98.6 ± 0.1 98.4 ± 0.3 0:100 99.3 ± 0.1 98.9 ± 0.1 98.7 ± 0.3 - The data shown in Table 6 indicate that a high aerosol purity was maintained as the drug coating thickness was increased, when air flowed through the bottom of the substrate (90:10 and 0:100 air flow ratio). Even a seven-fold increase in drug coating density (from 0.08 to 0.58 mg/cm2) resulted in no significant decrease in aerosol purity. The addition of even a small amount of air flow through the substrate was found to provide a significant increase in the amount of drug that can be coated onto the perforated substrate surface.
- The aerosol purity of bumetanide aerosolized from heat-oxidized, perforated 316 stainless steel substrates was measured as a function of both drug coating density and air flow ratio. Drug coating densities of 0.07, 0.10, and 0.14 mg/cm2 were tested, at across:bottom air flow ratios of 0:100, 50:50, and 100:0. Total air flow rate was 20 liters/minute.
- Table 7 presents aerosol purity data as a function of air flow ratio and drug coating density for aerosolization of bumetanide from a heat-oxidized, perforated 316 stainless steel substrate (n=3 for each condition tested). Total air flow rate was 20 liters/minute.
-
TABLE 7 Aerosolization of Bumetanide from Perforated Stainless Steel Substrates Drug Coating Density (mg/cm2) 0.10 Mean 0.14 Aerosol Relative Mean Relative Air Flow Purity Standard Aerosol Standard (Across:Bottom) (%) Deviation (%) Purity (%) Deviation (%) 100:0 95.7 0.38 94.8 0.14 50:50 98.8 0.08 98.9 0.02 0:100 98.8 0.06 98.8 0.08 - Table 8 presents emitted aerosol purity and emitted drug dose data as a function of air flow ratio for aerosolization of bumetanide from a heat-oxidized, perforated 316 stainless steel substrate (n=3 for each condition tested). Total air flow rate was 20 liters/minute.
-
TABLE 8 Aerosolization of Bumetanide from Perforated Stainless Steel Substrates Emitted Air Flow Aerosol Purity Emitted Drug (Across:Bottom) (%) SD (%) Dose (%) SD (%) 100:0 96.4 0.2 75 7 50:50 98.4 0.2 89 7 0:100 98.5 0.1 82 14 - The emitted drug dose was calculated using the following equation:
-
- The data presented in Tables 7 and 8 are represented graphically in
FIG. 10 , which is aplot 1000 showing aerosol purity (%) 1002 of bumetanide free base as a function ofdrug coating density 1004. The data shown in Tables 7 and 8 andFIG. 10 corroborate the results shown inFIG. 9 , where greater aerosol purities were observed as a greater proportion of the air flow was directed through the substrate. These data substantiate the conclusion that the addition of air flow from beneath the substrate allows for a larger amount of drug to be coated onto the perforated substrate surface, without a loss in aerosol purity. - The effects of varying the air flow ratio on aerosolized particle size were also examined. Table 9 shows mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and % drug recovery for aerosolization of bumetanide from heat-oxidized, perforated 316 stainless steel substrates, at various air flow ratios (n=3 for each condition tested). Drug coating density was approximately 0.07 mg/cm2. Total air flow rate was 28.3 liters/minute.
-
TABLE 9 Aerosolization of Bumetanide from Perforated Stainless Steel Substrates Air flow (Across:Bottom) MMAD (μm) GSD % Drug Recovery 100:0 3.6 ± 0.5 4.0 ± 0.5 63 ± 13 90:10 2.7 ± 0.1 2.0 ± 0.1 78 ± 10 0:100 0.4 ± 0.0 2.4 ± 0.1 69 ± 8 - As shown in Table 9, the particle size (MMAD) tended to decrease as the proportion of the air flow coming through the substrate (as opposed to across the substrate) was increased, allowing the aerosolized drug particle size to be tuned to a desired range by simply varying the across:bottom air flow ratio. The very small drug particle size obtained at the 0:100 across:bottom air flow ratio may indicate that there was substantially more dilution of the vaporized drug compound into the airstream than with the conventional (100% across) air flow arrangement.
- The effects of varying both the drug coating density and air flow ratio on aerosolized particle size were also examined. Table 10 shows mass median aerodynamic diameter (MMAD) and standard deviation (SD) for aerosolization of bumetanide from heat-oxidized, perforated 316 stainless steel substrates, at various drug coating densities and air flow ratios (n=3 for each condition tested). Total air flow rate was 28.3 liters/minute.
-
TABLE 10 Aerosolization of Bumetanide from Perforated Stainless Steel Substrates Drug Coating Density Air flow Average MMAD (mg/cm2) (Across:bottom) (μm) SD (μm) 0.08 90:10 2.2 0.4 0.26 90:10 1.6 0.2 0.58 100:0 1.7 0.2 90:10 1.9 0.1 0:100 0.9 0.1 - The data presented in Table 10 are illustrated graphically in
FIG. 11 , which is aplot 1100 of average MMAD 902 as a function of air flow ratio (across:bottom) 1104.Curves - The data shown in Table 10 and
FIG. 11 substantiate the previous findings that the particle size (MMAD) decreases as the proportion of the air flow coming through the substrate is increased, due to increased mixing of drug with the air. - Vardenafil condensation aerosols were produced by the substrate screening apparatus using perforated stainless steel substrates. The substrates were spray-coated with a 20 mg/mL solution of vardenafil free base (isolated from the HCl trihydrate salt available from Bosche Scientic, LLC, New Brunswick, N.J.) in dichloromethane/methanol (3:1 volume:volume) at drug coating densities of 0.112, 0.334, and 0.883 mg/cm2 (approximate coating thickness: 1.12, 3.34, and 8.83 μm). Total air flow rate was 28.3 liters/minute. Various airflow ratios and vaporization temperatures were evaluated.
- Table 11 presents aerosol purity data as a function of drug film thickness, substrate temperature, and air flow ratio for aerosolization of vardenafil from a perforated 316 stainless steel substrate (n=3 for each condition tested, unless otherwise indicated).
-
TABLE 11 Aerosol Purity of Vardenafil Aerosolized from Perforated Stainless Steel Substrates Aerosol Purity (%) Drug Air Flow Ratio (Across:Bottom) Film 100:0 75:25 Thickness Coat Substrate Temperature (° C.) (μm) Control 350 400 425 350 400 425 1.12 98.9* 95.3 95.3 95.0 97.0 96.6 96.6 3.34 98.8* 92.5 88.9 88.7 95.8 95.7 95.6 8.83 98.9* 89.5 83.2** 80.8 96.1 93.2 93.3 *n = 4. **n = 2. - In general, greater vardenafil drug purities were obtained with a 75:25 (across:bottom) air flow ratio than with a 100:0 air flow ratio. Aerosol purities were observed to decrease as the drug film thickness was increased. This effect was more pronounced with the 100:0 air flow ratio than with the 75:25 air flow ratio. Aerosol purity also tends to decrease as the substrate temperature during aerosolization was increased.
- Table 12 presents aerosolized drug yield data as a function of drug film thickness, substrate temperature, and air flow ratio for aerosolization of vardenafil from a perforated 316 stainless steel substrate (n=3 for each condition tested, unless otherwise indicated).
-
TABLE 12 Drug Yield of Vardenafil Aerosolized from Perforated Stainless Steel Substrates Aerosolized Drug Yield (%) Air flow ratio (Across:bottom) 100:0 75:25 Drug Film Substrate Temperature (° C.) Thickness (μm) 350 400 425 350 400 425 1.12 78.1 73.1 72.3 91.8 95.2 98.9 3.34 70.8* 68.8 67.6 89.1 86.5 84.2 8.83 33.6** 48.2 50.9 47.1** 89.2 85.4 *n = 1. **n = 2. - As with drug purities (shown in Table 12), greater vardenafil drug yields were obtained with a 75:25 (across:bottom) air flow ratio than with a 100:0 air flow ratio. Aerosolized drug yields were also seen to decrease as the drug film thickness was increased. Again, this effect was less pronounced with the 75:25 air flow ratio than with the 100:0 air flow ratio.
- In summary, the 75:25 (across:bottom) air flow ratio produced good results in terms of both aerosol purity and drug yield for vardenafil aerosolized from a perforated 316 stainless steel substrate. At aerosolization temperatures of 350° C., both aerosol purity and yield were good with the 75:25 air flow ratio and a drug film thickness of less than 3.3 μm. At substrate temperatures of 400° C. and 425° C., both aerosol purity and yield were very similar with either the 75:25 or 100:0 air flow ratios.
- Tadalafil condensation aerosols were produced by the substrate screening apparatus using perforated stainless steel substrates. The substrates were spray-coated with a 20 mg/mL solution of tadalafil free-base (isolated from the HCl trihydrate salt available from Bosch Scientific, LLC, New Brunswick, N.J.) in dichloromethane/methanol (3:1 volume:volume) at drug coating densities of 0.236, 0.604, and 1.17 mg/cm2 (approximate coating thickness: 2.36, 6.04, and 11.7 Mm). Total air flow rate was 28.3 liters/minute. Various airflow ratios and vaporization temperatures were evaluated.
- Table 13 presents aerosol purity data as a function of drug film thickness, substrate temperature, and air flow ratio for aerosolization of tadalafil from a perforated 316 stainless steel substrate (n=3 for each condition tested, unless otherwise indicated).
-
TABLE 13 Aerosol Purity of Tadalafil Aerosolized from Perforated Stainless Steel Substrates Drug Aerosol Purity (%) Film Air Flow Ratio (Across:Bottom) Thick- Coat 100:0 75:25 ness Con Substrate Temperature (° C.) (μm) trol 325 350 375 400 325 350 375 400 2.36 99.9* 97.8 98.0 97.4 97.8 99.2 98.9 98.8 99.0 6.04 99.9* 98.6 96.2 95.1 93.2 98.8 98.6 97.9 97.2 11.70 99.9* — 92.6 87.5 84.0 — 97.0 96.0 95.1 *n = 4. - As with vardenafil, greater tadalafil drug purities were obtained with a 75:25 (across:bottom) air flow ratio than with a 100:0 air flow ratio. Aerosol purities were also seen to decrease as the drug film thickness was increased. Again, this effect was much more pronounced with the 100:0 air flow ratio than with the 75:25 air flow ratio. Aerosol purity also tended to decrease as the substrate temperature during aerosolization was increased.
- Table 14 presents drug yield data as a function of drug film thickness, substrate temperature, and air flow ratio for aerosolization of tadalafil from a perforated 316 stainless steel substrate (n=3 for each condition tested, unless otherwise indicated).
-
TABLE 14 Drug Yield of Tadalafil Aerosolized from Perforated Stainless Steel Substrates Aerosolized Drug Yield (%) Air Flow Ratio (Across:Bottom) 100:0 75:25 Drug Film Substrate Temperature (° C.) Thickness (μm) 325 350 375 400 325 350 375 400 2.36 76.6 81.1 89.1 88.9 73.5 99.0 95.2 99.7 6.04 25.7* 66.9 60.4 76.6 26.1 40.2 85.3* 96.8 11.70 — 58.2 69.0 78.7 — 68.0 80.6 80.2 *n = 2. - As with vardenafil, greater tadalafil drug yields were obtained with a 75:25 (across:bottom) air flow ratio than with a 100:0 air flow ratio. Aerosolized drug yields were also seen to decrease as the drug film thickness is increased. Again, this effect was more pronounced with the 100:0 air flow ratio than with the 75:25 air flow ratio. In general, higher substrate temperatures during aerosolization tended to result in greater drug yields.
- In summary, the 75:25 (across:bottom) air flow ratio produced good results in terms of both aerosol purity and drug yield for tadalafil aerosolized from a perforated 316 stainless steel substrate. The 100:0 air flow ratio resulted in lower drug yields (<85%), even at substrate temperatures of 400° C. The 75:25 air flow ratio, at substrate temperatures of 350° C. and drug film thicknesses of 11.7 μm or more, resulted in drug yields less than 70%. Substrate temperatures of 375° C. and 400° C. result in yields of about 80%. The 75:25 air flow ratio, at substrate temperatures of 375° C. and drug film thicknesses of 11.7 μm, resulted in good drug yields and drug purities of about 96%.
- Fentanyl condensation aerosols were produced by the substrate screening apparatus using non-perforated polyimide film (KAPTON® polyimide film, available from DuPont, Wilmington, Del.). The substrates were spray-coated with fentanyl free base.
- Aerosol purity of the coated drug was measured by HPLC initially (storage time 0) and at various time intervals up to 90 weeks.
FIG. 12 is abar graph 1200 showing aerosol purity (%) 1202 of a fentanyl-coated polyimide film as a function of storage time 1204 at 40° C. The aerosol purity of fentanyl coated onto polyimide film remained very high (˜99.7%) after 90 weeks storage. - Prochlorperazine condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film (KAPTON® polyimide film, available from DuPont, Wilmington, Del.). Copper heater traces were formed on one surface of a sheet of polyimide film. Holes were formed between the heater traces by chemical etching. The polyimide film heating units were spray-coated on the polyimide film surface with a 25 mg/mL solution of prochlorperazine free base (available from Industria Chimica Milanese, Milano, Italy) in acetone. Total air flow rate was 28.3 liters/minute. Various airflow ratios were evaluated.
- The aerosol purity of prochlorperazine aerosolized from perforated polyimide film heating units was measured at various drug coating thicknesses and air flow ratios of 0:100, 90:10, and 100:0 across:bottom.
FIG. 13 is aplot 1300 showing aerosol purity (%) 1302 of prochlorperazine at various drug coating thicknesses 1304.Curves curve 1312 represents aerosolization of prochlorperazine from a non-perforated 304 stainless steel substrate.Dotted line 1314 represents the coated aerosol purity. - As previously observed with aerosolization of various drugs from perforated stainless steel substrates, as the percentage of air flow coming from under the bottom side of the substrate increased, aerosol purity level also increased, and a greater drug coating thickness can be used. When 100% of the air flow came through the substrate, aerosol purity levels of 98% or greater were obtained up to at least 30 μm drug coating thickness.
- The coated aerosol purity was compared with the aerosol purity of prochlorperazine vaporized from polyimide film substrates having “small” and “large” holes (refer to
FIGS. 2A and 2B ). Drug coating thickness was 14 μm; total air flow was set at 30 liters/minute. The data from this set of experiments are shown in Table 15, below. -
TABLE 15 Vaporization of Prochlorperazine from Perforated Polyimide Film Substrates Aerosol Purity (%) Small Holes Large Holes Air Flow Ratio Air Flow Ratio Coated Aerosol (Across:Bottom) (Across:Bottom) Purity (%) 100:0 75:25 100:0 75:25 98.85 94.8 97.4 97.1 97.7 - For the heaters with the small holes, aerosol purity declined from 97.4% to 94.8% as the air flow coming across the substrate was increased from 75% to 100%. For the large-hole heaters, there was no significant difference in aerosol purity as the relative amount of air flow coming across the substrate was increased. It is believed that the higher than expected aerosol purity coming from the large-holed substrates with 100% across air flow may be due to the presence of air flowing through the heater elements, even though no air is directly routed up from the bottom of the substrate.
- Adenosine condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates. The substrates were spray-coated with adenosine free base at various coating densities. Various airflow ratios and vaporization temperatures were evaluated.
-
FIG. 14 is aplot 1400 showing aerosol purity (%) 1402 of aerosolized adenosine free base as a function of drug coating density (mg/cm2) 1404.Curves Curves - As can be seen from the data presented in
plot 1400, greater aerosol purities were achieved using lower (350° C. as opposed to 375° C.) vaporization temperatures and greater air flow thorough the substrate as opposed to across the substrate. Aerosol purity showed a decrease with increases in drug coating density. - Baclofen condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates. The substrates were spray-coated with baclofen free base at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 15 is aplot 1500 showing aerosol purity (%) 1502 of aerosolized baclofen free base as a function of drug coating density (mg/cm2) 1504.Curves Curves 1510 and 1512 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 330° C. and 350° C., respectively. Data points 1514 represent an across:bottom air flow ratio of 27:1 and a vaporization temperature of 350° C. - As can be seen from the data presented in
plot 1500, greater aerosol purities were achieved using lower (330° C. as opposed to 350° C.) vaporization temperatures and greater air flow through the substrate as opposed to across the substrate. Very poor drug purities of around 20% were obtained when nearly all of the air flow was directed across the substrate (27:1 ratio). Aerosol purity showed a decrease with increases in drug coating density. - Ciclesonide condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates. The substrates were spray-coated with ciclesonide free base at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 16 is aplot 1600 showing aerosol purity (%) 1602 of aerosolized ciclesonide free base as a function of drug coating density (mg/cm2) 1604.Curves Curves Curves 1610 and 1612 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 325° C. and 360° C., respectively. -
Curves Curves - As can be seen from the data in
plot 1600, greater aerosol purities were achieved using greater air flow through substrate as opposed to across the substrate. Greater aerosol purities were achieved using lower vaporization temperatures (325° C. as opposed to 360° C.) for the perforated polyimide film substrates with the 1:3 air flow ratio. This trend was slightly reversed for the perforated polyimide film substrates with the 3:1 air flow ratio. Aerosol purity decreased with increases in drug coating density. This trend was particularly observed with the stainless steel substrates. - Cyclobenzaprine fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates. The substrates were spray-coated with cyclobenzaprine fumarate at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 17 is aplot 1700 showing aerosol purity (%) 1702 of aerosolized cyclobenzaprine fumarate as a function of drug coating density (mg/cm2) 1704.Curve 1706 represents a drug coating control.Curve 1708 represents an across:bottom air flow ratio of 6:1 (24:4 LPM) and a vaporization temperature of 375°C. Curve 1710 represents an across:bottom air flow ratio of 3:1 (21:7 LPM) and a vaporization temperature of 350°C. Curve 1712 represents an across:bottom air flow ratio of 1:1 (14:14 LPM) and a vaporization temperature of 350° C. - As can be seen from the data presented in
plot 1700, all three test conditions provided excellent (>99.7%) aerosol purities. In general, aerosol purities improved using lower (350° C. as opposed to 375° C.) vaporization temperatures and greater air flow through the substrate as opposed to across the substrate. Best results were achieved using a vaporization temperature of 350° C. and an air flow ratio of 3:1, although this set of test conditions was slightly more sensitive to increases in drug coating density. In general, although aerosol purity showed a decrease with increases in drug coating density, this effect was not significant at any of the test conditions. - Diphenhydramine fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates. The substrates were spray-coated with diphenhydramine fumarate at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 18 is aplot 1800 showing aerosol purity (%) 1802 of aerosolized diphenhydramine fumarate as a function of drug coating density (mg/cm2) 1804.Curves Curves Curves 1810 and 1812 represent an across:bottom air flow ratio of 1:3 (7:21 LPM) and vaporization temperatures of 325° C. and 350° C., respectively. -
Curves 1814 and 1986 show aerosol purity data for drug vaporized from non-perforated heat-passivated 304 stainless steel substrates, with no air flow ratio (i.e., 100% of the air flow was directed across the substrate).Curves - As can be seen from the data presented in
plot 1800, greater aerosol purities were achieved using lower vaporization temperatures (325° C. as opposed to 350° C.) and greater air flow through the substrate as opposed to across the substrate. For the polyimide film substrates, aerosol purity showed some decrease with increases in drug coating density. This trend was particularly observed with the stainless steel substrates. - Flunisolide condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates, perforated heat-passivated stainless steel substrates, and perforated SULFINERT-treated stainless steel substrates. (SULFINERT is an amorphous silicon. The SULFINERT-treated stainless steel substrates were obtained from Restek Corp., Bellefonte, Pa.) The substrates were spray-coated with flunisolide free base at various coating densities. All samples were tested using an across:bottom air flow ratio of 3:1 (21:7 LPM). Various vaporization temperatures were evaluated.
-
FIG. 19 is aplot 1900 showing aerosol purity (%) 1902 of aerosolized flunisolide free base as a function of drug coating density (mg/cm2) 1904.Curve 1906 represents a drug coating control.Curves Curves 1912 and 1914 show aerosol purity data for drug vaporized from perforated SULFINERT-treated 316 stainless steel substrates at vaporization temperatures of 325° C. and 375° C., respectively.Curves - As can be seen from the data presented in
plot 1900, for the polyimide film substrates and the SULFINERT-treated stainless steel substrates, increased vaporization temperature had little effect on aerosol purity. For the heat-passivated stainless steel substrates, aerosol purities showed a significant decrease with increases in vaporization temperature at the higher drug coating density densities. - Fluticasone propionate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates. The substrates were spray-coated with fluticasone propionate at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 20 is aplot 2000 showing aerosol purity (%) 2002 of aerosolized fluticasone propionate as a function of drug coating density (mg/cm2) 2004.Curves Curves Curves -
Curves Curves - As can be seen from the data presented in
plot 2000, for the polyimide film substrates, all four test conditions provided excellent (>97%) aerosol purities. For this particular drug aerosolized from polyimide film substrates, neither vaporization temperature nor air flow ratio appeared to have a significant effect on aerosol purity. For the stainless steel substrates, greater drug purities were obtained at lower vaporization temperatures. Drug coating density had a significant effect on aerosol purities for drug vaporized from the stainless steel substrates. - Mometasone fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates, non-perforated heat-passivated stainless steel substrates, and non-perforated SULFINATE-treated stainless steel substrates. The substrates were spray-coated with mometasone fumarate at various coating densities. The polyimide film samples were evaluated using an across:bottom air flow ratio of 3:1 (21:7 LPM). The stainless steel samples were evaluated with no air flow ratio. Various vaporization temperatures were evaluated.
-
FIG. 21 is aplot 2100 showing aerosol purity (%) 2102 of aerosolized mometasone fumarate as a function of drug coating density (mg/cm2) 2104.Curves Data point 2112 shows aerosol purity data for drug vaporized from non-perforated SULFINERT-treatedstainless steel 304 substrates at a vaporization temperature of 350°C. Data point 2114 shows aerosol purity data for drug vaporized from non-perforated heat-passivatedstainless steel 304 substrates at a vaporization temperature of 350° C. - As can be seen from the data presented in
plot 2100, for the polyimide film substrates, increased vaporization temperature had little effect on aerosol purity. On the other hand, drug coating density had a significant effect on aerosol purity. Aerosol purities for both the SULFINERT-treated and heat-passivated stainless steel substrates were poor. - Paroxetine fumarate condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates. The substrates were spray-coated with paroxetine fumarate at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 22 is aplot 2200 showing aerosol purity (%) 2202 of aerosolized paroxetine fumarate as a function of drug coating density (mg/cm2) 2204.Curves Curves Curves -
Curves Curves - As can be seen from the data presented in
plot 2200, for the polyimide film substrates, greater aerosol purities were achieved using lower vaporization temperatures (350° C. as opposed to 375° C.) and greater air flow through the substrate as opposed to across the substrate. The stainless steel substrates provided poor aerosol purities in general. For both the polyimide film and stainless steel substrates, aerosol purities decreased with increases in drug coating density. - Tadalafil condensation aerosols were produced by the substrate screening apparatus using perforated heat-passivated stainless steel substrates. The substrates were spray-coated with tadalafil free base at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 23 is aplot 2300 showingaerosol purity 2302 of aerosolized tadalafil free base as a function of drug coating density (mg/cm2) 2304.Curve 2306 represents a drug coating control.Curves Curves - As can be seen from the data presented in
plot 2300, greater aerosol purities were achieved using lower vaporization temperatures and greater air flow through the substrate as opposed to across the substrate. Although, in general, aerosol purities dropped as drug coating density increased, this effect was especially pronounced at the 1:0 air flow ratio. - Tizanadine condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates, non-perforated heat-passivated stainless steel substrates, and non-perforated non-passivated stainless steel substrates. The substrates were spray-coated with tizanadine free base at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 24 is aplot 2400 showing aerosol purity (%) 2402 of aerosolized tizanadine free base as a function of drug coating density (mg/cm2) 2404.Curve 2406 represents the drug coating control.Curves Curve 2414 shows aerosol purity data for drug vaporized from non-perforated non-passivated 304 stainless steel substrates, with no air flow ratio and a vaporization temperature of 400° C. -
Curves Curves - As can be seen from the data presented in
plot 2400, both of the polyimide film samples showed excellent (>98%) aerosol purity, regardless of the air flow ratio. For the heat-passivated stainless steel substrates, aerosol purity declined with increases in vaporization temperature and drug coating density. The non-passivated stainless steel substrates performed most poorly of all. - Vardenafil condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and perforated heat-passivated stainless steel substrates. The substrates were spray-coated with vardenafil free base at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 25 is aplot 2500 showing aerosol purity (%) 2502 of aerosolized vardenafil free base as a function of drug coating density (mg/cm2) 2504.Curve 2506 represents a drug coating control.Curves Curves -
Curves 2520 and 2522 show aerosol purity data for drug vaporized from perforated polyimide film substrates, at an across:bottom air flow ratio of 3:1 (21:7 LPM) and vaporization temperatures of 350° C. and 375° C., respectively. - As can be seen from the data presented in
plot 2500, the greatest aerosol purities were obtained at an air flow ratio of 3:1 and vaporization temperature of 350° C., for both the polyimide film and stainless steel substrates. These conditions also showed very little sensitivity to increases in drug coating density. Worst results were obtained with the stainless steel substrates at an air flow ratio of 1:0 and vaporization temperatures of 400° C. and 425° C. Under these conditions, a decrease in aerosol purity with increasing drug coating density was observed. - Zaleplon condensation aerosols were produced by the substrate screening apparatus using perforated polyimide film substrates and non-perforated heat-passivated stainless steel substrates. The substrates were spray-coated with zaleplon free base at various coating densities. Various air flow ratios and vaporization temperatures were evaluated.
-
FIG. 26 is aplot 2600 showing aerosol purity (%) 2602 of aerosolized zaleplon free base as a function of drug coating density (mg/cm2) 2604.Curve 2606 represents a drug coating control.Curves Curves - As can be seen from the data presented in
plot 2600, all four test conditions provided excellent (>99.4%) aerosol purities. For this particular drug, neither vaporization temperature nor air flow ratio appeared to have a significant effect on aerosol purity, regardless of the substrate. Although aerosol purity decreased with increased drug coating density, this effect appeared to be minimal. - Drug is dissolved or suspended in a solvent (e.g., dichloromethane or methanol). The solution or suspension is coated to about a 4 micron thickness on a stainless steel substrate of about 8 cm2 surface area. The substrate may either be a standard stainless steel foil or a heat-passivated stainless steel foil. The substrate is heated to a temperature sufficient to generate a thermal vapor (generally ˜350° C.) but at least to a temperature of 200° C. with an air flow typically of 20 L/min (1 m/s) passing over the film during heating. The heating is done in a volatilization chamber fitted with a trap (such as described in the Examples above). After vaporization is complete, airflow is discontinued and the resultant aerosol is analyzed for purity using the methods disclosed herein. If the resultant aerosol contains less than 10% drug degradation product, i.e., the TSR≧9, then the drug is a heat stable drug. If, however, at about 4 micron thickness, greater than 10% degradation is determined, the experiment is repeated at the same conditions, except that film thicknesses of about 1.5 microns, and of about 0.5 micron, respectively, are used. If a decrease in degradation products relative to the 4 micron thickness is seen at either of these thinner film thicknesses, a plot of film thickness versus purity is graphed and extrapolated out to a film thickness of 0.05 microns. The graph is used to determine if there exists a film thickness where the purity of the aerosol would be such that it contains less than 10% drug degradation products. If such a point exists on the graph, then the drug is defined as a heat stable drug.
- Drug (1 mg) is dissolved or suspended in a minimal amount of solvent (e.g., dichloromethane or methanol). The solution or suspension is pipetted onto the middle portion of a 3 cm by 3 cm piece of aluminum foil. The coated foil is wrapped around the end of a 1½ cm diameter vial and secured with parafilm. A hot plate is preheated to approximately 300° C., and the vial is placed on it foil side down. The vial is left on the hotplate for 10 s after volatilization or decomposition has begun. After removal from the hotplate, the vial is allowed to cool to room temperature. The foil is removed, and the vial is extracted with dichloromethane followed by saturated aqueous NaHCO3. The organic and aqueous extracts are shaken together, separated, and the organic extract is dried over Na2SO4. An aliquot of the organic solution is removed and injected into a reverse-phase HPLC with detection by absorption of 225 nm light. A drug is preferred for aerosolization where the purity of the drug isolated by this method is greater than 85%. Such a drug has a decomposition index less than 0.15. The decomposition index is arrived at by subtracting the aerosol purity fraction (i.e., 0.85) from 1.
- Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention. One of ordinary skill in the art can combine the foregoing embodiments or make various other embodiments and aspects of the method and device of the present invention to adapt them to specific usages and conditions. As such, these changes and modifications are properly, equitably, and intended to be within the full range of equivalents of the following claims.
Claims (48)
1. A drug supply unit comprising a substrate, wherein the substrate has a surface containing a plurality of holes, and wherein at least a portion of the surface is coated with a drug composition.
2. The drug supply unit of claim 1 , wherein the plurality of holes comprises at least 10 holes.
3. The drug supply unit of claim 2 , wherein the plurality of holes comprises at least 50 holes.
4. The drug supply unit of claim 3 , wherein the plurality of holes comprises at least 100 holes.
5. The drug supply unit of claim 1 , wherein the substrate has a thickness, and wherein the holes are circular and have a diameter at least as great as the thickness of the substrate.
6. The drug supply unit of claim 5 , wherein the substrate has a thickness of at least 5.0×10−4 inches.
7. The drug supply unit of claim 6 , wherein the substrate has a thickness in the range of 5.0×10−4 to 5.0×10−3 inches.
8. The drug supply unit of claim 7 , wherein the portion of the surface that is coated with a drug composition has a surface area in the range of 8 mm2 to 20 cm2.
9. The drug supply unit of claim 8 , wherein the portion of the surface that is coated with a drug composition has a surface area in the range of 9 mm2 to 15 cm2.
10. The drug supply unit of claim 1 , wherein the portion of the surface that is coated with a drug composition has a porosity in the range of 1% to 70%.
11. The drug supply unit of claim 10 , wherein the portion of the surface that is coated with a drug composition has a porosity in the range of 10% to 60%.
12. The drug supply unit of claim 11 , wherein the portion of the surface that is coated with a drug composition has a porosity in the range of 20% to 50%.
13. The drug supply unit of claim 1 , wherein the substrate comprises a metal.
14. The drug supply unit of claim 13 , wherein the metal is selected from the group consisting of stainless steel, aluminum, gold, copper, titanium, and combinations thereof.
15. The drug supply unit of claim 14 , wherein the metal is stainless steel.
16. The drug supply unit of claim 15 , wherein the stainless steel is heat-passivated.
17. The drug supply unit of claim 15 , wherein the stainless steel is amorphous silicon treated.
18. The drug supply unit of claim 1 , wherein the substrate comprises a polymer.
19. The drug supply unit of claim 18 , wherein the substrate has a thickness within the range of about 5.0×10−4 to 1.0×10−2 inches.
20. The drug supply unit of claim 18 , wherein the polymer is a polyimide.
21. The drug supply unit of claim 20 , wherein the substrate is a polyimide film having a first surface and second surface, and wherein electrically conductive traces are formed on the first surface of the polyimide film substrate.
22. The drug supply unit of claim 21 , wherein the drug composition is coated onto the first surface of the polyimide film substrate.
23. The drug supply unit of claim 21 , wherein the drug composition is coated onto the second surface of the polyimide film substrate.
24. The drug supply unit of claim 21 , wherein the drug is coated onto both the first surface and the second surface of the polyimide film substrate.
25. The drug supply unit of claim 1 , wherein the drug supply unit is configured to heat at least a portion of the substrate to a temperature of at least 200° C.
26. The drug supply unit of claim 1 , wherein the substrate is an exterior surface of the drug supply unit.
27. The drug supply unit of claim 1 , wherein the substrate is a separate layer of material in close proximity to an exterior surface of the drug supply unit.
28. The drug supply unit of claim 1 , wherein the drug supply unit comprises an electrically resistive heating unit.
29. An aerosol drug delivery device comprising:
a housing defining an airway;
a drug supply unit comprising a surface, wherein at least a portion of the surface includes a plurality of holes;
a heating element operatively associated with the drug supply unit; and
a drug composition coated onto at least a portion of the surface of the substrate;
wherein the heating element is configured to heat the substrate to a temperature sufficient to vaporize at least a portion of the drug.
30. A method of producing a drug-containing aerosol, the method comprising:
a. providing an aerosol drug delivery device comprising
a housing defining an airway;
a drug supply unit comprising a surface, wherein at least a portion of the surface includes a plurality of holes;
a heating element operatively associated with the drug supply unit; and
a drug composition coated onto at least a portion of the surface of the substrate;
wherein the heating element is configured to heat the substrate to a temperature sufficient to vaporize at least a portion of the drug.
b. providing an air flow through the plurality of holes while heating the substrate; and
c. allowing the vaporized drug to cool and condense into an aerosol comprising particles.
31. The method of claim 30 , wherein the substrate is an exterior surface of the drug supply unit.
32. The method of claim 30 , wherein the substrate is a separate layer of material in close proximity to an exterior surface of the drug supply unit.
33. The method of claim 30 , wherein the drug is heated to a temperature and for a duration that results in an acceptably low level of decomposition.
34. The method of claim 30 , wherein the vaporized drug is rapidly mixed into the air flow to cool and preclude additional decomposition of the drug.
35. The method of claim 30 , wherein the drug-containing aerosol has a purity level of at least 95%.
36. The method of claim 35 , wherein the drug-containing aerosol has a purity level of at least 96%.
37. The method of claim 36 , wherein the drug-containing aerosol has a purity level of at least 97%.
38. A drug supply unit, wherein the drug supply unit is configured to heat a drug coated on a surface of a substrate to a temperature sufficient to vaporize the drug, wherein a portion of the substrate includes a plurality of holes formed therethrough, and wherein the number of and spacing between the holes is sufficient that a drug vaporized from the substrate exhibits a purity that is greater than the purity of a drug vaporized from a substrate that does not include a plurality of holes formed therethrough.
39. The drug supply unit of claim 38 , wherein the drug supply unit comprises an electrically resistive heating unit.
40. An aerosol drug delivery device comprising:
a housing defining an airway;
a drug supply unit that is configured to heat a drug disposed on an exterior surface of a substrate to a temperature sufficient to vaporize the drug, wherein a portion of the exterior surface of the substrate includes a plurality of holes formed therethrough; and
a drug disposed on a portion of the exterior surface of the substrate,
wherein the number of and spacing between the holes is sufficient that, when the drug is vaporized from the substrate, the vaporized drug exhibits a purity that is greater than the purity of a drug vaporized from a substrate that does not include a plurality of holes formed therethrough.
41. A method of producing a drug-containing aerosol comprising:
providing an aerosol delivery device comprising
a housing defining an airway;
a drug supply unit that is configured to heat a drug disposed on a surface of a substrate to a temperature sufficient to vaporize the drug, wherein a portion of the exterior surface of the substrate includes a plurality of holes formed therethrough; and
a drug disposed on a portion of the exterior surface of the substrate,
providing an air flow through the plurality of holes while subsequently heating the substrate to a temperature sufficient to vaporize the drug; and
allowing the vaporized drug to condense into an aerosol comprising particles,
wherein the number of and spacing between the holes is sufficient that the vaporized drug exhibits a purity that is greater than the purity of a drug vaporized from a substrate that does not include a plurality of holes formed therethrough.
42. The method of claim 41 , wherein the substrate is an exterior surface of the drug supply unit.
43. The method of claim 41 , wherein the substrate is a separate layer of material in close proximity to an exterior surface of the drug supply unit.
44. The method of claim 41 , wherein the drug is heated to a temperature and for a duration that results in an acceptably low level of decomposition.
45. The method of claim 41 , wherein the vaporized drug is rapidly mixed into the air flow to cool and preclude additional decomposition of the drug.
46. The method of claim 41 , wherein the drug-containing aerosol has a purity level of at least 95%.
47. The method of claim 46 , wherein the drug-containing aerosol has a purity level of at least 96%.
48. The method of claim 47 , wherein the drug-containing aerosol has a purity level of at least 97%.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/045,674 US20080216828A1 (en) | 2007-03-09 | 2008-03-10 | Heating unit for use in a drug delivery device |
US15/289,772 US10625033B2 (en) | 2007-03-09 | 2016-10-10 | Heating unit for use in a drug delivery device |
US16/853,400 US11642473B2 (en) | 2007-03-09 | 2020-04-20 | Heating unit for use in a drug delivery device |
US18/144,775 US20230285691A1 (en) | 2007-03-09 | 2023-05-08 | Heating unit for use in a drug delivery device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89411607P | 2007-03-09 | 2007-03-09 | |
US12/045,674 US20080216828A1 (en) | 2007-03-09 | 2008-03-10 | Heating unit for use in a drug delivery device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/289,772 Continuation US10625033B2 (en) | 2007-03-09 | 2016-10-10 | Heating unit for use in a drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080216828A1 true US20080216828A1 (en) | 2008-09-11 |
Family
ID=39740406
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/045,674 Abandoned US20080216828A1 (en) | 2007-03-09 | 2008-03-10 | Heating unit for use in a drug delivery device |
US15/289,772 Active US10625033B2 (en) | 2007-03-09 | 2016-10-10 | Heating unit for use in a drug delivery device |
US16/853,400 Active 2029-04-14 US11642473B2 (en) | 2007-03-09 | 2020-04-20 | Heating unit for use in a drug delivery device |
US18/144,775 Pending US20230285691A1 (en) | 2007-03-09 | 2023-05-08 | Heating unit for use in a drug delivery device |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/289,772 Active US10625033B2 (en) | 2007-03-09 | 2016-10-10 | Heating unit for use in a drug delivery device |
US16/853,400 Active 2029-04-14 US11642473B2 (en) | 2007-03-09 | 2020-04-20 | Heating unit for use in a drug delivery device |
US18/144,775 Pending US20230285691A1 (en) | 2007-03-09 | 2023-05-08 | Heating unit for use in a drug delivery device |
Country Status (4)
Country | Link |
---|---|
US (4) | US20080216828A1 (en) |
EP (1) | EP2121088B1 (en) |
ES (1) | ES2594867T3 (en) |
WO (1) | WO2008112661A2 (en) |
Cited By (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040105819A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Respiratory drug condensation aerosols and methods of making and using them |
US20050034723A1 (en) * | 2003-08-04 | 2005-02-17 | Bryson Bennett | Substrates for drug delivery device and methods of preparing and use |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US7981401B2 (en) | 2002-11-26 | 2011-07-19 | Alexza Pharmaceuticals, Inc. | Diuretic aerosols and methods of making and using them |
US7987846B2 (en) | 2002-05-13 | 2011-08-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US8074644B2 (en) | 2001-06-05 | 2011-12-13 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US8173107B2 (en) | 2001-05-24 | 2012-05-08 | Alexza Pharmaceuticals, Inc. | Delivery of antipsychotics through an inhalation route |
US8333197B2 (en) | 2004-06-03 | 2012-12-18 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US8387612B2 (en) | 2003-05-21 | 2013-03-05 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
WO2013160112A3 (en) * | 2012-04-23 | 2014-04-03 | British American Tobacco (Investments) Limited | Heating smokeable material |
EP2723429A1 (en) * | 2011-08-16 | 2014-04-30 | Ploom, Inc. | Low temperature electronic vaporization device and methods |
US20150223523A1 (en) * | 2014-02-11 | 2015-08-13 | Timothy McCullough | Drug delivery system and method |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US9357803B2 (en) | 2011-09-06 | 2016-06-07 | British American Tobacco (Investments) Limited | Heat insulated apparatus for heating smokable material |
WO2016107767A1 (en) * | 2014-12-29 | 2016-07-07 | British American Tobacco (Investments) Limited | Heating device for apparatus for heating smokable material and method of manufacture |
US9414629B2 (en) | 2011-09-06 | 2016-08-16 | Britsh American Tobacco (Investments) Limited | Heating smokable material |
US20160354561A1 (en) * | 2014-02-11 | 2016-12-08 | Timothy McCullough | Methods and drug delivery devices using cannabis |
US9549573B2 (en) | 2013-12-23 | 2017-01-24 | Pax Labs, Inc. | Vaporization device systems and methods |
US9555199B2 (en) | 2010-03-10 | 2017-01-31 | Batmark Limited | Laminar evaporator |
US9609894B2 (en) | 2011-09-06 | 2017-04-04 | British American Tobacco (Investments) Limited | Heating smokable material |
US20170189628A1 (en) * | 2010-01-12 | 2017-07-06 | Omega Life Science Ltd. | Method and apparatus for producing fine concentrated aerosol |
US9724341B2 (en) | 2013-07-11 | 2017-08-08 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
EP3248485A1 (en) * | 2009-10-29 | 2017-11-29 | Philip Morris Products S.a.s. | An electrically heated smoking system with improved heater |
US10010695B2 (en) | 2011-02-11 | 2018-07-03 | Batmark Limited | Inhaler component |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
US10036574B2 (en) | 2013-06-28 | 2018-07-31 | British American Tobacco (Investments) Limited | Devices comprising a heat source material and activation chambers for the same |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US10045562B2 (en) | 2011-10-21 | 2018-08-14 | Batmark Limited | Inhaler component |
US10045567B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045568B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
CN108414609A (en) * | 2018-02-05 | 2018-08-17 | 吉林大学 | The on-line mass spectroscopy detection device of nutritional ingredient change procedure during a kind of Chinese medicine steams |
US10058130B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10104915B2 (en) | 2013-12-23 | 2018-10-23 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10111466B2 (en) | 2013-05-02 | 2018-10-30 | Nicoventures Holdings Limited | Electronic cigarette |
US10111470B2 (en) | 2013-12-23 | 2018-10-30 | Juul Labs, Inc. | Vaporizer apparatus |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
US10231484B2 (en) | 2007-12-18 | 2019-03-19 | Juul Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
US10314335B2 (en) | 2013-05-02 | 2019-06-11 | Nicoventures Holdings Limited | Electronic cigarette |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US10426193B2 (en) | 2013-06-04 | 2019-10-01 | Nicoventures Holdings Limited | Container |
US10463069B2 (en) | 2013-12-05 | 2019-11-05 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
EP3114947B1 (en) | 2012-07-16 | 2019-12-18 | Nicoventures Holdings Limited | Electronic vapour provision device |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
US10543323B2 (en) | 2008-10-23 | 2020-01-28 | Batmark Limited | Inhaler |
US10542777B2 (en) | 2014-06-27 | 2020-01-28 | British American Tobacco (Investments) Limited | Apparatus for heating or cooling a material contained therein |
US10602777B2 (en) | 2014-07-25 | 2020-03-31 | Nicoventures Holdings Limited | Aerosol provision system |
US10625033B2 (en) | 2007-03-09 | 2020-04-21 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US10653180B2 (en) | 2013-06-14 | 2020-05-19 | Juul Labs, Inc. | Multiple heating elements with separate vaporizable materials in an electric vaporization device |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
US10687555B2 (en) | 2014-06-27 | 2020-06-23 | Batmark Limited | Vaporizer assembly having a vaporizer and a matrix |
US10729176B2 (en) | 2011-09-06 | 2020-08-04 | British American Tobacco (Investments) Limited | Heating smokeable material |
US10765147B2 (en) | 2014-04-28 | 2020-09-08 | Batmark Limited | Aerosol forming component |
CN111672000A (en) * | 2020-06-09 | 2020-09-18 | 青岛市中医医院(青岛市海慈医院、青岛市康复医学研究所) | Traditional chinese medical science paediatrics is with atomizing inhalation device |
US10786635B2 (en) | 2010-08-26 | 2020-09-29 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US10834964B2 (en) | 2005-07-19 | 2020-11-17 | Juul Labs, Inc. | Method and system for vaporization of a substance |
US10865001B2 (en) | 2016-02-11 | 2020-12-15 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10881141B2 (en) | 2015-06-29 | 2021-01-05 | Nicoventures Holdings Limited | Electronic aerosol provision systems |
US10952468B2 (en) | 2013-05-06 | 2021-03-23 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
US11033055B2 (en) | 2015-06-29 | 2021-06-15 | Nicoventures Trading Limited | Electronic aerosol provision systems, inductive heating assemblies and cartridges for use therewith, and related methods |
US11039644B2 (en) | 2013-10-29 | 2021-06-22 | Nicoventures Trading Limited | Apparatus for heating smokeable material |
US11064725B2 (en) | 2015-08-31 | 2021-07-20 | British American Tobacco (Investments) Limited | Material for use with apparatus for heating smokable material |
US11083856B2 (en) | 2014-12-11 | 2021-08-10 | Nicoventures Trading Limited | Aerosol provision systems |
US11141548B2 (en) | 2016-07-26 | 2021-10-12 | British American Tobacco (Investments) Limited | Method of generating aerosol |
US11185110B2 (en) | 2015-06-29 | 2021-11-30 | Nicoventures Trading Limited | Electronic vapor provision system |
US11241042B2 (en) | 2012-09-25 | 2022-02-08 | Nicoventures Trading Limited | Heating smokeable material |
US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11253671B2 (en) | 2011-07-27 | 2022-02-22 | Nicoventures Trading Limited | Inhaler component |
US11272740B2 (en) | 2012-07-16 | 2022-03-15 | Nicoventures Holdings Limited | Electronic vapor provision device |
US11357258B2 (en) | 2014-12-29 | 2022-06-14 | Nicoventures Trading Limited | Cartridge for having a sleeve with slots surrounding a contact piece with corresponding contact arms |
US11412783B2 (en) | 2014-12-29 | 2022-08-16 | Nicoventures Trading Limited | Apparatus for heating smokable material |
US11452313B2 (en) | 2015-10-30 | 2022-09-27 | Nicoventures Trading Limited | Apparatus for heating smokable material |
US11478021B2 (en) | 2014-05-16 | 2022-10-25 | Juul Labs, Inc. | Systems and methods for aerosolizing a vaporizable material |
US11497249B2 (en) | 2019-09-16 | 2022-11-15 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
US11511054B2 (en) | 2015-03-11 | 2022-11-29 | Alexza Pharmaceuticals, Inc. | Use of antistatic materials in the airway for thermal aerosol condensation process |
USD977704S1 (en) | 2020-10-30 | 2023-02-07 | Nicoventures Trading Limited | Aerosol generator |
USD977706S1 (en) | 2020-10-30 | 2023-02-07 | Nicoventures Trading Limited | Aerosol generator |
US11571527B2 (en) * | 2017-03-30 | 2023-02-07 | Nicoventures Trading Limited | Article for use with an apparatus for heating an aerosol generating agent |
USD977705S1 (en) | 2020-10-30 | 2023-02-07 | Nicoventures Trading Limited | Aerosol generator |
US11647783B2 (en) | 2005-07-19 | 2023-05-16 | Juul Labs, Inc. | Devices for vaporization of a substance |
USD986482S1 (en) | 2020-10-30 | 2023-05-16 | Nicoventures Trading Limited | Aerosol generator |
USD986483S1 (en) | 2020-10-30 | 2023-05-16 | Nicoventures Trading Limited | Aerosol generator |
US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
US11659863B2 (en) | 2015-08-31 | 2023-05-30 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
USD989384S1 (en) | 2021-04-30 | 2023-06-13 | Nicoventures Trading Limited | Aerosol generator |
US11672279B2 (en) | 2011-09-06 | 2023-06-13 | Nicoventures Trading Limited | Heating smokeable material |
USD990765S1 (en) | 2020-10-30 | 2023-06-27 | Nicoventures Trading Limited | Aerosol generator |
US11730199B2 (en) | 2018-06-07 | 2023-08-22 | Juul Labs, Inc. | Cartridges for vaporizer devices |
US11744964B2 (en) | 2016-04-27 | 2023-09-05 | Nicoventures Trading Limited | Electronic aerosol provision system and vaporizer therefor |
US11825870B2 (en) | 2015-10-30 | 2023-11-28 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019010892A (en) * | 2017-03-15 | 2020-02-12 | Csp Technologies Inc | Inhaler and methods of using and making same. |
CA3090277A1 (en) * | 2018-02-02 | 2019-08-08 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
CA3214507A1 (en) * | 2021-04-14 | 2022-10-20 | Anthony James Hickey | Hot porous-solid metering systems and methods for generation of therapeutic aerosols by evaporation/condensation |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419650A (en) * | 1979-08-23 | 1983-12-06 | Georgina Chrystall Hirtle | Liquid contact relay incorporating gas-containing finely reticular solid motor element for moving conductive liquid |
US4484577A (en) * | 1981-07-23 | 1984-11-27 | Key Pharmaceuticals, Inc. | Drug delivery method and inhalation device therefor |
US4793366A (en) * | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US4947874A (en) * | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Smoking articles utilizing electrical energy |
US4947875A (en) * | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Flavor delivery articles utilizing electrical energy |
US4989619A (en) * | 1985-08-26 | 1991-02-05 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US5224498A (en) * | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
US5518179A (en) * | 1991-12-04 | 1996-05-21 | The Technology Partnership Limited | Fluid droplets production apparatus and method |
US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
US5694919A (en) * | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5735263A (en) * | 1993-01-29 | 1998-04-07 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5878752A (en) * | 1996-11-25 | 1999-03-09 | Philip Morris Incorporated | Method and apparatus for using, cleaning, and maintaining electrical heat sources and lighters useful in smoking systems and other apparatuses |
US5915378A (en) * | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5938117A (en) * | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
US5957124A (en) * | 1994-09-27 | 1999-09-28 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5960792A (en) * | 1993-01-29 | 1999-10-05 | Aradigm Corporation | Device for aerosolized delivery of peptide drugs |
US6014970A (en) * | 1998-06-11 | 2000-01-18 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
US6090403A (en) * | 1998-08-17 | 2000-07-18 | Lectec Corporation | Inhalation therapy decongestant with foraminous carrier |
US6095153A (en) * | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
US6550691B2 (en) * | 2001-05-22 | 2003-04-22 | Steve Pence | Reagent dispenser head |
US6681998B2 (en) * | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US7364897B2 (en) * | 2002-04-11 | 2008-04-29 | Sequenom, Inc. | Methods and devices for performing chemical reactions on a solid support |
US20080308096A1 (en) * | 2005-02-11 | 2008-12-18 | Pari Pharma Gmbh | Aerosol Generating Device and Inhalation Therapy Unit Provided with This Device |
US20100276505A1 (en) * | 2007-09-26 | 2010-11-04 | Roger Earl Smith | Drilling in stretched substrates |
US7832655B2 (en) * | 2006-09-22 | 2010-11-16 | The Procter & Gamble Company | Delivery system for generating liquid active materials using an electromechanical transducer |
US8684980B2 (en) * | 2010-07-15 | 2014-04-01 | Corinthian Ophthalmic, Inc. | Drop generating device |
Family Cites Families (594)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1803334A (en) | 1931-05-05 | Ootthujp lehmann | ||
US2243669A (en) | 1941-05-27 | Electrical vaporizer | ||
US1864980A (en) | 1932-06-28 | Vapobizeb | ||
US3080624A (en) | 1963-03-12 | weber iii | ||
US1239634A (en) | 1916-07-25 | 1917-09-11 | Frank J Stuart | Medical appliance. |
US1535486A (en) | 1922-08-28 | 1925-04-28 | James W Lundy | Electric-lamp bulb |
US1514682A (en) | 1923-05-03 | 1924-11-11 | Wilson Harold | Electric vaporizer |
US2086140A (en) | 1933-09-08 | 1937-07-06 | Silten Ernst | Automatic temperature regulated narcosis apparatus |
US2084299A (en) | 1934-12-15 | 1937-06-15 | Arthur G Borden | Medicament holder for nasal inhalers |
US2230753A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
US2230754A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
GB502761A (en) | 1938-01-29 | 1939-03-24 | Christopher Engelbreth | Improvements in and relating to hand inhalation apparatus |
US2309846A (en) | 1941-03-06 | 1943-02-02 | Holm Einar Marius | Inhaler |
FR921852A (en) | 1945-12-06 | 1947-05-21 | Diffuser of volatile products | |
US2469656A (en) | 1946-04-19 | 1949-05-10 | Peter H Lienert | Vaporizer |
US2714649A (en) | 1952-11-25 | 1955-08-02 | Lyle H Critzer | Vaporizer |
US2761055A (en) | 1953-06-10 | 1956-08-28 | Malcome Van Ike | Lamp-heated vaporizer |
US2741812A (en) | 1954-02-15 | 1956-04-17 | Tellier Andre | Perfume dispenser |
US2902484A (en) | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
US2887106A (en) | 1956-09-27 | 1959-05-19 | Robinson Joseph | Combined vaporizer and cover for medicament jar |
US2898649A (en) | 1956-11-19 | 1959-08-11 | Elaine T Cassidy | Perfume diffuser |
US3161478A (en) | 1959-05-29 | 1964-12-15 | Horst Corp Of America V D | Heat resistant porous structure |
US3371085A (en) | 1959-12-10 | 1968-02-27 | Hoffmann La Roche | 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones |
US3043977A (en) | 1960-03-30 | 1962-07-10 | Puritron Corp | Device and method for producing negative ions |
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
GB903866A (en) | 1961-05-09 | 1962-08-22 | Dausse Lab | Therapeutic preparations containing 7-substituted theophylline derivatives |
BE623427A (en) | 1961-10-10 | |||
US3299185A (en) | 1962-09-27 | 1967-01-17 | Ube Nitto Kasei Co | Dyeable polyolefin fibers containing a binary copolymer of styrene and acrylonitrile |
US3169095A (en) | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
NL289785A (en) | 1962-11-29 | |||
GB1063512A (en) | 1962-11-30 | 1967-03-30 | Benger Lab Ltd | Aerosols |
US3282729A (en) | 1963-02-27 | 1966-11-01 | Union Carbide Corp | Barrier coated thermoplastic olefin polymer substrates |
US3200819A (en) | 1963-04-17 | 1965-08-17 | Herbert A Gilbert | Smokeless non-tobacco cigarette |
NL298071A (en) | 1963-06-04 | |||
AT258912B (en) | 1964-05-27 | 1967-12-27 | Wander Ag Dr A | Process for the production of new 11-basic substituted dibenz [b, f] [1,4] oxazepines |
IL26896A (en) | 1966-01-19 | 1970-11-30 | Endo Lab | 14-hydroxynormorphines and 14-hydroxynormorphinones |
US3909463A (en) | 1968-11-29 | 1975-09-30 | Allied Chem | Grafted block copolymers of synthetic rubbers and polyolefins |
US3987052A (en) | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
US4008723A (en) | 1970-03-23 | 1977-02-22 | Imperial Chemical Industries Limited | Smoking mixture |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3831606A (en) | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
US3749547A (en) | 1971-09-09 | 1973-07-31 | Airco Inc | Flashlamp with improved combustible foil |
US3847650A (en) | 1971-09-09 | 1974-11-12 | Airco Inc | Flashlamp with improved combustion foil and method of making same |
US4166087A (en) | 1971-11-22 | 1979-08-28 | Cline-Buckner, Inc. | Automatic intermittent vapor dispenser |
US3701782A (en) | 1972-02-10 | 1972-10-31 | Upjohn Co | 1-carbolower alkoxy - 6 - phenyl-4h-s-triazolo(1,4)benzodiazepine compounds |
US3763347A (en) | 1972-04-13 | 1973-10-02 | Ncr Co | Vaporous lamp |
IE37524B1 (en) | 1972-04-20 | 1977-08-17 | Gallaher Ltd | Synthetic smoking product |
USRE30285E (en) | 1972-05-22 | 1980-05-27 | Spraying devices, in particular nebulizing devices | |
US3864326A (en) | 1972-05-22 | 1975-02-04 | Robert S Babington | Spraying devices, in particular nebulizing devices |
GB1366041A (en) | 1972-07-21 | 1974-09-11 | Kodama Bros Co Ltd | Device for volatilizing insecticides and the like |
US3949743A (en) | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
US3930796A (en) | 1973-09-13 | 1976-01-06 | Universal Oil Products Company | Catalytic fume control device |
US3982095A (en) | 1973-10-04 | 1976-09-21 | Searle Cardio-Pulmonary Systems Inc. | Respiratory humidifier |
US3882323A (en) | 1973-12-17 | 1975-05-06 | Us Navy | Method and apparatus for protecting sensitive information contained in thin-film microelectonic circuitry |
US3971377A (en) | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
US3894040A (en) | 1974-09-16 | 1975-07-08 | American Home Prod | 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters |
US4045156A (en) | 1974-12-23 | 1977-08-30 | Gte Sylvania Incorporated | Photoflash lamp |
US4020379A (en) | 1975-10-02 | 1977-04-26 | Eg&G, Inc. | Bulb-shaped flashtube with metal envelope |
US4104210A (en) | 1975-12-17 | 1978-08-01 | Monsanto Company | Thermoplastic compositions of high unsaturation diene rubber and polyolefin resin |
US4121583A (en) | 1976-07-13 | 1978-10-24 | Wen Yuan Chen | Method and apparatus for alleviating asthma attacks |
US4286604A (en) | 1976-10-05 | 1981-09-01 | Gallaher Limited | Smoking materials |
US4079742A (en) | 1976-10-20 | 1978-03-21 | Philip Morris Incorporated | Process for the manufacture of synthetic smoking materials |
US4160765A (en) | 1976-11-17 | 1979-07-10 | Smithkline Corporation | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
US4141369A (en) | 1977-01-24 | 1979-02-27 | Burruss Robert P | Noncombustion system for the utilization of tobacco and other smoking materials |
US4184099A (en) | 1977-04-27 | 1980-01-15 | International Flavors & Fragrances Inc. | Composition for slow release of volatile ingredients at _high temperature; and article comprising same |
DE2752384A1 (en) | 1977-08-29 | 1979-03-15 | Simes | PHARMACEUTICAL PREPARATION BASED ON ANTY-RELEASE AGENTS AND INHIBITANTS OF BETA ADRENERGIC RECEPTORS |
CA1107584A (en) | 1977-10-27 | 1981-08-25 | William V. Youdelis | Process for surface coating alloys to enhance corrosion resistance |
US4189200A (en) | 1977-11-14 | 1980-02-19 | Amp Incorporated | Sequentially actuated zero insertion force printed circuit board connector |
SE7812207L (en) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES |
US4183912A (en) | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
JPS54120065A (en) | 1978-02-24 | 1979-09-18 | Osaka Takeshi | Stick for blind person |
US4198200A (en) | 1978-05-18 | 1980-04-15 | Lord Corporation | Damage-preventive coatings |
US4284089A (en) | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
JPS5563397A (en) | 1978-10-31 | 1980-05-13 | Mitsubishi Electric Corp | Manufacture of bolling heat transmission surface |
US4276243A (en) | 1978-12-08 | 1981-06-30 | Western Electric Company, Inc. | Vapor delivery control system and method |
US4280629A (en) | 1979-01-08 | 1981-07-28 | Anchor Brush Company, Inc. | Container for nail polish or the like |
US4219031A (en) | 1979-03-05 | 1980-08-26 | Philip Morris Incorporated | Smoking product having core of fibrillar carbonized matter |
US4229931A (en) | 1979-03-05 | 1980-10-28 | Deere & Company | Hydraulic height sensing system with cylinder by-pass |
IL59407A (en) | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
US4251525A (en) | 1979-05-25 | 1981-02-17 | Smithkline Corporation | 3-Allyl-7,8-dihydroxy-6-halo-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
WO1981000903A1 (en) | 1979-09-29 | 1981-04-02 | Matsushita Electric Ind Co Ltd | Vapor generator |
US4340072A (en) | 1979-11-16 | 1982-07-20 | Imperial Group Limited | Smokeable device |
ATE3774T1 (en) | 1980-05-02 | 1983-06-15 | Schering Corporation | BECLOMETHASONE ESTER SOLVATE, PROCESS FOR THEIR PREPARATION AND PREPARATION OF A FORMULATION. |
US4391285A (en) | 1980-05-09 | 1983-07-05 | Philip Morris, Incorporated | Smoking article |
US4347855A (en) | 1980-07-23 | 1982-09-07 | Philip Morris Incorporated | Method of making smoking articles |
US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
US4376767A (en) | 1981-01-02 | 1983-03-15 | Merck & Co., Inc. | Pyridylmethyl esters of selected bio-affecting carboxylic acids |
US4346059A (en) | 1981-03-03 | 1982-08-24 | Donald Spector | Aroma-generating lamp structure |
DE3116951C2 (en) | 1981-04-29 | 1984-12-20 | Drägerwerk AG, 2400 Lübeck | Device for adding liquid anesthetics to the breathing gas to be supplied to the patient |
JPS5876038A (en) | 1981-10-28 | 1983-05-09 | 高森 正之 | Evaporation apparatus of insecticide or aromatic agent |
US4935073A (en) | 1981-11-27 | 1990-06-19 | Sri International | Process for applying coatings of zirconium and/or titantuim and a less noble metal to metal substrates and for converting the zirconium and/or titanium to an oxide, nitride, carbide, boride or silicide |
US4617232A (en) | 1982-04-15 | 1986-10-14 | Kennecott Corporation | Corrosion and wear resistant graphite material |
GB2122903B (en) | 1982-06-22 | 1986-11-05 | Masayuki Takamori | Vaporizers for vaporisable substances and support media for substances usable therewith |
DE3224849A1 (en) | 1982-07-02 | 1984-01-05 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | STEAM INHALER |
US4556539A (en) | 1982-08-27 | 1985-12-03 | Donald Spector | Disc-playing aroma generator |
US4508726A (en) | 1982-09-16 | 1985-04-02 | The Upjohn Company | Treatment of panic disorders with alprazolam |
US4474191A (en) | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
AT398259B (en) | 1982-09-30 | 1994-11-25 | Dainippon Jochugiku Kk | THERMAL SMOKER FOR A CHEMICAL PREPARATION |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4753758A (en) | 1983-05-19 | 1988-06-28 | Intertech Resources Inc. | Respiratory humidifier |
DE3320441A1 (en) | 1983-06-06 | 1984-12-06 | Siemens AG, 1000 Berlin und 8000 München | WRITING DEVICE WORKING WITH LIQUID DROPLETS WITH ROD-SHAPED PIEZOELECTRIC TRANSFORMERS CONNECTED ON BOTH ENDS WITH A NOZZLE PLATE |
US5038769A (en) | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
US4523589A (en) | 1983-06-29 | 1985-06-18 | Krauser Robert S | Method and apparatus for treating ailments |
DE3326089A1 (en) | 1983-07-20 | 1985-02-07 | Gödecke AG, 1000 Berlin | INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS |
DE3476197D1 (en) | 1983-08-01 | 1989-02-23 | Mclean Hospital Corp | Gaba esters and gaba analogue esters |
US4588721A (en) | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
ATE44470T1 (en) | 1983-11-08 | 1989-07-15 | Bunnell Life Systems Inc | HUMIDIFIER, ESPECIALLY FOR RESPIRATORY ASSISTANCE SYSTEMS. |
GB8405190D0 (en) | 1984-02-28 | 1984-04-04 | British Petroleum Co Plc | Thermoplastic elastomer composition |
US4627963A (en) | 1984-02-29 | 1986-12-09 | Lad Technology, Inc. | Heat activated dispenser and method of dispensing a vapor therefrom |
US4683231A (en) | 1984-03-02 | 1987-07-28 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4647428A (en) | 1984-06-04 | 1987-03-03 | Gyulay Joseph M | Air freshener method |
US4755508A (en) | 1984-06-26 | 1988-07-05 | Merck & Co., Inc. | Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin |
US4793365A (en) | 1984-09-14 | 1988-12-27 | R. J. Reynolds Tobacco Company | Smoking article |
US5020548A (en) | 1985-08-26 | 1991-06-04 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US4854331A (en) | 1984-09-14 | 1989-08-08 | R. J. Reynolds Tobacco Company | Smoking article |
US5067499A (en) | 1984-09-14 | 1991-11-26 | R. J. Reynolds Tobacco Company | Smoking article |
US5042509A (en) | 1984-09-14 | 1991-08-27 | R. J. Reynolds Tobacco Company | Method for making aerosol generating cartridge |
US4647433A (en) | 1984-10-01 | 1987-03-03 | Donald Spector | Long-life aroma-generating capsule |
CN1018607B (en) | 1984-12-21 | 1992-10-14 | 美国耳·杰·瑞诺兹烟草公司 | Smoking article |
GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
US5119834A (en) | 1985-04-15 | 1992-06-09 | R. J. Reynolds Tobacco Company | Smoking article with improved substrate |
US4928714A (en) | 1985-04-15 | 1990-05-29 | R. J. Reynolds Tobacco Company | Smoking article with embedded substrate |
ATE78158T1 (en) | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES. |
US4800903A (en) | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
US4722334A (en) | 1985-07-16 | 1988-02-02 | Transpirator Technologies, Inc. | Method and apparatus for pulmonary and cardiovascular conditioning of racehorses and competition animals |
US5105831A (en) | 1985-10-23 | 1992-04-21 | R. J. Reynolds Tobacco Company | Smoking article with conductive aerosol chamber |
US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US5060666A (en) | 1985-10-28 | 1991-10-29 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US5033483A (en) | 1985-10-28 | 1991-07-23 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
JPS62204756A (en) | 1986-03-04 | 1987-09-09 | 大研医工株式会社 | Drug volatilizing method and apparatus |
EP0259383B1 (en) | 1986-03-10 | 1991-01-23 | Kurt Dr. Burghart | Pharmaceutical preparation and process for preparing the same |
US4708151A (en) | 1986-03-14 | 1987-11-24 | R. J. Reynolds Tobacco Company | Pipe with replaceable cartridge |
US4765347A (en) | 1986-05-09 | 1988-08-23 | R. J. Reynolds Tobacco Company | Aerosol flavor delivery system |
US4771795A (en) | 1986-05-15 | 1988-09-20 | R. J. Reynolds Tobacco Company | Smoking article with dual burn rate fuel element |
US4917120A (en) | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
US4774971A (en) | 1986-06-03 | 1988-10-04 | Vieten Michael J | Cigarette substitute |
US4801411A (en) | 1986-06-05 | 1989-01-31 | Southwest Research Institute | Method and apparatus for producing monosize ceramic particles |
US4735217A (en) | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4858630A (en) | 1986-12-08 | 1989-08-22 | R. J. Reynolds Tobacco Company | Smoking article with improved aerosol forming substrate |
IL84516A0 (en) | 1986-12-12 | 1988-04-29 | Reynolds Tobacco Co R | Smoking articles comprising impact modifying agents |
US4734560A (en) | 1987-01-20 | 1988-03-29 | Medical Enterprises, Ltd. | Vaporizing unit |
US4819665A (en) | 1987-01-23 | 1989-04-11 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US4924883A (en) | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
US4968885A (en) | 1987-03-06 | 1990-11-06 | Extrel Corporation | Method and apparatus for introduction of liquid effluent into mass spectrometer and other gas-phase or particle detectors |
HU201685B (en) | 1987-04-23 | 1990-12-28 | Chinoin Gyogyszer Es Vegyeszet | For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition |
US4889850A (en) | 1987-05-11 | 1989-12-26 | Thornfeldt Carl R | Treatment of colic and teething |
US5017575A (en) | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
GB8713645D0 (en) | 1987-06-11 | 1987-07-15 | Imp Tobacco Ltd | Smoking device |
US5019122A (en) | 1987-08-21 | 1991-05-28 | R. J. Reynolds Tobacco Company | Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance |
US4935624A (en) | 1987-09-30 | 1990-06-19 | Cornell Research Foundation, Inc. | Thermal-assisted electrospray interface (TAESI) for LC/MS |
US5072726A (en) | 1987-10-09 | 1991-12-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Vaporizer for inhalation anesthetics during high-frequency jet ventilation and associated method |
US4911157A (en) | 1988-01-07 | 1990-03-27 | Pegasus Research Corporation | Self-regulating, heated nebulizer system |
US4906417A (en) | 1988-02-08 | 1990-03-06 | Associated Mills Inc. | Humidifier |
US4853517A (en) | 1988-03-28 | 1989-08-01 | John G. Bowen | Vaporizing unit |
DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
US5137034A (en) | 1988-05-16 | 1992-08-11 | R. J. Reynolds Tobacco Company | Smoking article with improved means for delivering flavorants |
US4881556A (en) | 1988-06-06 | 1989-11-21 | R. J. Reynolds Tobacco Company | Low CO smoking article |
US5264433A (en) | 1988-07-07 | 1993-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
CH678151A5 (en) | 1988-07-13 | 1991-08-15 | Heinz Hermann Weick | Self-medication nasal dispenser |
US5345951A (en) | 1988-07-22 | 1994-09-13 | Philip Morris Incorporated | Smoking article |
US4852561A (en) | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
EP0358114A3 (en) | 1988-09-08 | 1990-11-14 | R.J. Reynolds Tobacco Company | Aerosol delivery articles utilizing electrical energy |
US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
USRE36744E (en) | 1988-09-16 | 2000-06-20 | Ribogene, Inc. | Nasal administration of benzodiazepine hypnotics |
US4963289A (en) | 1988-09-19 | 1990-10-16 | The United States Of America As Represented By The United States Department Of Energy | Method for producing monodisperse aerosols |
US4917830A (en) | 1988-09-19 | 1990-04-17 | The United States Of America As Represented By The United States Department Of Energy | Monodisperse aerosol generator |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
HU200105B (en) | 1988-10-04 | 1990-04-28 | Ferenc Inkovics | Electrically actuated inhaler of uniform medicine feeding |
US4984158A (en) | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US4917119A (en) | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US4959380A (en) | 1988-12-19 | 1990-09-25 | Wilson Jordan E | Method of treating people to stop smoking and composition |
US4881541A (en) | 1988-12-21 | 1989-11-21 | The Regents Of The University Of California | Vaporizer for an anesthetic having a vapor pressure about one atmosphere |
GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
US4892109A (en) | 1989-03-08 | 1990-01-09 | Brown & Williamson Tobacco Corporation | Simulated smoking article |
DE3908161A1 (en) | 1989-03-13 | 1990-09-27 | Bat Cigarettenfab Gmbh | Smokable article |
EP0705614B1 (en) | 1989-04-28 | 2002-09-25 | Riker Laboratories, Inc. | Dry powder inhalation device |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
ATE140868T1 (en) | 1989-05-05 | 1996-08-15 | North Sydney Area Health Serv | INCREASE FERTILITY |
US5496359A (en) | 1989-07-25 | 1996-03-05 | Smith & Nephew Richards, Inc. | Zirconium oxide and zirconium nitride coated biocompatible leads |
US4941483A (en) | 1989-09-18 | 1990-07-17 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US6313176B1 (en) | 1989-10-17 | 2001-11-06 | Everett J. Ellinwood, Jr. | Dosing method of administering deprenyl via intraoral administration or inhalation administration |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5144962A (en) | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5093894A (en) | 1989-12-01 | 1992-03-03 | Philip Morris Incorporated | Electrically-powered linear heating element |
US5269327A (en) | 1989-12-01 | 1993-12-14 | Philip Morris Incorporated | Electrical smoking article |
US5408574A (en) | 1989-12-01 | 1995-04-18 | Philip Morris Incorporated | Flat ceramic heater having discrete heating zones |
WO1991007947A1 (en) | 1989-12-05 | 1991-06-13 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
US5109180A (en) | 1989-12-14 | 1992-04-28 | Phillips Petroleum Company | Apparatus providing a shatter-resistant electric lamp |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
GB9000042D0 (en) | 1990-01-03 | 1990-03-07 | Ralph John F | Decorative wall covering applied to steel radiators |
GB2239807A (en) | 1990-01-09 | 1991-07-17 | Boc Group Plc | Anaesthetic vaporiser |
US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
US5099861A (en) | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US5156170A (en) | 1990-02-27 | 1992-10-20 | R. J. Reynolds Tobacco Company | Cigarette |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5366770A (en) | 1990-04-17 | 1994-11-22 | Xingwu Wang | Aerosol-plasma deposition of films for electronic cells |
US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5192548A (en) | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
DE69132691T2 (en) | 1990-06-07 | 2002-06-20 | Astrazeneca Ab | Indole derivatives as 5-HT1-like agonists |
US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
SE9002052D0 (en) | 1990-06-08 | 1990-06-08 | Pharmacia Ab | SMOKING COMPOSITION |
US5455043A (en) | 1990-06-13 | 1995-10-03 | Fischel-Ghodsian; Fariba | Device for controlled release of vaporous medications through nasal route |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
EP0469797B2 (en) | 1990-08-02 | 2001-12-12 | Datex-Ohmeda Inc. | Anaesthetic vaporiser |
US5060667A (en) | 1990-08-16 | 1991-10-29 | Brown & Williamson Tobacco Corporation | Smoking article |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
NO904226D0 (en) | 1990-09-28 | 1990-09-28 | Forsvarets Forsknings | MOISTURE DEVICES. |
US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
US5095921A (en) | 1990-11-19 | 1992-03-17 | Philip Morris Incorporated | Flavor generating article |
US5179966A (en) | 1990-11-19 | 1993-01-19 | Philip Morris Incorporated | Flavor generating article |
HU219778B (en) | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Process for producing n-acyl-2,3-benzodiazepine derivatives, their acid additional salts and pharmaceutical compositions containing them and a grop of the compounds and pharmaceutical compositions containing them |
US5519019A (en) | 1990-12-21 | 1996-05-21 | Gyogyszerkutato Intezet | N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same |
FR2671487B1 (en) | 1991-01-14 | 1993-03-19 | Oreal | USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION. |
DE69229070T2 (en) | 1991-02-09 | 1999-11-18 | B S D Bio Science Dev Snc Di O | Antireactive anti-asthmatic effects of acetylsalicylic acid by inhalation |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5469750A (en) | 1991-03-05 | 1995-11-28 | Aradigm Corporation | Method and apparatus for sensing flow in two directions and automatic calibration thereof |
WO1994016759A1 (en) | 1991-03-05 | 1994-08-04 | Miris Medical Corporation | An automatic aerosol medication delivery system and methods |
US5226411A (en) | 1991-03-07 | 1993-07-13 | Walter Levine | Aerosol nebulizer heater |
US5479948A (en) | 1993-08-10 | 1996-01-02 | Philip Morris Incorporated | Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor |
US5249586A (en) | 1991-03-11 | 1993-10-05 | Philip Morris Incorporated | Electrical smoking |
US5505214A (en) | 1991-03-11 | 1996-04-09 | Philip Morris Incorporated | Electrical smoking article and method for making same |
US5186164A (en) | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
GB9109021D0 (en) | 1991-04-26 | 1991-06-12 | Boc Group Plc | Dosing pump |
GB9109442D0 (en) | 1991-05-01 | 1991-06-26 | Volex Group Plc | Apparatus for emitting a chemical agent |
US5261424A (en) | 1991-05-31 | 1993-11-16 | Philip Morris Incorporated | Control device for flavor-generating article |
US5160664A (en) | 1991-05-31 | 1992-11-03 | Msp Corporation | High output monodisperse aerosol generator |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5177071A (en) | 1991-06-17 | 1993-01-05 | Merck & Co., Inc. | 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder |
US5285798A (en) | 1991-06-28 | 1994-02-15 | R. J. Reynolds Tobacco Company | Tobacco smoking article with electrochemical heat source |
CA2069687A1 (en) | 1991-06-28 | 1992-12-29 | Chandra Kumar Banerjee | Tobacco smoking article with electrochemical heat source |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
WO1993011817A1 (en) | 1991-12-16 | 1993-06-24 | The University Of Melbourne | Improvements in the administration of aerosol compounds |
US5363842A (en) | 1991-12-20 | 1994-11-15 | Circadian, Inc. | Intelligent inhaler providing feedback to both patient and medical professional |
GB9200047D0 (en) | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
US5229120A (en) | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
US5397652A (en) | 1992-03-27 | 1995-03-14 | The Louis Berkman Company | Corrosion resistant, colored stainless steel and method of making same |
DK64592D0 (en) | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | PEPTIDES FOR THERAPEUTIC TREATMENT |
US5318033A (en) | 1992-04-17 | 1994-06-07 | Hewlett-Packard Company | Method and apparatus for increasing the frame rate and resolution of a phased array imaging system |
US5391081A (en) | 1992-05-13 | 1995-02-21 | University Of Florida Research Foundation, Incorporated | Method and apparatus for simulating neuromuscular stimulation during medical surgery |
US5584701A (en) | 1992-05-13 | 1996-12-17 | University Of Florida Research Foundation, Incorporated | Self regulating lung for simulated medical procedures |
US5525329A (en) | 1992-05-21 | 1996-06-11 | The Johns Hopkins University | Inhibition of phosphodiesterase in olfactory mucosa |
US5622944A (en) | 1992-06-12 | 1997-04-22 | Affymax Technologies N.V. | Testosterone prodrugs for improved drug delivery |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
KR100208979B1 (en) | 1992-06-12 | 1999-07-15 | 야스이 쇼사꾸 | Pharmaceutical preparation for intra-airway administration |
US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
US5322075A (en) | 1992-09-10 | 1994-06-21 | Philip Morris Incorporated | Heater for an electric flavor-generating article |
US5613505A (en) | 1992-09-11 | 1997-03-25 | Philip Morris Incorporated | Inductive heating systems for smoking articles |
US5369723A (en) | 1992-09-11 | 1994-11-29 | Philip Morris Incorporated | Tobacco flavor unit for electrical smoking article comprising fibrous mat |
US5333106A (en) | 1992-10-09 | 1994-07-26 | Circadian, Inc. | Apparatus and visual display method for training in the power use of aerosol pharmaceutical inhalers |
WO1994009842A1 (en) | 1992-10-28 | 1994-05-11 | Rosen Charles A | Method and devices for delivering drugs by inhalation |
US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US5970973A (en) | 1993-01-29 | 1999-10-26 | Aradigm Corporation | Method of delivering insulin lispro |
US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5888477A (en) | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5372148A (en) | 1993-02-24 | 1994-12-13 | Philip Morris Incorporated | Method and apparatus for controlling the supply of energy to a heating load in a smoking article |
US5468936A (en) | 1993-03-23 | 1995-11-21 | Philip Morris Incorporated | Heater having a multiple-layer ceramic substrate and method of fabrication |
GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
CN1082365A (en) | 1993-05-25 | 1994-02-23 | 潘昆年 | Nutrient health-protecting cigarette |
US6521187B1 (en) | 1996-05-31 | 2003-02-18 | Packard Instrument Company | Dispensing liquid drops onto porous brittle substrates |
CZ287275B6 (en) | 1993-06-03 | 2000-10-11 | Schrader Barthold Von | Inhalation apparatus |
US5666977A (en) | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
JP3553599B2 (en) | 1993-06-29 | 2004-08-11 | インジェット ディジタル エアロソルズ リミテッド | dispenser |
US5388574A (en) | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
DE4328243C1 (en) | 1993-08-19 | 1995-03-09 | Sven Mielordt | Smoke or inhalation device |
US5456247A (en) | 1993-08-26 | 1995-10-10 | Iowa State University Research Foundation, Inc. | Method for delivering drugs soluble in a vaporization vehicle |
US5462740A (en) | 1993-09-17 | 1995-10-31 | Athena Neurosciences, Inc. | Rectally-administered, epileptic-seizure-inhibiting composition |
US5400969A (en) | 1993-09-20 | 1995-03-28 | Keene; Christopher M. | Liquid vaporizer and diffuser |
SE9303574D0 (en) | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method of manufacturing thereof |
JP2574120B2 (en) | 1993-11-10 | 1997-01-22 | パラマウントベッド株式会社 | Low pressure air pad for pressure ulcer prevention |
FI98270C (en) | 1993-11-29 | 1997-05-26 | Instrumentarium Oy | Method and apparatus for evaporation of anesthetic agent |
MA23420A1 (en) | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | BICYCLIC FIBRINOGEN ANTAGONISTS. |
US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5522008A (en) | 1994-03-16 | 1996-05-28 | Bernard; Costello J. | Device for heating and vaporizing a vaporizable module |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
CA2189351C (en) | 1994-05-13 | 2008-12-30 | Stephen J. Farr | Narcotic containing aerosol formulation |
US5457101A (en) | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
WO1996000069A1 (en) | 1994-06-23 | 1996-01-04 | The Procter & Gamble Company | Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration |
MA23588A1 (en) | 1994-06-23 | 1995-12-31 | Procter & Gamble | TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME |
MA23587A1 (en) | 1994-06-23 | 1995-12-31 | Procter & Gamble | TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME |
CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
DE4425255A1 (en) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulation for inhalation application |
WO1996006087A1 (en) | 1994-08-22 | 1996-02-29 | Smithkline Beecham Corporation | Bicyclic compounds |
US5456677A (en) | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
CN1039506C (en) | 1994-09-12 | 1998-08-12 | 宝山钢铁(集团)公司 | Stereo-space static electricity prevention and curing method |
AU3596295A (en) | 1994-09-26 | 1996-04-19 | E.R. Squibb & Sons, Inc. | Stainless steel alkali treatment |
US5537507A (en) | 1994-09-28 | 1996-07-16 | Advanced Ceramics Corporation | Coated flash evaporator heater |
AU3380395A (en) | 1994-09-30 | 1996-04-26 | Niro Separation A/S | A plant and a process for dry-producing a web-formed product |
WO1996011689A1 (en) | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Spa | Use of cck-b receptor antagonists for the treatment of sleep disorders |
EP0788387A4 (en) | 1994-10-28 | 1998-07-08 | Aradigm Corp | Device and method of creating aerosolized mist of respiratory drug |
US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
US5540959A (en) | 1995-02-21 | 1996-07-30 | Howard J. Greenwald | Process for preparing a coated substrate |
AU4990696A (en) | 1995-02-24 | 1996-09-11 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
DE19507410C2 (en) | 1995-03-03 | 1997-05-22 | Gsf Forschungszentrum Umwelt | Method and device for producing aerosols |
US5641938A (en) | 1995-03-03 | 1997-06-24 | Primex Technologies, Inc. | Thermally stable gas generating composition |
US5565148A (en) | 1995-03-16 | 1996-10-15 | Minnesota Mining And Manufacturing Company | Device for selectively providing a multiplicity of aromas |
CA2216443A1 (en) | 1995-03-31 | 1996-10-03 | Aradigm Corporation | Intrapulmonary delivery of hematopoietic drug |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US5586550A (en) | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
EP1908488A3 (en) | 1995-04-14 | 2008-04-16 | SmithKline Beecham Corporation | Metered dose inhaler for salmeterol |
EP1870122A3 (en) | 1995-04-14 | 2008-03-12 | SmithKline Beecham Corporation | Metered dose inhaler |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
PL180880B1 (en) | 1995-04-14 | 2001-04-30 | Glaxo Wellcome Inc | Beclomethasone inhaler with dosis metering feature |
US5690809A (en) | 1995-04-18 | 1997-11-25 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts by pretreatment of hydrocarbon feed to reduce peroxides and oxygen impurities |
US5725756A (en) | 1995-04-18 | 1998-03-10 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts with supercritical reaction media |
US5776928A (en) | 1995-04-21 | 1998-07-07 | Eli Lilly And Company | Method for treating dyskinesias with olanzapine |
FR2733594B1 (en) | 1995-04-28 | 1997-06-06 | France Etat | DEVICE FOR THE SAMPLING OF GASEOUS SUBSTANCES, LIQUIDS, AEROSOLS OR EVEN OF POWDERY MATERIALS, FOR THEIR IN SITU ANALYSIS |
US7125866B1 (en) | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
US5809997A (en) | 1995-05-18 | 1998-09-22 | Medtrac Technologies, Inc. | Electronic medication chronolog device |
DE19519056A1 (en) | 1995-05-24 | 1997-01-16 | Klinge Co Chem Pharm Fab | Use of antidepressants for the treatment of asthma and / or respiratory diseases by inhalation |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
GB9512708D0 (en) | 1995-06-22 | 1995-08-23 | Reckitt & Colman Inc | Improvements in or relating to organic compounds |
US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
US6209538B1 (en) | 1995-08-02 | 2001-04-03 | Robert A. Casper | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US5591409A (en) | 1995-08-15 | 1997-01-07 | Watkins; Carl J. | Providing aromas |
SE9503141D0 (en) | 1995-09-12 | 1995-09-12 | Siemens Elema Ab | Anesthesia apparatus |
US5649554A (en) | 1995-10-16 | 1997-07-22 | Philip Morris Incorporated | Electrical lighter with a rotatable tobacco supply |
US6013050A (en) | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
AU7669496A (en) | 1995-11-03 | 1997-05-22 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US5564442A (en) | 1995-11-22 | 1996-10-15 | Angus Collingwood MacDonald | Battery powered nicotine vaporizer |
US6041777A (en) | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
ATE263546T1 (en) | 1995-12-14 | 2004-04-15 | Taisho Pharmaceutical Co Ltd | AEROSOL PREPARATION |
AU1335397A (en) | 1995-12-21 | 1997-07-17 | Eli Lilly And Company | Method for treating dermatitis |
SE9504580L (en) | 1995-12-21 | 1997-06-22 | Siemens Elema Ab | Procedure for gasification of an anesthetic fluid and a carburetor |
EP0955885A1 (en) | 1996-02-05 | 1999-11-17 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
US5829436A (en) | 1996-02-05 | 1998-11-03 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
GB9604329D0 (en) | 1996-02-29 | 1996-05-01 | Ici Plc | Electrostatic spraying |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
JP3986086B2 (en) | 1996-03-01 | 2007-10-03 | ザ ユニバーシティ オブ カンザス | Particle precipitation method and coating method using near-critical and supercritical anti-solvents |
JPH11505547A (en) | 1996-03-13 | 1999-05-21 | エール ユニバーシティ | Smoking cessation treatment with naltrexone and related compounds |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5944012A (en) | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
CA2250186A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating migraine pain |
CA2250042A1 (en) | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
GB2312848B (en) | 1996-04-26 | 1999-11-17 | Bespak Plc | Controlled flow inhalers |
CZ343798A3 (en) | 1996-04-29 | 1999-02-17 | Dura Pharmaceuticals, Inc. | Inhaling system for inhaling dry powder |
US5743251A (en) | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5929093A (en) | 1996-06-13 | 1999-07-27 | Mayo Foundation For Medical Education And Research | Bifunctional acetylcholinesterase reactivators |
JP3413208B2 (en) | 1996-06-17 | 2003-06-03 | 日本たばこ産業株式会社 | Flavor producing articles and flavor producing instruments |
US6089857A (en) | 1996-06-21 | 2000-07-18 | Japan Tobacco, Inc. | Heater for generating flavor and flavor generation appliance |
GB9613015D0 (en) | 1996-06-21 | 1996-08-28 | Reckitt & Colman Inc | Device |
AU3400797A (en) | 1996-06-27 | 1998-01-14 | Merck & Co., Inc. | A method for treating meniere's disease |
IL127955A0 (en) | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
US6004516A (en) | 1996-08-06 | 1999-12-21 | Illinois Institute Of Technology | Apparatus for generating odor upon electronic signal demand |
US6325475B1 (en) | 1996-09-06 | 2001-12-04 | Microfab Technologies Inc. | Devices for presenting airborne materials to the nose |
AU4807197A (en) | 1996-10-03 | 1998-04-24 | Paul Bunn | Hydrophilic microparticles and methods to prepare same |
US5934289A (en) | 1996-10-22 | 1999-08-10 | Philip Morris Incorporated | Electronic smoking system |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US5744469A (en) | 1996-11-26 | 1998-04-28 | Eli Lilly And Company | Method for treating dermatitis |
CA2222830C (en) | 1996-12-02 | 2004-03-30 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
CN1245423A (en) | 1996-12-30 | 2000-02-23 | 巴特勒纪念研究院 | Formulation and method for treating neoplasms by inhalation |
ES2236832T3 (en) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | PREPARATION OF PARTICLES FOR INHALATION. |
DK1014943T3 (en) | 1997-02-05 | 2002-10-14 | Jago Res Ag | Medical aerosol formulations |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US6192882B1 (en) | 1997-02-24 | 2001-02-27 | Aradigm Corporation | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
US6051257A (en) | 1997-02-24 | 2000-04-18 | Superior Micropowders, Llc | Powder batch of pharmaceutically-active particles and methods for making same |
US5829435A (en) | 1997-02-24 | 1998-11-03 | Aradigm Corporation | Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
US5769621A (en) | 1997-05-23 | 1998-06-23 | The Regents Of The University Of California | Laser ablation based fuel ignition |
US5907075A (en) | 1997-06-11 | 1999-05-25 | The University Of Kansas | Solid acid supercritical alkylation reactions using carbon dioxide and/or other co-solvents |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5928520A (en) | 1997-07-16 | 1999-07-27 | Abanaki Corporation | Method and apparatus for extracting ground water contaiminants |
KR100289448B1 (en) | 1997-07-23 | 2001-05-02 | 미즈노 마사루 | Flavor generator |
HUP9701284A3 (en) | 1997-07-24 | 2005-11-28 | Egyt Gyogyszervegyeszeti Gyar | Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system |
US6090212A (en) | 1997-08-15 | 2000-07-18 | Micro C Technologies, Inc. | Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate |
US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
CN1176075A (en) | 1997-08-29 | 1998-03-18 | 宋国合 | Combustion-less innoxious cigarette and its preparation |
US6138683A (en) | 1997-09-19 | 2000-10-31 | Thione International, Inc. | Smokeless tobacco products containing antioxidants |
DK1019022T4 (en) | 1997-09-29 | 2010-11-08 | Novartis Ag | Perforated microparticles and their method of use |
US6390453B1 (en) | 1997-10-22 | 2002-05-21 | Microfab Technologies, Inc. | Method and apparatus for delivery of fragrances and vapors to the nose |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
CN1123573C (en) | 1997-11-12 | 2003-10-08 | 拜尔公司 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
CA2317428C (en) | 1998-01-06 | 2008-08-05 | Philip Morris Products Inc. | Cigarette having reduced sidestream smoke |
IL137162A0 (en) | 1998-01-27 | 2001-07-24 | American Cyanamid Co | 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors |
US6044777A (en) | 1998-02-09 | 2000-04-04 | Walsh; Michael J. | Composite metal safe and method of making |
US5900249A (en) | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
US5996589A (en) | 1998-03-03 | 1999-12-07 | Brown & Williamson Tobacco Corporation | Aerosol-delivery smoking article |
CA2322193C (en) | 1998-03-05 | 2006-10-24 | Batelle Memorial Institute | Pulmonary dosing system and method |
CA2322805C (en) | 1998-03-05 | 2005-09-13 | Nippon Shinyaku Co., Ltd. | Fat emulsions for inhalational administration |
US5980566A (en) | 1998-04-11 | 1999-11-09 | Alt; Eckhard | Vascular and endoluminal stents with iridium oxide coating |
HUP0101627A3 (en) | 1998-04-14 | 2003-02-28 | Gen Hospital Corp Boston | Pharmaceutical compositions for treating neuropsychiatric disorders |
AU3764199A (en) | 1998-04-29 | 1999-11-16 | Genentech Inc. | Spray dried formulations of igf-i |
GB9810559D0 (en) | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
US6211171B1 (en) | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
EP1083951A4 (en) | 1998-06-12 | 2004-07-07 | Aradigm Corp | Methods of delivering aerosolized polynucleotides to the respiratory tract |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
CA2346029A1 (en) | 1998-10-02 | 2000-04-13 | Anthony R. Imondi | Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung |
US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US6509005B1 (en) | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
US6255334B1 (en) | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
JP2002529393A (en) | 1998-11-12 | 2002-09-10 | フランク ジー. ピルキーウィッツ, | Inhalation system |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
DE19854012C2 (en) | 1998-11-12 | 2001-05-10 | Reemtsma H F & Ph | Inhalable aerosol delivery system |
DE19854007C2 (en) | 1998-11-12 | 2001-05-17 | Reemtsma H F & Ph | Inhalable aerosol delivery system |
CZ303154B6 (en) | 1998-11-13 | 2012-05-09 | Jagotec Ag | Dry powder formulation for inhalation containing magnesium stearate |
US6070575A (en) | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
EP1196263A4 (en) | 1998-11-16 | 2004-10-27 | Aradigm Corp | Method of fabricating porous membrane with unique pore structure for aerosolized delivery of drugs |
US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
JP3506618B2 (en) | 1998-11-18 | 2004-03-15 | ウシオ電機株式会社 | Incandescent light bulb for yellow light emission |
DE69818872T2 (en) | 1998-12-11 | 2004-05-19 | Pharmachemie B.V. | PHARMACEUTICAL PREPARATIONS FOR INHALATION OF AN OPIOID |
IL142816A0 (en) | 1998-12-24 | 2002-03-10 | Du Pont Pharm Co | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
AR022423A1 (en) | 1999-01-27 | 2002-09-04 | American Cyanamid Co | COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
SI1031347T1 (en) | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
US6376550B1 (en) | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
US6591839B2 (en) | 1999-02-17 | 2003-07-15 | Dieter Meyer | Filter material for reducing harmful substances in tobacco smoke |
US6053176A (en) | 1999-02-23 | 2000-04-25 | Philip Morris Incorporated | Heater and method for efficiently generating an aerosol from an indexing substrate |
WO2000051491A1 (en) | 1999-03-05 | 2000-09-08 | Battelle Memorial Institute | Method for safely and effectively administering a drug by inhalation |
US6444326B1 (en) | 1999-03-05 | 2002-09-03 | Restek Corporation | Surface modification of solid supports through the thermal decomposition and functionalization of silanes |
US6228445B1 (en) | 1999-04-06 | 2001-05-08 | Crucible Materials Corp. | Austenitic stainless steel article having a passivated surface layer |
CA2370302A1 (en) | 1999-04-27 | 2000-11-02 | Benjamin Lee Hughes | Insulin crystals for pulmonary administration |
ATE274955T1 (en) | 1999-05-03 | 2004-09-15 | Battelle Memorial Institute | MEDICINAL COMPOSITIONS FOR AEROSOL FORMATION AND INHALATION PURPOSES |
US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
US6309986B1 (en) | 1999-05-07 | 2001-10-30 | S. C. Johnson & Son, Inc. | Mat for dispensing volatile materials |
JP4722295B2 (en) | 1999-05-27 | 2011-07-13 | エイカスフィアー・インコーポレーテッド | Porous drug matrix and method for producing the same |
US6709739B1 (en) | 1999-06-03 | 2004-03-23 | Case Western Reserve University | Closed cell metal composites |
US6328033B1 (en) | 1999-06-04 | 2001-12-11 | Zohar Avrahami | Powder inhaler |
ES2424713T4 (en) | 1999-06-11 | 2014-01-23 | Aradigm Corporation | Method of producing a spray |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
EP1218048A4 (en) | 1999-07-16 | 2009-08-26 | Aradigm Corp | System for effecting smoke cessation |
EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
WO2001017614A2 (en) | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
US6235177B1 (en) | 1999-09-09 | 2001-05-22 | Aerogen, Inc. | Method for the construction of an aperture plate for dispensing liquid droplets |
AU781452B2 (en) | 1999-09-15 | 2005-05-26 | Aradigm Corporation | Pore structures for reduced pressure aerosolization |
KR20020043223A (en) | 1999-09-30 | 2002-06-08 | 해피 페너 ; 해리 에이치. 페너 2세 | Certain alkylene diamine-substituted heterocycles |
DE60005386T2 (en) | 1999-10-15 | 2004-06-24 | F. Hoffmann-La Roche Ag | BENZODIAZEPINE DERIVATIVES AND THEIR USE AS METABOTROPE GLUTAMATE RECEPTOR ANTAGONISTS |
TWI310688B (en) | 1999-10-29 | 2009-06-11 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
WO2001041732A1 (en) | 1999-12-06 | 2001-06-14 | Gore Stanley L | Compositions and methods for intranasal delivery of active agents to the brain |
DE19959766A1 (en) | 1999-12-11 | 2001-06-13 | Bosch Gmbh Robert | Glow plug |
DE10001035A1 (en) | 2000-01-13 | 2001-07-26 | Bayer Ag | Active ingredient chip with integrated heating element |
ES2305057T3 (en) | 2000-02-28 | 2008-11-01 | Pharmakodex Limited | DEVICE FOR THE ADMINISTRATION OF ORAL PHARMACES. |
AU2000235236A1 (en) | 2000-03-10 | 2001-09-24 | The Regents Of The University Of California | Laser ignition |
BR0117281B1 (en) | 2000-03-23 | 2013-02-19 | apparatus and method for piercing a tobacco rod. | |
US6632047B2 (en) | 2000-04-14 | 2003-10-14 | Board Of Regents, The University Of Texas System | Heater element for use in an in situ thermal desorption soil remediation system |
JP2001299916A (en) | 2000-04-18 | 2001-10-30 | Kao Corp | Mask-shaped inhalator |
US6551617B1 (en) | 2000-04-20 | 2003-04-22 | Bristol-Myers Squibb Company | Taste masking coating composition |
WO2001080895A2 (en) | 2000-04-26 | 2001-11-01 | First Horizon Pharmaceutical Corporation | Methods and compositions for the treatment of cardiac indications |
MY136453A (en) | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
WO2001093846A2 (en) | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
WO2001095903A1 (en) | 2000-06-15 | 2001-12-20 | Respiratorius Ab | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction |
GB0015981D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
FR2812545B1 (en) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS |
WO2002016235A1 (en) | 2000-08-18 | 2002-02-28 | Norton Healthcare Limited | Spray device |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
AU2002246500A1 (en) | 2000-10-27 | 2002-07-30 | Emlin Biosciences | Thermal vaporizing device for drug delivery |
US20030121906A1 (en) | 2000-11-29 | 2003-07-03 | Abbott Richard C. | Resistive heaters and uses thereof |
US6701921B2 (en) | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US6443152B1 (en) | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
US7594507B2 (en) | 2001-01-16 | 2009-09-29 | Hewlett-Packard Development Company, L.P. | Thermal generation of droplets for aerosol |
FI20010115A0 (en) | 2001-01-18 | 2001-01-18 | Orion Corp | A process for preparing nanoparticles |
US6680668B2 (en) | 2001-01-19 | 2004-01-20 | Vishay Intertechnology, Inc. | Fast heat rise resistor using resistive foil |
US20020176841A1 (en) | 2001-03-19 | 2002-11-28 | Praecis Pharmaceuticals Inc. | Pharmaceutical formulations for sustained release |
GB0108930D0 (en) | 2001-04-10 | 2001-05-30 | Boots Co Plc | Therapeutic agents |
US20030004142A1 (en) | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
US6554201B2 (en) | 2001-05-02 | 2003-04-29 | Aerogen, Inc. | Insert molded aerosol generator and methods |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US6759029B2 (en) | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20030138508A1 (en) | 2001-12-18 | 2003-07-24 | Novack Gary D. | Method for administering an analgesic |
EP1392260A2 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
JP2005503425A (en) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | Delivery of drug ester by the prescribed inhalation route |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20030118512A1 (en) | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
WO2002094232A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antidepressants through an inhalation route |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7458374B2 (en) * | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
DE60231611D1 (en) | 2001-05-24 | 2009-04-30 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF OPIOIDES BY INHALATION |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
JP4357842B2 (en) | 2001-05-24 | 2009-11-04 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Delivery of alprazolam, estazolam, midazolam or triazolam by a prescribed inhalation route |
AP1512A (en) | 2001-06-19 | 2005-12-15 | Mueller Norbert | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders. |
TWI239251B (en) | 2001-07-31 | 2005-09-11 | Chrysalis Tech Inc | Method and apparatus for generating a volatilized liquid |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
US6568390B2 (en) | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US6648950B2 (en) | 2001-10-15 | 2003-11-18 | Hewlett-Packard Development Company, L.P. | Electro-thermal odor-releasing inks and methods for releasing odors from the same |
US6779520B2 (en) | 2001-10-30 | 2004-08-24 | Iep Pharmaceutical Devices Inc. | Breath actuated dry powder inhaler |
GB0126150D0 (en) | 2001-10-31 | 2002-01-02 | Gw Pharma Ltd | A device method and resistive element for vaporising a substance |
WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1455875A2 (en) | 2001-11-21 | 2004-09-15 | Alexza Molecular Delivery Corporation | Open-celled substrates for drug delivery |
US6684880B2 (en) | 2001-12-04 | 2004-02-03 | Hewlett-Packard Development Company, L.P. | Applicator for dispensing bioactive compositions and methods for using the same |
US20030106551A1 (en) | 2001-12-06 | 2003-06-12 | Sprinkel F. Murphy | Resistive heater formed inside a fluid passage of a fluid vaporizing device |
US6804458B2 (en) | 2001-12-06 | 2004-10-12 | Chrysalis Technologies Incorporated | Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate |
US6681769B2 (en) | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
US6701922B2 (en) | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US6772756B2 (en) | 2002-02-09 | 2004-08-10 | Advanced Inhalation Revolutions Inc. | Method and system for vaporization of a substance |
US6961515B2 (en) | 2002-02-15 | 2005-11-01 | Dekko Technologies, Inc. | PTC heater with flexible printed circuit board |
US6728478B2 (en) | 2002-02-21 | 2004-04-27 | Dekko Heating Technologies, Inc. | Heated chemical delivery system |
EP1503744A1 (en) | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
DE60320100T2 (en) | 2002-06-06 | 2009-06-18 | S.C. Johnson & Son, Inc., Racine | Device for localized surface volatilization |
US7040314B2 (en) | 2002-09-06 | 2006-05-09 | Philip Morris Usa Inc. | Aerosol generating devices and methods for generating aerosols suitable for forming propellant-free aerosols |
US6772757B2 (en) | 2002-10-25 | 2004-08-10 | Chrysalis Technologies Incorporated | Concentric controlled temperature profile fluid vaporizing device |
JP2004149447A (en) | 2002-10-30 | 2004-05-27 | Andrew Chii Wen Won | Nicotine-containing ointment |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
CA2507159A1 (en) | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
JP2006514633A (en) | 2002-11-26 | 2006-05-11 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Treatment of headache with antipsychotics delivered by inhalation |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
EP3473251B1 (en) | 2002-12-20 | 2023-12-13 | NicoNovum AB | A nicotine-cellulose combination |
US7360537B2 (en) | 2003-04-16 | 2008-04-22 | Trudell Medical International | Antistatic medication delivery apparatus |
JP4601619B2 (en) | 2003-05-21 | 2010-12-22 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Built-in heating unit and medicine supply unit using the same |
JP4869927B2 (en) | 2003-08-04 | 2012-02-08 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Substrates and preparation methods and uses for drug delivery devices |
US20050037506A1 (en) | 2003-08-04 | 2005-02-17 | Alexza Molecular Delivery Corporation | Methods of determining film thicknesses for an aerosol delivery article |
US7387788B1 (en) | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
EP1703932A1 (en) | 2003-12-15 | 2006-09-27 | Alexza Molecular Delivery Corporation | Treatment of breakthrough pain by drug aerosol inhalation |
WO2005059804A2 (en) | 2003-12-16 | 2005-06-30 | Alexza Pharmaceuticals, Inc. | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
EP2246086A3 (en) * | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
US20060032496A1 (en) | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
US20100006092A1 (en) | 2004-08-12 | 2010-01-14 | Alexza Pharmaceuticals, Inc. | Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages |
US20060120962A1 (en) | 2004-10-12 | 2006-06-08 | Rabinowitz Joshua D | Cardiac safe, rapid medication delivery |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (en) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Hydroxybenzoate salts of metanicotine compounds |
KR20070112164A (en) | 2005-02-15 | 2007-11-22 | 엘란 파마 인터내셔널 리미티드 | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
KR101405545B1 (en) | 2005-11-28 | 2014-07-03 | 마리누스 파마슈티컬스 | Ganaxolone formulations and methods for the making and use thereof |
US7785482B2 (en) | 2005-12-07 | 2010-08-31 | General Electric Company | Method of making an ignition device |
US7494344B2 (en) | 2005-12-29 | 2009-02-24 | Molex Incorporated | Heating element connector assembly with press-fit terminals |
CN101437496A (en) | 2006-03-16 | 2009-05-20 | 尼科诺瓦姆股份公司 | Chewing gum compositions providing rapid release of nicotine |
US8251060B2 (en) | 2006-11-15 | 2012-08-28 | Perfetti and Perfetti, LLC | Device and method for delivering an aerosol drug |
WO2008080170A1 (en) | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
US7513781B2 (en) | 2006-12-27 | 2009-04-07 | Molex Incorporated | Heating element connector assembly with insert molded strips |
US20080210225A1 (en) | 2007-03-01 | 2008-09-04 | Rapha Institute For Health | Disposable antistatic spacer |
ES2594867T3 (en) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
GB0714577D0 (en) | 2007-07-26 | 2007-09-05 | Sonitor Technologies As | Mobile object communication and position determination |
US20080306285A1 (en) | 2007-04-27 | 2008-12-11 | Alexza Pharmaceuticals, Inc. | Heat-Labile Prodrugs |
DE102007041921A1 (en) | 2007-09-04 | 2009-03-05 | Siemens Ag | Method for producing and contacting electronic components by means of a substrate plate, in particular DCB ceramic substrate plate |
US20090180968A1 (en) | 2008-01-11 | 2009-07-16 | Alexza Pharmaceuticals, Inc. | Metal Coordination Complexes Of Volatile Drugs |
AU2009246316B2 (en) | 2008-05-16 | 2014-06-19 | Nono Inc. | Treatment for epilepsy |
US20100065052A1 (en) | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100068155A1 (en) | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Reactant Formulations and Methods for Controlled Heating |
US20100163029A1 (en) | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for administering an inhalable compound |
US20100300433A1 (en) | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US8425704B2 (en) | 2009-08-04 | 2013-04-23 | The United States Of America As Represented By The Secretary Of The Army | Silicon-based explosive devices and methods of manufacture |
US20100181387A1 (en) | 2009-12-01 | 2010-07-22 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
WO2012072256A2 (en) | 2010-12-02 | 2012-06-07 | Ucb Pharma Gmbh | Once daily formulation of lacosamide |
EP2468116A1 (en) | 2010-12-24 | 2012-06-27 | Philip Morris Products S.A. | An aerosol generating system having means for handling consumption of a liquid substrate |
PT3415139T (en) | 2011-06-14 | 2022-06-20 | Neurelis Inc | Administration of benzodiazepine |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US20130156823A1 (en) | 2011-12-20 | 2013-06-20 | MAP Pharmacauticals, Inc. | Excipient-free Aerosol Formulation |
US9277770B2 (en) | 2013-03-14 | 2016-03-08 | R. J. Reynolds Tobacco Company | Atomizer for an aerosol delivery device formed from a continuously extending wire and related input, cartridge, and method |
ES2821907T3 (en) | 2013-07-11 | 2021-04-28 | Alexza Pharmaceuticals Inc | Nicotine salt with metasalicylic acid |
WO2015042412A1 (en) | 2013-09-20 | 2015-03-26 | E-Nicotine Technology. Inc. | Devices and methods for modifying delivery devices |
CN107750177B (en) | 2015-03-11 | 2022-03-11 | 艾利斯达医药品公司 | Use of antistatic materials in airways for hot aerosol condensation processes |
KR102525253B1 (en) | 2016-04-29 | 2023-04-26 | 더 트러스티스 오브 프린세톤 유니버시티 | Method and Apparatus for Controlled Drug Vaporization |
JP7379154B2 (en) | 2016-12-09 | 2023-11-14 | アレクザ・ファーマシューティカルズ・インコーポレイテッド | How to treat epilepsy |
CA3090277A1 (en) | 2018-02-02 | 2019-08-08 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
-
2008
- 2008-03-10 ES ES08754883.0T patent/ES2594867T3/en active Active
- 2008-03-10 US US12/045,674 patent/US20080216828A1/en not_active Abandoned
- 2008-03-10 EP EP08754883.0A patent/EP2121088B1/en active Active
- 2008-03-10 WO PCT/US2008/056452 patent/WO2008112661A2/en active Application Filing
-
2016
- 2016-10-10 US US15/289,772 patent/US10625033B2/en active Active
-
2020
- 2020-04-20 US US16/853,400 patent/US11642473B2/en active Active
-
2023
- 2023-05-08 US US18/144,775 patent/US20230285691A1/en active Pending
Patent Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419650A (en) * | 1979-08-23 | 1983-12-06 | Georgina Chrystall Hirtle | Liquid contact relay incorporating gas-containing finely reticular solid motor element for moving conductive liquid |
US4484577A (en) * | 1981-07-23 | 1984-11-27 | Key Pharmaceuticals, Inc. | Drug delivery method and inhalation device therefor |
US4989619A (en) * | 1985-08-26 | 1991-02-05 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US4793366A (en) * | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US4947874A (en) * | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Smoking articles utilizing electrical energy |
US4947875A (en) * | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Flavor delivery articles utilizing electrical energy |
US5224498A (en) * | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
US5938117A (en) * | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
US5518179A (en) * | 1991-12-04 | 1996-05-21 | The Technology Partnership Limited | Fluid droplets production apparatus and method |
US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
US5934272A (en) * | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5915378A (en) * | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US5735263A (en) * | 1993-01-29 | 1998-04-07 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5694919A (en) * | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5960792A (en) * | 1993-01-29 | 1999-10-05 | Aradigm Corporation | Device for aerosolized delivery of peptide drugs |
US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
US5957124A (en) * | 1994-09-27 | 1999-09-28 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US5878752A (en) * | 1996-11-25 | 1999-03-09 | Philip Morris Incorporated | Method and apparatus for using, cleaning, and maintaining electrical heat sources and lighters useful in smoking systems and other apparatuses |
US6014970A (en) * | 1998-06-11 | 2000-01-18 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
US6095153A (en) * | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
US6090403A (en) * | 1998-08-17 | 2000-07-18 | Lectec Corporation | Inhalation therapy decongestant with foraminous carrier |
US6681998B2 (en) * | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US6550691B2 (en) * | 2001-05-22 | 2003-04-22 | Steve Pence | Reagent dispenser head |
US7364897B2 (en) * | 2002-04-11 | 2008-04-29 | Sequenom, Inc. | Methods and devices for performing chemical reactions on a solid support |
US20080308096A1 (en) * | 2005-02-11 | 2008-12-18 | Pari Pharma Gmbh | Aerosol Generating Device and Inhalation Therapy Unit Provided with This Device |
US7832655B2 (en) * | 2006-09-22 | 2010-11-16 | The Procter & Gamble Company | Delivery system for generating liquid active materials using an electromechanical transducer |
US20100276505A1 (en) * | 2007-09-26 | 2010-11-04 | Roger Earl Smith | Drilling in stretched substrates |
US8684980B2 (en) * | 2010-07-15 | 2014-04-01 | Corinthian Ophthalmic, Inc. | Drop generating device |
Cited By (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173107B2 (en) | 2001-05-24 | 2012-05-08 | Alexza Pharmaceuticals, Inc. | Delivery of antipsychotics through an inhalation route |
US9440034B2 (en) | 2001-05-24 | 2016-09-13 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US10350157B2 (en) | 2001-05-24 | 2019-07-16 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US11065400B2 (en) | 2001-06-05 | 2021-07-20 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US9308208B2 (en) | 2001-06-05 | 2016-04-12 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US8074644B2 (en) | 2001-06-05 | 2011-12-13 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US9439907B2 (en) | 2001-06-05 | 2016-09-13 | Alexza Pharmaceutical, Inc. | Method of forming an aerosol for inhalation delivery |
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US9687487B2 (en) | 2001-06-05 | 2017-06-27 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US7987846B2 (en) | 2002-05-13 | 2011-08-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US8506935B2 (en) | 2002-11-26 | 2013-08-13 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US20040105819A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Respiratory drug condensation aerosols and methods of making and using them |
US7981401B2 (en) | 2002-11-26 | 2011-07-19 | Alexza Pharmaceuticals, Inc. | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US8387612B2 (en) | 2003-05-21 | 2013-03-05 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9370629B2 (en) | 2003-05-21 | 2016-06-21 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US20050034723A1 (en) * | 2003-08-04 | 2005-02-17 | Bryson Bennett | Substrates for drug delivery device and methods of preparing and use |
US8333197B2 (en) | 2004-06-03 | 2012-12-18 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US10834964B2 (en) | 2005-07-19 | 2020-11-17 | Juul Labs, Inc. | Method and system for vaporization of a substance |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US11647783B2 (en) | 2005-07-19 | 2023-05-16 | Juul Labs, Inc. | Devices for vaporization of a substance |
US10625033B2 (en) | 2007-03-09 | 2020-04-21 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US10231484B2 (en) | 2007-12-18 | 2019-03-19 | Juul Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
US11612702B2 (en) | 2007-12-18 | 2023-03-28 | Juul Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US10543323B2 (en) | 2008-10-23 | 2020-01-28 | Batmark Limited | Inhaler |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
EP4295712A3 (en) * | 2009-10-29 | 2024-03-20 | Philip Morris Products S.A. | An electrically heated smoking system with improved heater |
EP3248484A1 (en) * | 2009-10-29 | 2017-11-29 | Philip Morris Products S.a.s. | An electrically heated smoking system with improved heater |
EP3248485A1 (en) * | 2009-10-29 | 2017-11-29 | Philip Morris Products S.a.s. | An electrically heated smoking system with improved heater |
EP3248487A1 (en) * | 2009-10-29 | 2017-11-29 | Philip Morris Products S.a.s. | An electrically heated smoking system with improved heater |
EP4070675A1 (en) * | 2009-10-29 | 2022-10-12 | Philip Morris Products S.A. | An electrically heated smoking system with improved heater |
EP3248486A1 (en) * | 2009-10-29 | 2017-11-29 | Philip Morris Products S.a.s. | An electrically heated smoking system with improved heater |
EP3248483A1 (en) * | 2009-10-29 | 2017-11-29 | Philip Morris Products S.a.s. | An electrically heated smoking system with improved heater |
US20170189628A1 (en) * | 2010-01-12 | 2017-07-06 | Omega Life Science Ltd. | Method and apparatus for producing fine concentrated aerosol |
US10857311B2 (en) * | 2010-01-12 | 2020-12-08 | Omega Life Science Ltd. | Method and apparatus for producing fine concentrated aerosol |
US20210046258A1 (en) * | 2010-01-12 | 2021-02-18 | Omega Life Science Ltd | Method and apparatus for producing fine concentrated aerosol |
US9555199B2 (en) | 2010-03-10 | 2017-01-31 | Batmark Limited | Laminar evaporator |
US11484670B2 (en) | 2010-03-10 | 2022-11-01 | Nicoventures Trading Limited | Laminar evaporator |
US11839714B2 (en) | 2010-08-26 | 2023-12-12 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US11484668B2 (en) | 2010-08-26 | 2022-11-01 | Alexza Pharmauceticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US10786635B2 (en) | 2010-08-26 | 2020-09-29 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US10010695B2 (en) | 2011-02-11 | 2018-07-03 | Batmark Limited | Inhaler component |
US10918820B2 (en) | 2011-02-11 | 2021-02-16 | Batmark Limited | Inhaler component |
US11253671B2 (en) | 2011-07-27 | 2022-02-22 | Nicoventures Trading Limited | Inhaler component |
EP2723429A4 (en) * | 2011-08-16 | 2015-04-01 | Ploom Inc | Low temperature electronic vaporization device and methods |
EP2723429A1 (en) * | 2011-08-16 | 2014-04-30 | Ploom, Inc. | Low temperature electronic vaporization device and methods |
US9408416B2 (en) | 2011-08-16 | 2016-08-09 | Pax Labs, Inc. | Low temperature electronic vaporization device and methods |
US11904089B2 (en) | 2011-08-16 | 2024-02-20 | Juul Labs, Inc. | Devices for vaporization of a substance |
US11672279B2 (en) | 2011-09-06 | 2023-06-13 | Nicoventures Trading Limited | Heating smokeable material |
US9357803B2 (en) | 2011-09-06 | 2016-06-07 | British American Tobacco (Investments) Limited | Heat insulated apparatus for heating smokable material |
US10729176B2 (en) | 2011-09-06 | 2020-08-04 | British American Tobacco (Investments) Limited | Heating smokeable material |
US9554598B2 (en) | 2011-09-06 | 2017-01-31 | British American Tobacco (Investments) Limited | Heat insulated apparatus for heating smokable material |
US9609894B2 (en) | 2011-09-06 | 2017-04-04 | British American Tobacco (Investments) Limited | Heating smokable material |
US9414629B2 (en) | 2011-09-06 | 2016-08-16 | Britsh American Tobacco (Investments) Limited | Heating smokable material |
US11051551B2 (en) | 2011-09-06 | 2021-07-06 | Nicoventures Trading Limited | Heating smokable material |
US9980523B2 (en) | 2011-09-06 | 2018-05-29 | British American Tobacco (Investments) Limited | Heating smokable material |
US9999256B2 (en) | 2011-09-06 | 2018-06-19 | British American Tobacco (Investments) Limited | Heating smokable material |
US10045562B2 (en) | 2011-10-21 | 2018-08-14 | Batmark Limited | Inhaler component |
WO2013160112A3 (en) * | 2012-04-23 | 2014-04-03 | British American Tobacco (Investments) Limited | Heating smokeable material |
US10881138B2 (en) | 2012-04-23 | 2021-01-05 | British American Tobacco (Investments) Limited | Heating smokeable material |
AU2013251940B2 (en) * | 2012-04-23 | 2016-03-31 | Nicoventures Trading Limited | Heating smokeable material |
US11039647B2 (en) | 2012-07-16 | 2021-06-22 | Nicoventures Trading Limited | Electronic vapor provision device |
US11039643B2 (en) | 2012-07-16 | 2021-06-22 | Nicoventures Trading Limited | Electronic vapor provision device |
EP3114947B1 (en) | 2012-07-16 | 2019-12-18 | Nicoventures Holdings Limited | Electronic vapour provision device |
US11272740B2 (en) | 2012-07-16 | 2022-03-15 | Nicoventures Holdings Limited | Electronic vapor provision device |
US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
US11241042B2 (en) | 2012-09-25 | 2022-02-08 | Nicoventures Trading Limited | Heating smokeable material |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10638792B2 (en) | 2013-03-15 | 2020-05-05 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10314335B2 (en) | 2013-05-02 | 2019-06-11 | Nicoventures Holdings Limited | Electronic cigarette |
US10111466B2 (en) | 2013-05-02 | 2018-10-30 | Nicoventures Holdings Limited | Electronic cigarette |
US10952468B2 (en) | 2013-05-06 | 2021-03-23 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
US10426193B2 (en) | 2013-06-04 | 2019-10-01 | Nicoventures Holdings Limited | Container |
US10653180B2 (en) | 2013-06-14 | 2020-05-19 | Juul Labs, Inc. | Multiple heating elements with separate vaporizable materials in an electric vaporization device |
US10036574B2 (en) | 2013-06-28 | 2018-07-31 | British American Tobacco (Investments) Limited | Devices comprising a heat source material and activation chambers for the same |
US10166224B2 (en) | 2013-07-11 | 2019-01-01 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US9724341B2 (en) | 2013-07-11 | 2017-08-08 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
US11458130B2 (en) | 2013-07-11 | 2022-10-04 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
US11039644B2 (en) | 2013-10-29 | 2021-06-22 | Nicoventures Trading Limited | Apparatus for heating smokeable material |
US10463069B2 (en) | 2013-12-05 | 2019-11-05 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US11744277B2 (en) | 2013-12-05 | 2023-09-05 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US11510433B2 (en) | 2013-12-05 | 2022-11-29 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058130B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10045568B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US10045567B2 (en) | 2013-12-23 | 2018-08-14 | Juul Labs, Inc. | Vaporization device systems and methods |
US9549573B2 (en) | 2013-12-23 | 2017-01-24 | Pax Labs, Inc. | Vaporization device systems and methods |
US10264823B2 (en) | 2013-12-23 | 2019-04-23 | Juul Labs, Inc. | Vaporization device systems and methods |
US10058124B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10667560B2 (en) | 2013-12-23 | 2020-06-02 | Juul Labs, Inc. | Vaporizer apparatus |
US11752283B2 (en) | 2013-12-23 | 2023-09-12 | Juul Labs, Inc. | Vaporization device systems and methods |
US10070669B2 (en) | 2013-12-23 | 2018-09-11 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10701975B2 (en) | 2013-12-23 | 2020-07-07 | Juul Labs, Inc. | Vaporization device systems and methods |
US10912331B2 (en) | 2013-12-23 | 2021-02-09 | Juul Labs, Inc. | Vaporization device systems and methods |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10104915B2 (en) | 2013-12-23 | 2018-10-23 | Juul Labs, Inc. | Securely attaching cartridges for vaporizer devices |
US10201190B2 (en) | 2013-12-23 | 2019-02-12 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10111470B2 (en) | 2013-12-23 | 2018-10-30 | Juul Labs, Inc. | Vaporizer apparatus |
US10117465B2 (en) | 2013-12-23 | 2018-11-06 | Juul Labs, Inc. | Vaporization device systems and methods |
US10117466B2 (en) | 2013-12-23 | 2018-11-06 | Juul Labs, Inc. | Vaporization device systems and methods |
US20160354561A1 (en) * | 2014-02-11 | 2016-12-08 | Timothy McCullough | Methods and drug delivery devices using cannabis |
US10661036B2 (en) | 2014-02-11 | 2020-05-26 | Timothy McCullough | Methods and delivery devices using herbal extracts |
WO2015123317A1 (en) * | 2014-02-11 | 2015-08-20 | Mccullough Timothy | Methods and drug delivery devices using cannabis |
US11395891B2 (en) | 2014-02-11 | 2022-07-26 | Vapor Cartridge Technology Llc | Methods and delivery devices using herbal extracts |
US10821240B2 (en) * | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US20150223523A1 (en) * | 2014-02-11 | 2015-08-13 | Timothy McCullough | Drug delivery system and method |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US9380813B2 (en) * | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
US9408986B2 (en) | 2014-02-11 | 2016-08-09 | Timothy McCullough | Methods and devices using cannabis vapors |
US11779718B2 (en) | 2014-04-28 | 2023-10-10 | Nicoventures Trading Limited | Aerosol forming component |
US10765147B2 (en) | 2014-04-28 | 2020-09-08 | Batmark Limited | Aerosol forming component |
US11478021B2 (en) | 2014-05-16 | 2022-10-25 | Juul Labs, Inc. | Systems and methods for aerosolizing a vaporizable material |
US10542777B2 (en) | 2014-06-27 | 2020-01-28 | British American Tobacco (Investments) Limited | Apparatus for heating or cooling a material contained therein |
US10687555B2 (en) | 2014-06-27 | 2020-06-23 | Batmark Limited | Vaporizer assembly having a vaporizer and a matrix |
US10602777B2 (en) | 2014-07-25 | 2020-03-31 | Nicoventures Holdings Limited | Aerosol provision system |
US10512282B2 (en) | 2014-12-05 | 2019-12-24 | Juul Labs, Inc. | Calibrated dose control |
US11083856B2 (en) | 2014-12-11 | 2021-08-10 | Nicoventures Trading Limited | Aerosol provision systems |
WO2016107767A1 (en) * | 2014-12-29 | 2016-07-07 | British American Tobacco (Investments) Limited | Heating device for apparatus for heating smokable material and method of manufacture |
RU2664228C1 (en) * | 2014-12-29 | 2018-08-15 | Бритиш Америкэн Тобэкко (Инвестментс) Лимитед | Heating device for a device for heating a material which can be smoked and a method of manufacture |
US11166492B2 (en) | 2014-12-29 | 2021-11-09 | British American Tobacco (Investments) Limited | Heating device for apparatus for heating smokable material and method of manufacture |
RU2677846C1 (en) * | 2014-12-29 | 2019-01-21 | Бритиш Америкэн Тобэкко (Инвестментс) Лимитед | Heating device for a device for heating a material which can be smoked and a method of manufacture |
US11412783B2 (en) | 2014-12-29 | 2022-08-16 | Nicoventures Trading Limited | Apparatus for heating smokable material |
US10609958B2 (en) | 2014-12-29 | 2020-04-07 | British American Tobacco (Investments) Limited | Heating device for apparatus for heating smokable material and method of manufacture |
US11357258B2 (en) | 2014-12-29 | 2022-06-14 | Nicoventures Trading Limited | Cartridge for having a sleeve with slots surrounding a contact piece with corresponding contact arms |
US11511054B2 (en) | 2015-03-11 | 2022-11-29 | Alexza Pharmaceuticals, Inc. | Use of antistatic materials in the airway for thermal aerosol condensation process |
US11185110B2 (en) | 2015-06-29 | 2021-11-30 | Nicoventures Trading Limited | Electronic vapor provision system |
US11896055B2 (en) | 2015-06-29 | 2024-02-13 | Nicoventures Trading Limited | Electronic aerosol provision systems |
US11033055B2 (en) | 2015-06-29 | 2021-06-15 | Nicoventures Trading Limited | Electronic aerosol provision systems, inductive heating assemblies and cartridges for use therewith, and related methods |
US10881141B2 (en) | 2015-06-29 | 2021-01-05 | Nicoventures Holdings Limited | Electronic aerosol provision systems |
US11882877B2 (en) | 2015-06-29 | 2024-01-30 | Nicoventures Trading Limited | Electronic vapor provision system |
US11659863B2 (en) | 2015-08-31 | 2023-05-30 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US11064725B2 (en) | 2015-08-31 | 2021-07-20 | British American Tobacco (Investments) Limited | Material for use with apparatus for heating smokable material |
US11825870B2 (en) | 2015-10-30 | 2023-11-28 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US11452313B2 (en) | 2015-10-30 | 2022-09-27 | Nicoventures Trading Limited | Apparatus for heating smokable material |
US10865001B2 (en) | 2016-02-11 | 2020-12-15 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US11744964B2 (en) | 2016-04-27 | 2023-09-05 | Nicoventures Trading Limited | Electronic aerosol provision system and vaporizer therefor |
USD929036S1 (en) | 2016-06-16 | 2021-08-24 | Pax Labs, Inc. | Vaporizer cartridge and device assembly |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD913583S1 (en) | 2016-06-16 | 2021-03-16 | Pax Labs, Inc. | Vaporizer device |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
US11141548B2 (en) | 2016-07-26 | 2021-10-12 | British American Tobacco (Investments) Limited | Method of generating aerosol |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11717479B2 (en) | 2016-12-09 | 2023-08-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11571527B2 (en) * | 2017-03-30 | 2023-02-07 | Nicoventures Trading Limited | Article for use with an apparatus for heating an aerosol generating agent |
USD927061S1 (en) | 2017-09-14 | 2021-08-03 | Pax Labs, Inc. | Vaporizer cartridge |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
CN108414609A (en) * | 2018-02-05 | 2018-08-17 | 吉林大学 | The on-line mass spectroscopy detection device of nutritional ingredient change procedure during a kind of Chinese medicine steams |
US11730199B2 (en) | 2018-06-07 | 2023-08-22 | Juul Labs, Inc. | Cartridges for vaporizer devices |
US11497249B2 (en) | 2019-09-16 | 2022-11-15 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
CN111672000A (en) * | 2020-06-09 | 2020-09-18 | 青岛市中医医院(青岛市海慈医院、青岛市康复医学研究所) | Traditional chinese medical science paediatrics is with atomizing inhalation device |
USD986482S1 (en) | 2020-10-30 | 2023-05-16 | Nicoventures Trading Limited | Aerosol generator |
USD977706S1 (en) | 2020-10-30 | 2023-02-07 | Nicoventures Trading Limited | Aerosol generator |
USD977704S1 (en) | 2020-10-30 | 2023-02-07 | Nicoventures Trading Limited | Aerosol generator |
USD977705S1 (en) | 2020-10-30 | 2023-02-07 | Nicoventures Trading Limited | Aerosol generator |
USD990765S1 (en) | 2020-10-30 | 2023-06-27 | Nicoventures Trading Limited | Aerosol generator |
USD986483S1 (en) | 2020-10-30 | 2023-05-16 | Nicoventures Trading Limited | Aerosol generator |
USD989384S1 (en) | 2021-04-30 | 2023-06-13 | Nicoventures Trading Limited | Aerosol generator |
Also Published As
Publication number | Publication date |
---|---|
US20200246559A1 (en) | 2020-08-06 |
WO2008112661A3 (en) | 2009-03-26 |
US20170049974A1 (en) | 2017-02-23 |
WO2008112661A2 (en) | 2008-09-18 |
US20230285691A1 (en) | 2023-09-14 |
US11642473B2 (en) | 2023-05-09 |
EP2121088B1 (en) | 2016-07-13 |
ES2594867T3 (en) | 2016-12-23 |
US10625033B2 (en) | 2020-04-21 |
EP2121088A2 (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11642473B2 (en) | Heating unit for use in a drug delivery device | |
US20220401431A1 (en) | Nicotine salt with meta-salicylic acid and applications therein | |
US20210106775A1 (en) | Electrical condensation aerosol device | |
JP4578772B2 (en) | Delivery of sedative sleeping pills by a prescribed inhalation route | |
US20040105818A1 (en) | Diuretic aerosols and methods of making and using them | |
JP2004531555A (en) | Delivery of alprazolam, estazolam, midazolam or triazolam by a given inhalation route | |
JP6773675B2 (en) | Use of antistatic material in airways for thermal aerosol condensation process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALEXZA PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WENSLEY, MARTIN J.;GLAZER, MARC;BRESSON, JAMES;AND OTHERS;REEL/FRAME:021010/0654;SIGNING DATES FROM 20080414 TO 20080415 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |